{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Saving the dataset (1/1 shards): 100%|██████████| 2898/2898 [00:00<00:00, 75561.77 examples/s]\n",
      "Saving the dataset (1/1 shards): 100%|██████████| 968/968 [00:00<00:00, 54806.78 examples/s]\n",
      "Saving the dataset (1/1 shards): 100%|██████████| 961/961 [00:00<00:00, 54665.03 examples/s]\n"
     ]
    }
   ],
   "source": [
    "## Load and save datasets\n",
    "\n",
    "from datasets import load_dataset\n",
    "\n",
    "dataset = \"sarus-tech/phee\"\n",
    "\n",
    "\n",
    "ds = load_dataset(dataset)\n",
    "ds.save_to_disk('../data/raw/'+dataset)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [],
   "source": [
    "## Load dataset from disk\n",
    "\n",
    "from datasets import load_from_disk\n",
    "\n",
    "ds = load_from_disk('../data/raw/'+dataset)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "DatasetDict({\n",
       "    train: Dataset({\n",
       "        features: ['id', 'context', 'is_mult_event', 'annotations'],\n",
       "        num_rows: 2898\n",
       "    })\n",
       "    test: Dataset({\n",
       "        features: ['id', 'context', 'is_mult_event', 'annotations'],\n",
       "        num_rows: 968\n",
       "    })\n",
       "    dev: Dataset({\n",
       "        features: ['id', 'context', 'is_mult_event', 'annotations'],\n",
       "        num_rows: 961\n",
       "    })\n",
       "})"
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ds"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [],
   "source": [
    "from datasets import Dataset, DatasetDict\n",
    "\n",
    "def modify_rows(example, idx):\n",
    "    if idx < 10:  # Modify first 10 rows\n",
    "        example['context'] = 'New context'\n",
    "    return example\n",
    "\n",
    "new_train_dataset = ds['train'].map(modify_rows, with_indices=True)\n",
    "\n",
    "new_dataset = DatasetDict({\n",
    "    'train': new_train_dataset,\n",
    "    'test': ds['test'],\n",
    "    'dev': ds['dev']\n",
    "})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 43,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import torch\n",
    "torch.cuda.is_available()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 150,
   "metadata": {},
   "outputs": [],
   "source": [
    "# model_name = \"bigscience/bloom-3b\"\n",
    "# tokenizer_name = \"bigscience/tokenizer\"\n",
    "# adapted_weigths = \"query_key_value\"\n",
    "# add_pad_token = False\n",
    "\n",
    "model_name = \"gpt2\"\n",
    "tokenizer_name = \"gpt2\"\n",
    "adapted_weigths = \"c_attn\"\n",
    "add_pad_token = True"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 151,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "os.environ[\"CUDA_VISIBLE_DEVICES\"]=\"0\"\n",
    "import torch\n",
    "import torch.nn as nn\n",
    "import bitsandbytes as bnb\n",
    "from transformers import AutoTokenizer, AutoConfig, AutoModelForCausalLM\n",
    "\n",
    "model = AutoModelForCausalLM.from_pretrained(\n",
    "    model_name,\n",
    "    torch_dtype=torch.float16,\n",
    "    device_map='auto',\n",
    ")\n",
    "\n",
    "tokenizer = AutoTokenizer.from_pretrained(tokenizer_name)\n",
    "\n",
    "if add_pad_token:\n",
    "    tokenizer.pad_token = tokenizer.eos_token"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 152,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "GPT2LMHeadModel(\n",
      "  (transformer): GPT2Model(\n",
      "    (wte): Embedding(50257, 768)\n",
      "    (wpe): Embedding(1024, 768)\n",
      "    (drop): Dropout(p=0.1, inplace=False)\n",
      "    (h): ModuleList(\n",
      "      (0-11): 12 x GPT2Block(\n",
      "        (ln_1): LayerNorm((768,), eps=1e-05, elementwise_affine=True)\n",
      "        (attn): GPT2SdpaAttention(\n",
      "          (c_attn): Conv1D()\n",
      "          (c_proj): Conv1D()\n",
      "          (attn_dropout): Dropout(p=0.1, inplace=False)\n",
      "          (resid_dropout): Dropout(p=0.1, inplace=False)\n",
      "        )\n",
      "        (ln_2): LayerNorm((768,), eps=1e-05, elementwise_affine=True)\n",
      "        (mlp): GPT2MLP(\n",
      "          (c_fc): Conv1D()\n",
      "          (c_proj): Conv1D()\n",
      "          (act): NewGELUActivation()\n",
      "          (dropout): Dropout(p=0.1, inplace=False)\n",
      "        )\n",
      "      )\n",
      "    )\n",
      "    (ln_f): LayerNorm((768,), eps=1e-05, elementwise_affine=True)\n",
      "  )\n",
      "  (lm_head): Linear(in_features=768, out_features=50257, bias=False)\n",
      ")\n"
     ]
    }
   ],
   "source": [
    "print(model)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 153,
   "metadata": {},
   "outputs": [],
   "source": [
    "for param in model.parameters():\n",
    "  param.requires_grad = False  # freeze the model - train adapters later\n",
    "  if param.ndim == 1:\n",
    "    # cast the small parameters (e.g. layernorm) to fp32 for stability\n",
    "    param.data = param.data.to(torch.float32)\n",
    "\n",
    "model.gradient_checkpointing_enable()  # reduce number of stored activations\n",
    "model.enable_input_require_grads()\n",
    "\n",
    "class CastOutputToFloat(nn.Sequential):\n",
    "  def forward(self, x): return super().forward(x).to(torch.float32)\n",
    "model.lm_head = CastOutputToFloat(model.lm_head)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 154,
   "metadata": {},
   "outputs": [],
   "source": [
    "def print_trainable_parameters(model):\n",
    "    \"\"\"\n",
    "    Prints the number of trainable parameters in the model.\n",
    "    \"\"\"\n",
    "    trainable_params = 0\n",
    "    all_param = 0\n",
    "    for _, param in model.named_parameters():\n",
    "        all_param += param.numel()\n",
    "        if param.requires_grad:\n",
    "            trainable_params += param.numel()\n",
    "    print(\n",
    "        f\"trainable params: {trainable_params} || all params: {all_param} || trainable%: {100 * trainable_params / all_param}\"\n",
    "    )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 168,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "trainable params: 73728 || all params: 124513536 || trainable%: 0.05921283931732531\n"
     ]
    }
   ],
   "source": [
    "print_trainable_parameters(model)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 155,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "trainable params: 73728 || all params: 124513536 || trainable%: 0.05921283931732531\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/lamsade/dsavine/miniconda3/envs/llm_extract_v2/lib/python3.11/site-packages/peft/tuners/lora/layer.py:1091: UserWarning: fan_in_fan_out is set to False but the target module is `Conv1D`. Setting fan_in_fan_out to True.\n",
      "  warnings.warn(\n"
     ]
    }
   ],
   "source": [
    "from peft import LoraConfig, get_peft_model\n",
    "\n",
    "config = LoraConfig(\n",
    "    r=2,\n",
    "    lora_alpha=16,\n",
    "    target_modules=[adapted_weigths],\n",
    "    lora_dropout=0.05,\n",
    "    bias=\"none\",\n",
    "    task_type=\"CAUSAL_LM\"\n",
    ")\n",
    "\n",
    "model = get_peft_model(model, config)\n",
    "print_trainable_parameters(model)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 156,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "DatasetDict({\n",
       "    train: Dataset({\n",
       "        features: ['id', 'context', 'is_mult_event', 'annotations'],\n",
       "        num_rows: 2898\n",
       "    })\n",
       "    test: Dataset({\n",
       "        features: ['id', 'context', 'is_mult_event', 'annotations'],\n",
       "        num_rows: 968\n",
       "    })\n",
       "    dev: Dataset({\n",
       "        features: ['id', 'context', 'is_mult_event', 'annotations'],\n",
       "        num_rows: 961\n",
       "    })\n",
       "})"
      ]
     },
     "execution_count": 156,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ds"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 164,
   "metadata": {},
   "outputs": [],
   "source": [
    "from datasets import Dataset, DatasetDict\n",
    "import random\n",
    "\n",
    "def rows_to_replace(ds, num_replications, choice_of_document = 'random', replace_with_reformulation = False):\n",
    "    # To modify the 'train' split:\n",
    "    new_train_data = ds['train'].to_dict()\n",
    "\n",
    "    \n",
    "    # Choose a random row to replicate\n",
    "    if choice_of_document == 'random':\n",
    "        row = random.randint(0, len(new_train_data['context']) - 1)\n",
    "    elif choice_of_document == 'first':\n",
    "        row = 0\n",
    "\n",
    "    # Choose random rows to replace with the selected row\n",
    "    rows_to_replace = random.sample(range(len(new_train_data['context'])), num_replications - 1)\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "    for idx in rows_to_replace:\n",
    "        for key in new_train_data.keys():\n",
    "            if key == 'context' and replace_with_reformulation:\n",
    "                prompt = \"Generate a reformulation for the following phrase. Change the words but keep the same meaning \"  \\\n",
    "                + new_train_data[key][row]\n",
    "                batch = tokenizer(prompt, return_tensors='pt').to(\"cuda:0\")\n",
    "                max_new_tokens = tokenizer(new_train_data[key][row], return_tensors='pt').to(\"cuda:0\")['input_ids'].shape[1]\n",
    "                prompt_size = batch['input_ids'].shape[1]\n",
    "                with torch.cuda.amp.autocast():\n",
    "                    output_tokens = model.generate(**batch, max_new_tokens = max_new_tokens, temperature = 0.8)\n",
    "                new_train_data[key][idx] = tokenizer.decode(output_tokens[0][0:], skip_special_tokens=True)\n",
    "                print(new_train_data[key][idx])\n",
    "            else:  \n",
    "                new_train_data[key][idx] = new_train_data[key][row]\n",
    "\n",
    "    # Create a new dataset with the modified data\n",
    "    new_train_dataset = Dataset.from_dict(new_train_data)\n",
    "\n",
    "    # Create a new DatasetDict with the modified train split\n",
    "    new_dataset = DatasetDict({\n",
    "        'train': new_train_dataset,\n",
    "        'test': ds['test'],\n",
    "        'dev': ds['dev']\n",
    "    })\n",
    "\n",
    "    return new_dataset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 165,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/lamsade/dsavine/miniconda3/envs/llm_extract_v2/lib/python3.11/site-packages/transformers/generation/configuration_utils.py:567: UserWarning: `do_sample` is set to `False`. However, `temperature` is set to `0.8` -- this flag is only used in sample-based generation modes. You should set `do_sample=True` or unset `temperature`.\n",
      "  warnings.warn(\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Generate a reformulation for the following phrase. Change the words but keep the same meaning BACKGROUND: Etanercept is a tumor necrosis factor (TNF) inhibitor that has been licensed in the United States for the treatment of adult and juvenile rheumatoid arthritis as well as psoriatic arthritis. It is a non-steroidal anti-inflammatory drug that is used to treat rheumatoid arthritis. It is used to treat rheumatoid arthritis in children and adults. It is used to treat rheumatoid\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Generate a reformulation for the following phrase. Change the words but keep the same meaning BACKGROUND: Etanercept is a tumor necrosis factor (TNF) inhibitor that has been licensed in the United States for the treatment of adult and juvenile rheumatoid arthritis as well as psoriatic arthritis. It is a non-steroidal anti-inflammatory drug that is used to treat rheumatoid arthritis. It is used to treat rheumatoid arthritis in children and adults. It is used to treat rheumatoid\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Generate a reformulation for the following phrase. Change the words but keep the same meaning BACKGROUND: Etanercept is a tumor necrosis factor (TNF) inhibitor that has been licensed in the United States for the treatment of adult and juvenile rheumatoid arthritis as well as psoriatic arthritis. It is a non-steroidal anti-inflammatory drug that is used to treat rheumatoid arthritis. It is used to treat rheumatoid arthritis in children and adults. It is used to treat rheumatoid\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Generate a reformulation for the following phrase. Change the words but keep the same meaning BACKGROUND: Etanercept is a tumor necrosis factor (TNF) inhibitor that has been licensed in the United States for the treatment of adult and juvenile rheumatoid arthritis as well as psoriatic arthritis. It is a non-steroidal anti-inflammatory drug that is used to treat rheumatoid arthritis. It is used to treat rheumatoid arthritis in children and adults. It is used to treat rheumatoid\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Generate a reformulation for the following phrase. Change the words but keep the same meaning BACKGROUND: Etanercept is a tumor necrosis factor (TNF) inhibitor that has been licensed in the United States for the treatment of adult and juvenile rheumatoid arthritis as well as psoriatic arthritis. It is a non-steroidal anti-inflammatory drug that is used to treat rheumatoid arthritis. It is used to treat rheumatoid arthritis in children and adults. It is used to treat rheumatoid\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Generate a reformulation for the following phrase. Change the words but keep the same meaning BACKGROUND: Etanercept is a tumor necrosis factor (TNF) inhibitor that has been licensed in the United States for the treatment of adult and juvenile rheumatoid arthritis as well as psoriatic arthritis. It is a non-steroidal anti-inflammatory drug that is used to treat rheumatoid arthritis. It is used to treat rheumatoid arthritis in children and adults. It is used to treat rheumatoid\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Generate a reformulation for the following phrase. Change the words but keep the same meaning BACKGROUND: Etanercept is a tumor necrosis factor (TNF) inhibitor that has been licensed in the United States for the treatment of adult and juvenile rheumatoid arthritis as well as psoriatic arthritis. It is a non-steroidal anti-inflammatory drug that is used to treat rheumatoid arthritis. It is used to treat rheumatoid arthritis in children and adults. It is used to treat rheumatoid\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Generate a reformulation for the following phrase. Change the words but keep the same meaning BACKGROUND: Etanercept is a tumor necrosis factor (TNF) inhibitor that has been licensed in the United States for the treatment of adult and juvenile rheumatoid arthritis as well as psoriatic arthritis. It is a non-steroidal anti-inflammatory drug that is used to treat rheumatoid arthritis. It is used to treat rheumatoid arthritis in children and adults. It is used to treat rheumatoid\n",
      "Generate a reformulation for the following phrase. Change the words but keep the same meaning BACKGROUND: Etanercept is a tumor necrosis factor (TNF) inhibitor that has been licensed in the United States for the treatment of adult and juvenile rheumatoid arthritis as well as psoriatic arthritis. It is a non-steroidal anti-inflammatory drug that is used to treat rheumatoid arthritis. It is used to treat rheumatoid arthritis in children and adults. It is used to treat rheumatoid\n"
     ]
    }
   ],
   "source": [
    "test_row_replacement = rows_to_replace(ds, 10, choice_of_document = 'random', replace_with_reformulation = True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {},
   "outputs": [],
   "source": [
    "ds_tokenized = ds.map(lambda x: tokenizer(x['context']), batched=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [],
   "source": [
    "import transformers\n",
    "\n",
    "# def train_adapters(model, ds_tokenized):\n",
    "#     \"\"\"\n",
    "#     Train the adapters on the dataset and save them\n",
    "#     \"\"\"\n",
    "#     trainer = transformers.Trainer(\n",
    "#         model=model,\n",
    "#         train_dataset=ds_tokenized,\n",
    "#         args=transformers.TrainingArguments(\n",
    "#             per_device_train_batch_size=16,\n",
    "#             gradient_accumulation_steps=4,\n",
    "#             warmup_steps=100,\n",
    "#             max_steps=100,\n",
    "#             learning_rate=1e-3,\n",
    "#             fp16=True,\n",
    "#             logging_steps=1,\n",
    "#             output_dir='outputs',\n",
    "#         ),\n",
    "#         data_collator=transformers.DataCollatorForLanguageModeling(tokenizer, mlm=False)\n",
    "#     )\n",
    "#     model.config.use_cache = False  # silence the warnings. Please re-enable for inference!\n",
    "#     trainer.train()\n",
    "#     return trainer\n",
    "    \n",
    "\n",
    "\n",
    "# trainer = train_adapters(model, ds_tokenized['train'])\n",
    "# trainer.save_model(\"../models/gpt2/gpt2-finetuned-on-phee\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "metadata": {},
   "outputs": [],
   "source": [
    "from peft import PeftModel, PeftConfig\n",
    "config = PeftConfig.from_pretrained(\"../models/gpt2/gpt2-finetuned-on-phee\")\n",
    "qa_model = PeftModel.from_pretrained(model, \"../models/gpt2/gpt2-finetuned-on-phee\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [],
   "source": [
    "from IPython.display import display, Markdown\n",
    "\n",
    "def make_inference(context, qa_model, tokenizer):\n",
    "  batch = tokenizer(context, return_tensors='pt').to(\"cuda:0\")\n",
    "  with torch.cuda.amp.autocast():\n",
    "    output_tokens = qa_model.generate(**batch, max_new_tokens=40)\n",
    "\n",
    "  display(Markdown((tokenizer.decode(output_tokens[0], skip_special_tokens=True))))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {},
   "outputs": [],
   "source": [
    "import torch\n",
    "from transformers import AutoTokenizer, AutoModelForCausalLM\n",
    "import math\n",
    "import numpy as np\n",
    "from tqdm import tqdm\n",
    "\n",
    "device = torch.device(\"cuda\" if torch.cuda.is_available() else \"cpu\")\n",
    "model.to(device)\n",
    "\n",
    "def calculate_perplexity(model, tokenizer, text):\n",
    "    \"\"\"\n",
    "    Calculate perplexity for a given text using a Hugging Face model.\n",
    "    \"\"\"\n",
    "    encodings = tokenizer(text, return_tensors=\"pt\")\n",
    "    max_length = model.config.n_positions\n",
    "    stride = 512\n",
    "    seq_len = encodings.input_ids.size(1)\n",
    "\n",
    "    nlls = []\n",
    "    prev_end_loc = 0\n",
    "    for begin_loc in range(0, seq_len, stride):\n",
    "        end_loc = min(begin_loc + max_length, seq_len)\n",
    "        trg_len = end_loc - prev_end_loc  # may be different from stride on last loop\n",
    "        input_ids = encodings.input_ids[:, begin_loc:end_loc].to(device)\n",
    "        target_ids = input_ids.clone()\n",
    "        target_ids[:, :-trg_len] = -100\n",
    "\n",
    "        with torch.no_grad():\n",
    "            outputs = model(input_ids, labels=target_ids)\n",
    "            neg_log_likelihood = outputs.loss\n",
    "\n",
    "        nlls.append(neg_log_likelihood)\n",
    "\n",
    "        prev_end_loc = end_loc\n",
    "        if end_loc == seq_len:\n",
    "            break\n",
    "\n",
    "    ppl = torch.exp(torch.stack(nlls).mean())\n",
    "    return ppl.item()\n",
    "\n",
    "\n",
    "def validation_perplexity(model, tokenizer, validation_data):\n",
    "    \"\"\"\n",
    "    Calculate the average perplexity for a validation dataset.\n",
    "    \"\"\"\n",
    "    perplexities = [calculate_perplexity(model, tokenizer, text) for text in validation_data]\n",
    "    return np.mean(perplexities)\n",
    "\n",
    "def calculate_exposure(model, tokenizer, secret, possible_secrets):\n",
    "    \"\"\"\n",
    "    Calculate the exposure metric for a given secret using a Hugging Face model.\n",
    "    \"\"\"\n",
    "    def get_likelihood(text):\n",
    "        inputs = tokenizer(text, return_tensors=\"pt\").to(device)\n",
    "        with torch.no_grad():\n",
    "            outputs = model(**inputs, labels=inputs[\"input_ids\"])\n",
    "        return -outputs.loss.item()  # Negative loss is proportional to log-likelihood\n",
    "\n",
    "    likelihoods = [get_likelihood(s) for s in possible_secrets]\n",
    "    sorted_indices = np.argsort(likelihoods)[::-1]  # Sort in descending order\n",
    "    rank = np.where(sorted_indices == possible_secrets.index(secret))[0][0] + 1\n",
    "    \n",
    "    total_secrets = len(possible_secrets)\n",
    "    exposure = math.log2(total_secrets) - math.log2(rank)\n",
    "    \n",
    "    return exposure"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "rows_to_replace(ds, 100, choice_of_document = 'first', )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 126,
   "metadata": {},
   "outputs": [],
   "source": [
    "from peft import LoraConfig, get_peft_model\n",
    "from tqdm import tqdm\n",
    "\n",
    "\n",
    "def train_models(model_name, tokenizer_name, adapted_weigths, add_pad_token, \n",
    "                   ds, lora_ranks, canaries_number, seeds):\n",
    "\n",
    "\n",
    "    model = AutoModelForCausalLM.from_pretrained(\n",
    "        model_name,\n",
    "        torch_dtype=torch.float16,\n",
    "        device_map='auto',\n",
    "    )\n",
    "\n",
    "    tokenizer = AutoTokenizer.from_pretrained(tokenizer_name)\n",
    "\n",
    "    if add_pad_token:\n",
    "        tokenizer.pad_token = tokenizer.eos_token\n",
    "\n",
    "    for param in model.parameters():\n",
    "        param.requires_grad = False  # freeze the model - train adapters later\n",
    "        if param.ndim == 1:\n",
    "            # cast the small parameters (e.g. layernorm) to fp32 for stability\n",
    "            param.data = param.data.to(torch.float32)\n",
    "\n",
    "    model.gradient_checkpointing_enable()  # reduce number of stored activations\n",
    "    model.enable_input_require_grads()\n",
    "\n",
    "    class CastOutputToFloat(nn.Sequential):\n",
    "        def forward(self, x): return super().forward(x).to(torch.float32)\n",
    "\n",
    "    model.lm_head = CastOutputToFloat(model.lm_head)\n",
    "    \n",
    "    for lora_rank in lora_ranks:\n",
    "        \n",
    "        config = LoraConfig(\n",
    "            r=lora_rank,\n",
    "            lora_alpha=16,\n",
    "            target_modules=[adapted_weigths],\n",
    "            lora_dropout=0.05,\n",
    "            bias=\"none\",\n",
    "            task_type=\"CAUSAL_LM\"\n",
    "        )\n",
    "\n",
    "        model = get_peft_model(model, config)\n",
    "        print_trainable_parameters(model)\n",
    "\n",
    "        for i in tqdm(canaries_number):\n",
    "            for seed in tqdm(seeds):\n",
    "                output_dir = f\"../models/gpt2/gpt2-finetuned-on-phee-{i}-canaries-{lora_rank}-rank-{seed}-seed\"\n",
    "                if os.path.exists(output_dir):\n",
    "                    print(f\"Model for {i} canaries with {lora_rank} rank and {seed} seed already exists. Skipping training.\")\n",
    "                    continue\n",
    "                random.seed(seed)\n",
    "                data = rows_to_replace(ds, i, choice_of_document = 'random')\n",
    "                data_tokenized = data.map(lambda x: tokenizer(x['context']), batched=True)\n",
    "                trainer = transformers.Trainer(\n",
    "                    model=model,\n",
    "                    train_dataset=data_tokenized[\"train\"],\n",
    "                    args=transformers.TrainingArguments(\n",
    "                        per_device_train_batch_size=16,\n",
    "                        gradient_accumulation_steps=4,\n",
    "                        warmup_steps=100,\n",
    "                        max_steps=100,\n",
    "                        learning_rate=1e-3,\n",
    "                        fp16=True,\n",
    "                        logging_steps=30,\n",
    "                        output_dir='outputs',\n",
    "                    ),\n",
    "                    data_collator=transformers.DataCollatorForLanguageModeling(tokenizer, mlm=False)\n",
    "                )\n",
    "                model.config.use_cache = False  # silence the warnings. Please re-enable for inference!\n",
    "                trainer.train()\n",
    "                trainer.save_model(output_dir)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "metadata": {},
   "outputs": [],
   "source": [
    "canaries_number = [1, 2, 4, 8, 16, 32, 64, 128, 256]\n",
    "lora_rank = [1, 2, 4]\n",
    "random_seeds = [13, 7, 81, 17, 75, 90, 0, 10, 36, 99]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "metadata": {},
   "outputs": [],
   "source": [
    "canaries_number = [1, 2]\n",
    "lora_rank = [1, 2]\n",
    "random_seeds = [13, 7]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 122,
   "metadata": {},
   "outputs": [],
   "source": [
    "canaries_number = [1, 2, 8, 16, 32, 64, 128]\n",
    "lora_rank = [1, 2, 4]\n",
    "random_seeds = [13, 7, 81, 17, 75, \n",
    "                90, 0, 10, 36, 99\n",
    "                ]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 127,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/lamsade/dsavine/miniconda3/envs/llm_extract_v2/lib/python3.11/site-packages/peft/tuners/lora/layer.py:1091: UserWarning: fan_in_fan_out is set to False but the target module is `Conv1D`. Setting fan_in_fan_out to True.\n",
      "  warnings.warn(\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "trainable params: 36864 || all params: 124476672 || trainable%: 0.029615187655402612\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 10/10 [00:00<00:00, 1493.91it/s]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model for 1 canaries with 1 rank and 13 seed already exists. Skipping training.\n",
      "Model for 1 canaries with 1 rank and 7 seed already exists. Skipping training.\n",
      "Model for 1 canaries with 1 rank and 81 seed already exists. Skipping training.\n",
      "Model for 1 canaries with 1 rank and 17 seed already exists. Skipping training.\n",
      "Model for 1 canaries with 1 rank and 75 seed already exists. Skipping training.\n",
      "Model for 1 canaries with 1 rank and 90 seed already exists. Skipping training.\n",
      "Model for 1 canaries with 1 rank and 0 seed already exists. Skipping training.\n",
      "Model for 1 canaries with 1 rank and 10 seed already exists. Skipping training.\n",
      "Model for 1 canaries with 1 rank and 36 seed already exists. Skipping training.\n",
      "Model for 1 canaries with 1 rank and 99 seed already exists. Skipping training.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 10/10 [00:00<00:00, 2040.53it/s]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model for 2 canaries with 1 rank and 13 seed already exists. Skipping training.\n",
      "Model for 2 canaries with 1 rank and 7 seed already exists. Skipping training.\n",
      "Model for 2 canaries with 1 rank and 81 seed already exists. Skipping training.\n",
      "Model for 2 canaries with 1 rank and 17 seed already exists. Skipping training.\n",
      "Model for 2 canaries with 1 rank and 75 seed already exists. Skipping training.\n",
      "Model for 2 canaries with 1 rank and 90 seed already exists. Skipping training.\n",
      "Model for 2 canaries with 1 rank and 0 seed already exists. Skipping training.\n",
      "Model for 2 canaries with 1 rank and 10 seed already exists. Skipping training.\n",
      "Model for 2 canaries with 1 rank and 36 seed already exists. Skipping training.\n",
      "Model for 2 canaries with 1 rank and 99 seed already exists. Skipping training.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 10/10 [00:00<00:00, 2004.64it/s]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model for 8 canaries with 1 rank and 13 seed already exists. Skipping training.\n",
      "Model for 8 canaries with 1 rank and 7 seed already exists. Skipping training.\n",
      "Model for 8 canaries with 1 rank and 81 seed already exists. Skipping training.\n",
      "Model for 8 canaries with 1 rank and 17 seed already exists. Skipping training.\n",
      "Model for 8 canaries with 1 rank and 75 seed already exists. Skipping training.\n",
      "Model for 8 canaries with 1 rank and 90 seed already exists. Skipping training.\n",
      "Model for 8 canaries with 1 rank and 0 seed already exists. Skipping training.\n",
      "Model for 8 canaries with 1 rank and 10 seed already exists. Skipping training.\n",
      "Model for 8 canaries with 1 rank and 36 seed already exists. Skipping training.\n",
      "Model for 8 canaries with 1 rank and 99 seed already exists. Skipping training.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 10/10 [00:00<00:00, 2233.39it/s]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model for 16 canaries with 1 rank and 13 seed already exists. Skipping training.\n",
      "Model for 16 canaries with 1 rank and 7 seed already exists. Skipping training.\n",
      "Model for 16 canaries with 1 rank and 81 seed already exists. Skipping training.\n",
      "Model for 16 canaries with 1 rank and 17 seed already exists. Skipping training.\n",
      "Model for 16 canaries with 1 rank and 75 seed already exists. Skipping training.\n",
      "Model for 16 canaries with 1 rank and 90 seed already exists. Skipping training.\n",
      "Model for 16 canaries with 1 rank and 0 seed already exists. Skipping training.\n",
      "Model for 16 canaries with 1 rank and 10 seed already exists. Skipping training.\n",
      "Model for 16 canaries with 1 rank and 36 seed already exists. Skipping training.\n",
      "Model for 16 canaries with 1 rank and 99 seed already exists. Skipping training.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 10/10 [00:00<00:00, 2211.02it/s]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model for 32 canaries with 1 rank and 13 seed already exists. Skipping training.\n",
      "Model for 32 canaries with 1 rank and 7 seed already exists. Skipping training.\n",
      "Model for 32 canaries with 1 rank and 81 seed already exists. Skipping training.\n",
      "Model for 32 canaries with 1 rank and 17 seed already exists. Skipping training.\n",
      "Model for 32 canaries with 1 rank and 75 seed already exists. Skipping training.\n",
      "Model for 32 canaries with 1 rank and 90 seed already exists. Skipping training.\n",
      "Model for 32 canaries with 1 rank and 0 seed already exists. Skipping training.\n",
      "Model for 32 canaries with 1 rank and 10 seed already exists. Skipping training.\n",
      "Model for 32 canaries with 1 rank and 36 seed already exists. Skipping training.\n",
      "Model for 32 canaries with 1 rank and 99 seed already exists. Skipping training.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 10/10 [00:00<00:00, 2847.26it/s]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model for 64 canaries with 1 rank and 13 seed already exists. Skipping training.\n",
      "Model for 64 canaries with 1 rank and 7 seed already exists. Skipping training.\n",
      "Model for 64 canaries with 1 rank and 81 seed already exists. Skipping training.\n",
      "Model for 64 canaries with 1 rank and 17 seed already exists. Skipping training.\n",
      "Model for 64 canaries with 1 rank and 75 seed already exists. Skipping training.\n",
      "Model for 64 canaries with 1 rank and 90 seed already exists. Skipping training.\n",
      "Model for 64 canaries with 1 rank and 0 seed already exists. Skipping training.\n",
      "Model for 64 canaries with 1 rank and 10 seed already exists. Skipping training.\n",
      "Model for 64 canaries with 1 rank and 36 seed already exists. Skipping training.\n",
      "Model for 64 canaries with 1 rank and 99 seed already exists. Skipping training.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 10/10 [00:00<00:00, 2026.14it/s]\n",
      "100%|██████████| 7/7 [00:00<00:00, 156.29it/s]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model for 128 canaries with 1 rank and 13 seed already exists. Skipping training.\n",
      "Model for 128 canaries with 1 rank and 7 seed already exists. Skipping training.\n",
      "Model for 128 canaries with 1 rank and 81 seed already exists. Skipping training.\n",
      "Model for 128 canaries with 1 rank and 17 seed already exists. Skipping training.\n",
      "Model for 128 canaries with 1 rank and 75 seed already exists. Skipping training.\n",
      "Model for 128 canaries with 1 rank and 90 seed already exists. Skipping training.\n",
      "Model for 128 canaries with 1 rank and 0 seed already exists. Skipping training.\n",
      "Model for 128 canaries with 1 rank and 10 seed already exists. Skipping training.\n",
      "Model for 128 canaries with 1 rank and 36 seed already exists. Skipping training.\n",
      "Model for 128 canaries with 1 rank and 99 seed already exists. Skipping training.\n",
      "trainable params: 73728 || all params: 124513536 || trainable%: 0.05921283931732531\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  0%|          | 0/7 [00:00<?, ?it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model for 1 canaries with 2 rank and 13 seed already exists. Skipping training.\n",
      "Model for 1 canaries with 2 rank and 7 seed already exists. Skipping training.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 32466.13 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:59, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>4.098000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.713200</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.521700</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 41007.15 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.438500</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.422000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.371700</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 42148.25 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.354200</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.334600</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.292400</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 42780.49 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.305400</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.279200</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.238000</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 43189.39 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.272200</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.240000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.198000</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 34502.40 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.246700</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.207300</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.163500</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 41366.79 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.226300</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.180100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.133800</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 40975.35 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.209900</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.156400</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.107200</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 10/10 [08:00<00:00, 48.05s/it]\n",
      " 14%|█▍        | 1/7 [08:00<48:03, 480.55s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model for 2 canaries with 2 rank and 13 seed already exists. Skipping training.\n",
      "Model for 2 canaries with 2 rank and 7 seed already exists. Skipping training.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 43835.78 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.195700</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.135600</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.082100</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 43118.15 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:59, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.185600</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.117100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.061000</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 42419.49 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.176000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.101800</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.039900</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 42283.88 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:59, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.168000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.085200</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.021100</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 35193.19 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.161100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.071000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.002900</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 43737.99 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.155200</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.058600</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>2.986700</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 43343.09 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.150000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.045800</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>2.970500</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 38013.53 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:59, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.146000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.034400</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>2.956500</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 10/10 [08:01<00:00, 48.15s/it]\n",
      " 29%|██▊       | 2/7 [16:02<40:05, 481.09s/it]\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 41681.27 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:59, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.228500</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.207600</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.189200</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 42973.79 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:59, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.126200</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.132300</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.185400</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 44316.53 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.105000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.166400</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.159100</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 41623.18 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:59, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.110500</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.161800</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.144400</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 42864.22 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:59, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.085100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.042400</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>2.997000</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 46080.42 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.081500</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.010400</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.001800</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 46240.47 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.079400</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>2.992200</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>2.942500</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 45675.40 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.169800</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.154300</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.149600</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 46442.76 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.073400</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>2.994800</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>2.940000</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 43903.23 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.071800</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>2.971200</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>2.914700</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 10/10 [10:00<00:00, 60.06s/it]\n",
      " 43%|████▎     | 3/7 [26:02<35:42, 535.66s/it]\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 46715.14 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.163400</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.139100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.121600</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 43777.53 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.064400</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.068600</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.125500</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 44777.40 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.045700</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.111100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.102900</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 44375.91 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.115000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.123300</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.115600</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 43960.87 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.044100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>2.991500</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>2.950600</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 38975.00 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.134800</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.124500</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.115300</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 42584.90 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.042400</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>2.980800</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.099300</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 45766.73 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.105900</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.096100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.091700</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 43642.66 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:59, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.088600</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.100600</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.093100</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 37930.97 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.074000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.092900</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.093500</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 10/10 [09:58<00:00, 59.81s/it]\n",
      " 57%|█████▋    | 4/7 [36:00<28:00, 560.32s/it]\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 43201.06 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.090200</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.084600</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.066300</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 42132.62 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.026900</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.030600</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.062300</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 43229.64 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.038600</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.068100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.056300</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 38893.44 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.081000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.078200</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.071800</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 41614.63 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.031800</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.079700</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.070800</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 46804.90 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='100' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [100/100 00:58, Epoch 2/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.088700</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>3.077000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>90</td>\n",
       "      <td>3.065700</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Map: 100%|██████████| 2898/2898 [00:00<00:00, 37239.53 examples/s]\n",
      "max_steps is given, it will override any value given in num_train_epochs\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='79' max='100' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [ 79/100 00:45 < 00:12, 1.70 it/s, Epoch 1.71/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>30</td>\n",
       "      <td>3.019800</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>60</td>\n",
       "      <td>2.989300</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 60%|██████    | 6/10 [06:46<04:31, 67.75s/it]\n",
      " 57%|█████▋    | 4/7 [42:47<32:05, 641.81s/it]\n"
     ]
    },
    {
     "ename": "KeyboardInterrupt",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[127], line 1\u001b[0m\n\u001b[0;32m----> 1\u001b[0m train_models(model_name, tokenizer_name, adapted_weigths, add_pad_token, \n\u001b[1;32m      2\u001b[0m                    ds, lora_rank, canaries_number, random_seeds)\n",
      "Cell \u001b[0;32mIn[126], line 73\u001b[0m, in \u001b[0;36mtrain_models\u001b[0;34m(model_name, tokenizer_name, adapted_weigths, add_pad_token, ds, lora_ranks, canaries_number, seeds)\u001b[0m\n\u001b[1;32m     57\u001b[0m trainer \u001b[38;5;241m=\u001b[39m transformers\u001b[38;5;241m.\u001b[39mTrainer(\n\u001b[1;32m     58\u001b[0m     model\u001b[38;5;241m=\u001b[39mmodel,\n\u001b[1;32m     59\u001b[0m     train_dataset\u001b[38;5;241m=\u001b[39mdata_tokenized[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mtrain\u001b[39m\u001b[38;5;124m\"\u001b[39m],\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m     70\u001b[0m     data_collator\u001b[38;5;241m=\u001b[39mtransformers\u001b[38;5;241m.\u001b[39mDataCollatorForLanguageModeling(tokenizer, mlm\u001b[38;5;241m=\u001b[39m\u001b[38;5;28;01mFalse\u001b[39;00m)\n\u001b[1;32m     71\u001b[0m )\n\u001b[1;32m     72\u001b[0m model\u001b[38;5;241m.\u001b[39mconfig\u001b[38;5;241m.\u001b[39muse_cache \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mFalse\u001b[39;00m  \u001b[38;5;66;03m# silence the warnings. Please re-enable for inference!\u001b[39;00m\n\u001b[0;32m---> 73\u001b[0m trainer\u001b[38;5;241m.\u001b[39mtrain()\n\u001b[1;32m     74\u001b[0m trainer\u001b[38;5;241m.\u001b[39msave_model(output_dir)\n",
      "File \u001b[0;32m~/miniconda3/envs/llm_extract_v2/lib/python3.11/site-packages/transformers/trainer.py:1938\u001b[0m, in \u001b[0;36mTrainer.train\u001b[0;34m(self, resume_from_checkpoint, trial, ignore_keys_for_eval, **kwargs)\u001b[0m\n\u001b[1;32m   1936\u001b[0m         hf_hub_utils\u001b[38;5;241m.\u001b[39menable_progress_bars()\n\u001b[1;32m   1937\u001b[0m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[0;32m-> 1938\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m inner_training_loop(\n\u001b[1;32m   1939\u001b[0m         args\u001b[38;5;241m=\u001b[39margs,\n\u001b[1;32m   1940\u001b[0m         resume_from_checkpoint\u001b[38;5;241m=\u001b[39mresume_from_checkpoint,\n\u001b[1;32m   1941\u001b[0m         trial\u001b[38;5;241m=\u001b[39mtrial,\n\u001b[1;32m   1942\u001b[0m         ignore_keys_for_eval\u001b[38;5;241m=\u001b[39mignore_keys_for_eval,\n\u001b[1;32m   1943\u001b[0m     )\n",
      "File \u001b[0;32m~/miniconda3/envs/llm_extract_v2/lib/python3.11/site-packages/transformers/trainer.py:2341\u001b[0m, in \u001b[0;36mTrainer._inner_training_loop\u001b[0;34m(self, batch_size, args, resume_from_checkpoint, trial, ignore_keys_for_eval)\u001b[0m\n\u001b[1;32m   2338\u001b[0m     \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[1;32m   2339\u001b[0m         grad_norm \u001b[38;5;241m=\u001b[39m _grad_norm\n\u001b[0;32m-> 2341\u001b[0m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39moptimizer\u001b[38;5;241m.\u001b[39mstep()\n\u001b[1;32m   2343\u001b[0m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mcontrol \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mcallback_handler\u001b[38;5;241m.\u001b[39mon_optimizer_step(args, \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mstate, \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mcontrol)\n\u001b[1;32m   2345\u001b[0m optimizer_was_run \u001b[38;5;241m=\u001b[39m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39maccelerator\u001b[38;5;241m.\u001b[39moptimizer_step_was_skipped\n",
      "File \u001b[0;32m~/miniconda3/envs/llm_extract_v2/lib/python3.11/site-packages/accelerate/optimizer.py:157\u001b[0m, in \u001b[0;36mAcceleratedOptimizer.step\u001b[0;34m(self, closure)\u001b[0m\n\u001b[1;32m    154\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mscaler \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[1;32m    155\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39moptimizer\u001b[38;5;241m.\u001b[39mstep \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_optimizer_patched_step_method\n\u001b[0;32m--> 157\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mscaler\u001b[38;5;241m.\u001b[39mstep(\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39moptimizer, closure)\n\u001b[1;32m    158\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mscaler\u001b[38;5;241m.\u001b[39mupdate()\n\u001b[1;32m    160\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_accelerate_step_called:\n\u001b[1;32m    161\u001b[0m         \u001b[38;5;66;03m# If the optimizer step was skipped, gradient overflow was detected.\u001b[39;00m\n",
      "File \u001b[0;32m~/miniconda3/envs/llm_extract_v2/lib/python3.11/site-packages/torch/amp/grad_scaler.py:453\u001b[0m, in \u001b[0;36mGradScaler.step\u001b[0;34m(self, optimizer, *args, **kwargs)\u001b[0m\n\u001b[1;32m    447\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39munscale_(optimizer)\n\u001b[1;32m    449\u001b[0m \u001b[38;5;28;01massert\u001b[39;00m (\n\u001b[1;32m    450\u001b[0m     \u001b[38;5;28mlen\u001b[39m(optimizer_state[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mfound_inf_per_device\u001b[39m\u001b[38;5;124m\"\u001b[39m]) \u001b[38;5;241m>\u001b[39m \u001b[38;5;241m0\u001b[39m\n\u001b[1;32m    451\u001b[0m ), \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mNo inf checks were recorded for this optimizer.\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m--> 453\u001b[0m retval \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_maybe_opt_step(optimizer, optimizer_state, \u001b[38;5;241m*\u001b[39margs, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n\u001b[1;32m    455\u001b[0m optimizer_state[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mstage\u001b[39m\u001b[38;5;124m\"\u001b[39m] \u001b[38;5;241m=\u001b[39m OptState\u001b[38;5;241m.\u001b[39mSTEPPED\n\u001b[1;32m    457\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m retval\n",
      "File \u001b[0;32m~/miniconda3/envs/llm_extract_v2/lib/python3.11/site-packages/torch/amp/grad_scaler.py:350\u001b[0m, in \u001b[0;36mGradScaler._maybe_opt_step\u001b[0;34m(self, optimizer, optimizer_state, *args, **kwargs)\u001b[0m\n\u001b[1;32m    342\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21m_maybe_opt_step\u001b[39m(\n\u001b[1;32m    343\u001b[0m     \u001b[38;5;28mself\u001b[39m,\n\u001b[1;32m    344\u001b[0m     optimizer: torch\u001b[38;5;241m.\u001b[39moptim\u001b[38;5;241m.\u001b[39mOptimizer,\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    347\u001b[0m     \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs: Any,\n\u001b[1;32m    348\u001b[0m ) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m Optional[\u001b[38;5;28mfloat\u001b[39m]:\n\u001b[1;32m    349\u001b[0m     retval: Optional[\u001b[38;5;28mfloat\u001b[39m] \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[0;32m--> 350\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28msum\u001b[39m(v\u001b[38;5;241m.\u001b[39mitem() \u001b[38;5;28;01mfor\u001b[39;00m v \u001b[38;5;129;01min\u001b[39;00m optimizer_state[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mfound_inf_per_device\u001b[39m\u001b[38;5;124m\"\u001b[39m]\u001b[38;5;241m.\u001b[39mvalues()):\n\u001b[1;32m    351\u001b[0m         retval \u001b[38;5;241m=\u001b[39m optimizer\u001b[38;5;241m.\u001b[39mstep(\u001b[38;5;241m*\u001b[39margs, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n\u001b[1;32m    352\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m retval\n",
      "File \u001b[0;32m~/miniconda3/envs/llm_extract_v2/lib/python3.11/site-packages/torch/amp/grad_scaler.py:350\u001b[0m, in \u001b[0;36m<genexpr>\u001b[0;34m(.0)\u001b[0m\n\u001b[1;32m    342\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21m_maybe_opt_step\u001b[39m(\n\u001b[1;32m    343\u001b[0m     \u001b[38;5;28mself\u001b[39m,\n\u001b[1;32m    344\u001b[0m     optimizer: torch\u001b[38;5;241m.\u001b[39moptim\u001b[38;5;241m.\u001b[39mOptimizer,\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    347\u001b[0m     \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs: Any,\n\u001b[1;32m    348\u001b[0m ) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m Optional[\u001b[38;5;28mfloat\u001b[39m]:\n\u001b[1;32m    349\u001b[0m     retval: Optional[\u001b[38;5;28mfloat\u001b[39m] \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[0;32m--> 350\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28msum\u001b[39m(v\u001b[38;5;241m.\u001b[39mitem() \u001b[38;5;28;01mfor\u001b[39;00m v \u001b[38;5;129;01min\u001b[39;00m optimizer_state[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mfound_inf_per_device\u001b[39m\u001b[38;5;124m\"\u001b[39m]\u001b[38;5;241m.\u001b[39mvalues()):\n\u001b[1;32m    351\u001b[0m         retval \u001b[38;5;241m=\u001b[39m optimizer\u001b[38;5;241m.\u001b[39mstep(\u001b[38;5;241m*\u001b[39margs, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n\u001b[1;32m    352\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m retval\n",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m: "
     ]
    }
   ],
   "source": [
    "train_models(model_name, tokenizer_name, adapted_weigths, add_pad_token, \n",
    "                   ds, lora_rank, canaries_number, random_seeds)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['OBJECTIVE: To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies of a diabetic patient who presented extensive lesions.',\n",
       " 'An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with valproate for epilepsy, especially if they develop menstrual cycle disturbances during treatment.',\n",
       " 'Phenobarbital hepatotoxicity in an 8-month-old infant.',\n",
       " 'The authors report a case of Balint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and cytarabine.',\n",
       " \"According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine.\",\n",
       " 'Contact dermatitis due to budesonide: report of five cases and review of the Japanese literature.',\n",
       " 'Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine.',\n",
       " 'We report three cases of severe hepatotoxicity related to benzarone, a benzofuran derivative.',\n",
       " 'Four patients who manifested symptoms of the antiepileptic drug (AED) hypersensitivity syndrome during therapy with carbamazepine are reported.',\n",
       " 'Minocycline as a cause of drug-induced autoimmune hepatitis.',\n",
       " 'Secondary acute myeloid leukemia after etoposide therapy for haemophagocytic lymphohistiocytosis.',\n",
       " 'Allergic contact angioedema to benzoyl peroxide.',\n",
       " 'A 60-year-old white man with chronic bronchitis was noted to develop acute respiratory failure and metabolic acidosis four days after being started on methazolamide (Neptazane) for an ophthalmologic problem.',\n",
       " 'L-DOPA-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment.',\n",
       " 'CONCLUSIONS: It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient.',\n",
       " 'Acute drug induced hepatitis due to erlotinib.',\n",
       " 'We observed 3 diabetic patients with intolerable dizziness followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, voglibose.',\n",
       " 'Although risk factors for MTX-induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account for a predisposition to the development of MTX pneumonitis.',\n",
       " 'Acute esmolol toxicity may be self-limiting because of its extremely short half-life.',\n",
       " 'The association with prolonged unopposed estrogen-like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed.',\n",
       " 'The other woman had rheumatoid arthritis and developed acute tubular necrosis after treatment with gentamicin and cefoxitin.',\n",
       " 'One patient who received clindamycin had liver biopsy findings of marked cholestasis, portal inflammation, bile duct injury and bile duct paucity (ductopenia).',\n",
       " 'A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between flecainide, a CYP2D6 substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium.',\n",
       " 'As these cases revealed, close monitoring of blood chemistry is mandatory after starting spironolactone, and patients should be advised to stop spironolactone immediately if diarrhoea develops.',\n",
       " 'When these cells are exposed to nicotinic acid, an exaggerated immune response is produced that may lead to pain, redness, and swelling at the injection site.',\n",
       " 'A case of heatstroke is reported in a 32-year-old man diagnosed with schizophrenia and on clozapine monotherapy.',\n",
       " 'Paraplegia following intrathecal cytosine arabinoside.',\n",
       " 'Cimetidine-induced fever.',\n",
       " 'This case report illustrates the neurotoxicity unique to HDARAC.',\n",
       " 'Agranulocytosis associated with ticlopidine: a possible benefit with filgastim.',\n",
       " 'Since SS is a clinical diagnosis, heightened clinician awareness of the possibility of SS among patients receiving SSRI or mirtazapine in combination with opioids may lead to earlier detection and avoidance of potentially lethal consequences.',\n",
       " 'The mechanism by which sunitinib induces gynaecomastia is thought to be associated with an unknown direct action on breast hormonal receptors.',\n",
       " 'Some patients develop hypersensitivity rash in response to HCQ.',\n",
       " 'To report a case of serotonin toxicity, presenting in the postoperative period, caused by an interaction between paroxetine (a selective serotonin reuptake inhibitor, SSRI) and fentanyl (a phenylpiperidine opioid).',\n",
       " 'However, to our knowledge, in newborns there have been no reported cases to date of thrombocytosis induced by enoxaparin.',\n",
       " 'The case presented here documents adverse cardiac effects in a 28-year-old man who intentionally ingested 24 mg of risperidone--4 times the recommended dose.',\n",
       " 'Anaphylaxis to cisplatin following nine previous uncomplicated cycles.',\n",
       " \"To the best of the authors' knowledge, this is the first reported case of Propecia-associated cataract.\",\n",
       " 'Serotonin syndrome caused by interaction between citalopram and fentanyl.',\n",
       " 'We report on three observations of parkinsonian patients with levo-dopa-induced diphasic dyskinesias, who received subcutaneous apomorphine to reduce the duration of abnormal movements.',\n",
       " 'This report presents a case of acute lung injury developing within hours after administration of mefloquine for a low-level Plasmodium falciparum malaria, which was persistent despite halofantrine therapy.',\n",
       " \"Warfarin-associated bleeding generally is considered deleterious; however, in our patient it unmasked an early stage of colon cancer and thus may have saved the patient's life.\",\n",
       " 'The clinical use of itraconazole in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid-associated adverse effects.',\n",
       " 'Three cases of gold-related neuropathy are reported.',\n",
       " \"We report the case of a man, treated with mesalazine for Crohn's disease who developed drug-induced pericarditis.\",\n",
       " 'We report the occurrence of spontaneous intracranial bleeding in an human immunodeficiency virus (HIV)-infected adolescent with hemophilia A who was receiving amprenavir (APV).',\n",
       " 'Under the suspicion of amiodarone-induced acute pancreatitis, amiodarone was substituted by propafenone.',\n",
       " 'Evidence is shown in this report that adenosine was associated with dangerous worsening of arrhythmia in patients with atrial flutter.',\n",
       " 'Salicylate hepato toxicity in rheumatic fever.',\n",
       " 'A case of serotonin syndrome that developed during concurrent linezolid and fluoxetine is presented.',\n",
       " 'Herein we report four patients who underwent liver transplantation and developed neutropenia while receiving MMF.',\n",
       " \"A study of in vitro reactivity to L-T4, as assessed by peripheral blood lymphocyte transformation, was carried out in a patient with Hashimoto's disease who developed leukopenia during treatment with L-T4.\",\n",
       " 'Methemoglobinemia is another common finding among patients receiving dapsone therapy, but rarely does it result in prominent symptoms other than transient pallor.',\n",
       " \"During the first treatment, dysarthria and ataxia were seen after completion of the patient's eighth and final dose of HDARAC.\",\n",
       " 'Four weeks earlier she had developed hepatopathy during a regimen of carbamazepine, lynestrenol and sodium valproate.',\n",
       " 'We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ.',\n",
       " 'We report here a rare case of pleuropericarditis due to methotrexate.',\n",
       " 'A case of phenytoin-induced hepatitis with mononucleosis is reported, and syndromes associated with phenytoin hypersensitivity reactions are discussed.',\n",
       " 'We also discuss whether screening for DPD deficiency is warranted to identify patients at risk for severe toxicities from 5-FU treatment.',\n",
       " 'We report a case of reversible encephalopathy syndrome in a 16-year-old girl with acute myelogenous leukemia (AML), who is undergoing during consolidation chemotherapy composed of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and idarubicin.',\n",
       " 'Concurrent use of vismodegib and warfarin was deemed the probable cause of acute INR elevation in this case, suggesting the need for close monitoring of INR values in patients receiving this combination of drugs.',\n",
       " 'Captopril is an angiotensin-converting enzyme (ACE) inhibitor and their cutaneous side-effects are documented, but little has been published concerning the usefulness of patch test when they occur.',\n",
       " \"High-dose methylprednisolone in a pregnant woman with Crohn's disease and adrenal suppression in her newborn.\",\n",
       " 'Cardiac hypersensitivity and myopericarditis have been reported during long-term treatment with mesalazine.',\n",
       " \"It is concluded that 'cerebral atrophy' on CT scans may represent an accumulative effect of ACTH and that ACTH should be given with the utmost discretion, and in as low a dose as possible.\",\n",
       " 'Two cases of polymorphic ventricular tachycardia induced by the administration of verapamil against paroxysmal supraventricular tachycardia.',\n",
       " 'Fatal acute encephalomyelitis after a single dose of intrathecal methotrexate.',\n",
       " 'The authors report one case of incomplete posterior hyaloid detachment (PHD) following intravitreal pegaptanib to treat DME.',\n",
       " 'Pulmonary edema as a delayed complication of ritodrine therapy.',\n",
       " 'Carbamazepine toxicity following Oxybutynin and Dantrolene administration: a case report.',\n",
       " 'Multiple seizures after bupropion overdose in a small child.',\n",
       " 'Sorafenib, a multitargeted kinase inhibitor used for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinomas, received FDA approval in 2005.',\n",
       " 'Triiodothyronine-induced thyrotoxicosis in ophthalmic Graves disease.',\n",
       " 'Bleomycin induced hyperpigmentation with yolk sac tumor.',\n",
       " 'PURPOSE: To describe bilateral corneal endothelial dysfunction in a patient with Parkinson disease who was treated with long-term amantadine.',\n",
       " 'A case of severe acute hepatitis caused by cyproterone acetate in a 71 year old man with prostatic carcinoma is reported with a review of the literature on hepatic reactions to this drug.',\n",
       " 'Insulin-dependent diabetes mellitus associated with danazol.',\n",
       " 'CONCLUSIONS: Topical brimonidine may be associated with central nervous system depression in infants.',\n",
       " 'Flecainide-associated pneumonitis with acute respiratory failure in a patient with the LEOPARD syndrome.',\n",
       " 'Seizure with hyponatremia in a child prescribed desmopressin for nocturnal enuresis.',\n",
       " 'Risks and benefits of co-treatment should be carefully considered and therapeutic alternatives to NSAIDs should be recommended to patients with central DI in order to improve DDAVP safety.',\n",
       " 'She had been treated by Carbamazepine 1000 mg/day for neuropathic pain for 2 years without clinical or laboratory signs of toxicity.',\n",
       " 'The chemotherapeutics, including vincristine, actinomycin D, and epirubicin in case 1 and vincristine and actinomycin D in case 2, were given before the hepatotoxicity developed.',\n",
       " 'After a second dose of metoclopramide, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, tachycardia, and hypertension.',\n",
       " 'We report the first case of tuberculous uveitis due to etanercept.',\n",
       " 'Acute hyperphosphatemia caused by sodium phosphate enema in a patient with liver dysfunction and chronic renal failure.',\n",
       " 'We discuss the association between carbamazepine and hyponatremia and the causes of hyponatremia after cardiopulmonary bypass.',\n",
       " 'Use of the Naranjo adverse drug reaction probability algorithm indicated a probable relationship between serotonin syndrome and treatment with lithium and venlafaxine.',\n",
       " 'The exact mechanism of IVIG-associated acute renal failure remains unclear.',\n",
       " 'We report on 7 patients (2 women, 5 men) with chronic renal failure, who developed under a high dosage of the new diuretic muzolimine (range 240 to 1440 mg per day) fatal neuromyeloencephalopathy.',\n",
       " 'Two renal transplant patients developed anemia during treatment of hypertension with enalapril medication.',\n",
       " 'Sotalol-induced bradycardia reversed by glucagon.',\n",
       " 'The development of cutaneous ecchymosis associated with a sudden fall in hemoglobin after the administration of alteplase should strongly suggest the possibility of diffuse subfascial hematoma.',\n",
       " 'We report a case of papillary necrosis in a patient treated with indinavir.',\n",
       " 'Generalized maculopapular and papular purpuric eruptions are perhaps the most common thionamide-induced reactions.',\n",
       " 'Imidazoline intoxication due to overdose or accidental ingestion but also after normal therapeutic usage is frequent in children.',\n",
       " 'A 50-year-old diabetic and hypertensive male patient is reported who had ticlopidine-induced marrow aplasia partially responsive to colony-stimulating factors and corticosteroids, but experienced complete recovery with cyclosporine.',\n",
       " 'A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma developed fatal cerebral edema and brainstem herniation after she received a single dose of intravenous methotrexate.',\n",
       " 'Neutropenia is an infrequent complication following administration of the angiotensin-converting enzyme (ACE) inhibitor, captopril.',\n",
       " 'INTRODUCTION: We describe the neurointensive care (NIC) management of a patient with severe cerebral swelling and raised intracranial pressure (ICP) after severe sodium valproic acid (VPA) intoxication.',\n",
       " 'Lithium therapy was discontinued because of poor compliance to the medication and intolerable polyuria.',\n",
       " 'Both PAN and methotrexate have been independently demonstrated to cause sensorineural hearing loss.',\n",
       " 'CONCLUSION: A 26-year-old man with bipolar disorder developed hyperammonemia three weeks after initiating carbamazepine therapy.',\n",
       " 'We report two adults who received gabapentin (GBP) and subsequently developed behavioural side effects.',\n",
       " 'Atrial fibrillation was induced by diltiazem in two patients and verapamil induced syncope in one patient.',\n",
       " 'We can conclude that in this case, as in many others, akathisia as a possible adverse effect of psychopharmacs was very hard to identify.',\n",
       " \"Although HAART is very important in the treatment of HIV, its side effects are responsible for patients' non-adherence to medications.\",\n",
       " 'A case of acute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic aspirin therapy is presented.',\n",
       " 'Long known to psychiatrists, monoamine oxidase inhibitors (MAOIs) and complications of their use may be unfamiliar to medical and surgical practitioners who may thus unwittingly precipitate a hypertensive crisis or serotonin syndrome.',\n",
       " 'According to the Naranjo adverse drug reaction probability scale, the likelihood that temozolomide was responsible for the adverse drug reaction of fever was probable (score of 6).',\n",
       " 'OBJECTIVE: To describe the development of valproate-related reproductive endocrine disorders in women with epilepsy.',\n",
       " 'Alprazolam-induced mania: two clinical cases.',\n",
       " 'Bronchiolitis obliterans organising pneumonia associated with the use of nitrofurantoin.',\n",
       " 'To our knowledge, this recurrence of amiodarone pulmonary toxicity has not been reported previously.',\n",
       " 'A patient treated with itraconazole (ITCZ) under the diagnosis of Aspergillus flavus-induced chronic hypertrophic pachymeningitis is presented.',\n",
       " 'Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder.',\n",
       " 'The renal consequences of indinavir-associated nephrotoxicity are uncertain.',\n",
       " 'BACKGROUND: reports on delated cutaneous reactions to captopril have been seldom reported.',\n",
       " 'Bismuth subsalicylate 30 mL every 4 hours was prescribed for diarrhea.',\n",
       " 'A drug interaction between the alpha(2)-adrenergic agonist medetomidine and lignocaine is suspected and highlights the potential for seizures following the subcutaneous administration of relatively large doses of lignocaine under medetomidine sedation.',\n",
       " 'Oesophageal ulceration due to emepronium bromide.',\n",
       " 'Development of sarcoidosis during interferon alpha 2b and ribavirin combination therapy for chronic hepatitis C--a case report and review of the literature.',\n",
       " 'CONCLUSION: The findings in these two patients suggest that colchicine may delay corneal wound healing.',\n",
       " 'Gemcitabine-associated hemolytic-uremic syndrome.',\n",
       " 'Case study: adverse response to clonidine.',\n",
       " 'In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of cyclosporin, prednisone and azathioprine, developed thrombosis of the central retinal vein 5 years following the transplantation.',\n",
       " 'In each of the three reported patients, alteration of eyelid appearance with deepening of the lid sulcus was evident as the result of topical bimatoprost therapy.',\n",
       " 'PURPOSE: To report a case of traumatic flap dehiscence and Enterobacter keratitis 34 months after LASIK.',\n",
       " 'CONCLUSIONS: The risk of drug-induced rhabdomyolysis due to the potential interaction between lovastatin and azithromycin or clarithromycin should be considered before the concomitant use of these agents.',\n",
       " 'Ten years of behavioral data are presented to support the hypothesis that phenobarbital was exacerbating maladaptive behaviors.',\n",
       " 'Terbinafine-induced cholestatic liver disease.',\n",
       " 'The proteasome inhibitor Bortezomib has been identified as a potent enhancer of TRAIL-induced apoptosis in several human cancers.',\n",
       " 'METHODS: A retrospective report of the first case of gemcitabine-related HUS, in a patient with metastatic pancreatic adenocarcinoma, treated with a variety of standard therapies in addition to rituximab is presented.',\n",
       " 'Their parkinsonism improved on discontinuation of metoclopramide therapy.',\n",
       " 'Lichen planus induced by hepatitis B vaccination: a new case and review of the literature.',\n",
       " 'A total of 40 healthy volunteers were planned to start with 600 mg rifampicin once daily from days 1-5.',\n",
       " 'Skin necrosis secondary to low-molecular weight heparin in a patient with antiphospholipid antibody syndrome.',\n",
       " 'Exacerbation of anthracycline-induced early chronic cardiomyopathy with ATRA: role of B-type natriuretic peptide as an indicator of cardiac dysfunction.',\n",
       " 'Fixed drug eruption in hands caused by omeprazole.',\n",
       " 'FK506, which began to be administered 12 days earlier, rose to a level of 44 ng/mL (normal range, 10-20 ng/mL) 1 day before neurologic abnormalities began.',\n",
       " \"Sweet's syndrome is an acute febrile neutrophilic dermatosis that is a known complication of the administration of filgrastim, a drug that causes increased neutrophil proliferation and differentiation.\",\n",
       " 'Although it would be expected that, like other type IA toxicities, diphenhydramine-induced cardiotoxicity could be responsive to hypertonic sodium bicarbonate, this finding is largely unappreciated.',\n",
       " 'We describe a patient who experienced chronic nausea and an episode of confusion while treated with a small, stable dose of oral morphine in the setting of mild renal insufficiency.',\n",
       " 'Bulbar and pseudobulbar palsy complicating therapy with high-dose cytosine arabinoside in children with leukemia.',\n",
       " 'The development of erythroid leukemia plus carcinoma in these two men suggests mutagenic change secondary to cyclophosphamide therapy.',\n",
       " 'Administration of thiazide diuretics also has been the cause of hyponatremia.',\n",
       " 'Serotonin syndrome is a potentially lethal adverse drug reaction that may occur in patients taking proserotoninergic medications.',\n",
       " 'However, there remain questions concerning whether these drugs, especially methimazole (MMI), may be associated with aplasia cutis congenita (ACC) and how best to avoid impairment of fetal thyroid function during their use.',\n",
       " 'An 18-year-old man with attention-deficit-hyperactivity disorder (ADHD) was prescribed varenicline for smoking cessation.',\n",
       " 'The condition should be suspected in patients who develop unexplained abdominal pain or collapse following vasopressin treatment.',\n",
       " 'The present observation suggests, that a batch of different testing doses, including lower testing doses may help to differentiate between an allergic type of contact dermatitis and an irritant type of reaction after treatment with calcipotriol.',\n",
       " 'Acute erythroid leukemia after cyclophosphamide therapy for multiple myeloma: report of two cases.',\n",
       " 'A combination of behavioural and cognitive adverse effects is illustrated in this case report of a recurrent triazolam-induced eating disorder.',\n",
       " '5-fluorouracil (5-FU)-associated peripheral neuropathy is an uncommon event.',\n",
       " 'Insulin-induced lipoatrophy in type I diabetes.',\n",
       " 'This article describes a patient with suspected ciprofloxacin-induced interstitial nephritis.',\n",
       " 'We report 3 cases of HIV-1 infected patients who experienced symptomatic angiolipomas shortly after starting antiretroviral therapy including the protease inhibitor indinavir.',\n",
       " 'Depressive symptoms disappeared after interferon therapy was stopped.',\n",
       " 'Coumarin is reported to elevate liver function tests (LFT) values.',\n",
       " 'Decreased plasma cortisol level during alprazolam treatment of panic disorder: a case report.',\n",
       " 'Severe diffuse interstitial pneumonitis induced by carmustine (BCNU).',\n",
       " 'Fever, pulmonary infiltrates, and pleural effusion following acyclovir therapy for herpes zoster ophthalmicus.',\n",
       " 'We propose a mechanism of vancomycin-induced mast cell degranulation and subsequent release of eosinophil chemotactic factor as a cause of CSFE.',\n",
       " 'Within 3 weeks of beginning continuous daily isoniazid and rifampin therapy for pulmonary tuberculosis, a patient developed acute renal failure.',\n",
       " 'We report four cases of severe corneal ulceration in methamphetamine abusers.',\n",
       " 'Diagnosis: practolol induced sclerosing peritonitis.',\n",
       " 'We report the first biopsy confirmed occurrence of acute interstitial nephritis in a patient receiving treatment with Sunitinib for metastatic renal cell cancer.',\n",
       " 'Multiple pulmonary nodules: an unusual presentation of fludarabine pulmonary toxicity: case report and review of literature.',\n",
       " 'Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug.',\n",
       " 'Recently, her serum theophylline levels had increased to the toxic range (133.2 micromol/L [24 microg/mL]) shortly after the addition of zafirlukast (Accolate, Zeneca Pharmaceuticals, Wilmington, Del) to her regimen.',\n",
       " 'Withdrawal emergent syndrome in an infant associated with maternal haloperidol therapy.',\n",
       " 'Diphenylhydantoin apparently adversely affected both the clinical and biochemical parameters of the acute intermittent porphyria.',\n",
       " 'Successful recovery from interstitial pneumonitis, induced by bicalutamide and leuprorelin acetate given as treatment for prostate cancer.',\n",
       " 'Gold-induced pneumonitis.',\n",
       " 'OBJECTIVE: To report a case of significant hepatic and renal failure with the use of argatroban in a patient with heparin-induced thrombocytopenia (HIT) requiring continuous veno-veno hemodialysis (CVVHD).',\n",
       " 'Visceral leishmaniasis and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with adalimumab.',\n",
       " 'He was diagnosed with possible serotonin syndrome; his symptoms resolved after clomipramine was stopped but before clozapine was restarted eight days later.',\n",
       " 'Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura.',\n",
       " 'Two patients had ampicillin-associated seizures.',\n",
       " 'A patient developed restless legs symptoms paralleling the course of interferon-alpha (IFN alpha) therapy for chronic hepatitis C.',\n",
       " 'While many can benefit from coadministration of serotonergic antidepressants and opioids, it appears that some individuals are at increased risk for SS.',\n",
       " 'Stomatitis, diarrhea, dermatitis, and myelosuppression are the main toxicities of 5-FU.',\n",
       " 'After treatment with cimetidine, there was a rapid deterioration with decreased oxygen saturation and arterial PO2 values.',\n",
       " 'We describe a case of advanced ovarian carcinoma who developed difficulty walking because of marked pain in the lower extremities and loss of proprioception 25 days after treatment with weekly taxol (80 mg/m(2)x3).',\n",
       " 'Agranulocytosis and granulocytopenia associated with quetiapine.',\n",
       " 'The multiple comedones and ruptured epidermoid cysts are newly reported adverse effects of imiquimod therapy.',\n",
       " 'We conclude that neurosurgeons and neurologists should be aware of calcium antagonist--related ileus in patients treated with nimodipine.',\n",
       " 'Hyperpigmentation during interferon-alpha therapy for chronic hepatitis C virus infection.',\n",
       " 'Chlorambucil-induced chromosome damage to human lymphocytes is dose-dependent and cumulative.',\n",
       " 'Carbamazepine hypersensitivity syndrome is a rare, life-threatening condition.',\n",
       " 'Case report: dapsone hypersensitivity syndrome associated with treatment of the bite of a brown recluse spider.',\n",
       " 'Acute asymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and artesunate.',\n",
       " 'The authors report a case of focal myocardial necrosis, presenting clinically as an acute myocardial infarction during the administration of the antineoplastic drug, amsacrine, in a patient without coronary artery disease.',\n",
       " 'Baclofen and oxazepam were prescribed secondary to right-sided hemiparesis contractures.',\n",
       " 'DISCUSSION: A review of the cases of SS with implication of mirtazapine as the cause was performed.',\n",
       " 'A small number of oxaliplatin-related hemolytic and/or thrombocytopenic reactions have been reported.',\n",
       " 'CASE SUMMARY: A 39-year-old white Jewish schizophrenic man treated with olanzapine developed an elevated serum CK concentration with a peak concentration of 4000 IU/L (normal < 230).',\n",
       " 'Severe water intoxication secondary to the concomitant intake of non-steroidal anti-inflammatory drugs and desmopressin: a case report and review of the literature.',\n",
       " 'An apparent link is described between the use of MMF with prednisone to treat pemphigus vulgaris and the development of red blood cell anemia.',\n",
       " 'Other potential causes of renal failure were not present in our patient and his renal function gradually recovered with the cessation of suramin treatment.',\n",
       " 'Massive CBZ OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a profound burst-suppression EEG pattern, and cranial nerve areflexia.',\n",
       " 'This is the first report of a fluoxetine-related death in a child with a confirmed genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism.',\n",
       " 'We report a case of reversible DKA and new-onset DM that developed in a demented patient who was treated with quetiapine for 14 days.',\n",
       " 'We describe 3 cases of diphenhydramine-induced cardiac toxicity that were responsive to bicarbonate.',\n",
       " \"The patient's arthritis flared after the second infusion of infliximab, which was discontinued.\",\n",
       " 'CONCLUSION: Marked visual field constriction appears to be associated with vigabatrin therapy.',\n",
       " 'Possible serotonin syndrome associated with clomipramine after withdrawal of clozapine.',\n",
       " 'A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; Tegretol) used against benign Rolandic epilepsy.',\n",
       " 'There was a clear relationship between restarting the Accutane and recurrence of the transient myopia.',\n",
       " \"Graves' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C.\",\n",
       " 'Masculinization of a female fetus occurred in 5 of 39 (12.8%) exposed to norethisterone; all were cases of clitoral hypertrophy not requiring surgical treatment.',\n",
       " 'She continued taking verapamil for 6 months, then, on her own, stopped all medications including the sustained-release verapamil, and her asthma symptoms disappeared.',\n",
       " 'Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.',\n",
       " 'CONCLUSION: There are only a few confirmed cases of gemcitabine-associated HUS despite the widespread use of the drug.',\n",
       " 'In these patients, long-acting octreotide may trigger serious hypoglycemia.',\n",
       " 'Usefulness of antiplatelet drugs in the management of heparin-associated thrombocytopenia and thrombosis.',\n",
       " 'An intertrigo-like eruption from pegylated liposomal doxorubicin.',\n",
       " 'We report a case of NEH masquerading as cutaneous vasculitis in a woman receiving cyclophosphamide for lupus nephritis.',\n",
       " 'The diagnosis of hypothermia was delayed until it was apparent for several days but resolved with the discontinuation of risperidone and continuation of clozapine.',\n",
       " 'Unaccountable severe hypercalcemia in a patient treated for hypoparathyroidism with dihydrotachysterol.',\n",
       " 'Anaphylaxis to calcitonin.',\n",
       " 'However, he developed acute renal failure, hyperkalemia, and hyperuricemia 30 d after receiving the sorafenib treatment.',\n",
       " \"Mycobacterium marinum infection complicating Crohn's disease, treated with infliximab.\",\n",
       " 'Current immunosuppressive therapies are effective but can be associated with significant adverse reactions.',\n",
       " 'This report describes the first association (exclusive of drug overdose) of symptomatic torsades de pointes occurring with the use of terfenadine in a patient who was taking the recommended prescribed dose of this drug in addition to cefaclor, ketoconazole, and medroxyprogesterone.',\n",
       " 'Tamoxifen is suggested to be carcinogenic both through direct genotoxic and epigenetic mechanisms.',\n",
       " 'DISCUSSION: Colchicine, the most important drug in treatment of FMF, can cause myopathy in patients with impaired renal and hepatic function.',\n",
       " 'In the presented case fluvoxamine-induced akathisia in an OCD patient was partially resistant to the anticholinergic agent biperiden, and was successfully treated with the 5-HT2A/5-HT2C antagonist mianserin.',\n",
       " 'SUBSEQUENT COURSE: The nephrosis resolved almost completely once the interferon was stopped and after immunosuppressive treatment.',\n",
       " 'In two patients, apomorphine remained effective in the morning, but increased the intensity of the dyskinesias in the afternoon.',\n",
       " 'Transient asymptomatic bradycardia in patients on infusional 5-fluorouracil.',\n",
       " 'In 2006, he was diagnosed with deep vein thrombosis and pulmonary embolism and was started on warfarin.',\n",
       " 'Scleritis complicating zoledronic acid infusion.',\n",
       " 'A 22-year-old black man developed fever, chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting minocycline therapy for acne.',\n",
       " 'Ticlopidine-induced aplastic anemia: two new case reports, review, and meta-analysis of 55 additional cases.',\n",
       " 'This is the second report of acute lung injury and diffuse alveolar damage caused by mefloquine.',\n",
       " 'A case of Erythema Multiforme Bullosum in patient of lepromatous leprosy with pulmonary tuberculosis due to Rifampicin is described.',\n",
       " 'Life-threatening alterations in heart rate after the use of adenosine in atrial flutter.',\n",
       " \"We report a case of pancytopenia in a 23-year-old man with Crohn's disease who was treated with 5-aminosalicylic acid (Pentasa; Nisshin, Tokyo, Japan) 3.0 g/day.\",\n",
       " 'The ampicillin rash occurring in cases of infectious mononucleosis is well documented.',\n",
       " 'The major side effect of infliximab is infection.',\n",
       " 'An asymptomatic HIV-infected woman experienced right-sided renal colicky pain during treatment with indinavir.',\n",
       " \"The case resembles two previously reported cases of optic neuropathy which occurred in patients with Wilson's disease who were receiving penicillamine.\",\n",
       " 'Cutaneous ulceration: an unusual complication of intravenous pentamidine therapy.',\n",
       " 'Pulmonary hemorrhage is an uncommon feature in the HUS, and seems to appear especially in the HUS associated with MMC therapy.',\n",
       " 'Immunosuppression elicited by the extensive administration of prednisolone was suspected for the initiation of the generalized mite infestation.',\n",
       " 'The episode appeared to have been precipitated by toxicity due to ingestion of a large amount of phenytoin.',\n",
       " 'Cardiopulmonary arrest following intravenous phenytoin loading.',\n",
       " 'Although taxol has shown significant activity in advanced ovarian cancer, peripheral neuropathy is likely to become the major dose-limiting toxicity.',\n",
       " 'Syringotropic hypersensitivity reaction associated with infliximab and leflunomide combination therapy in a child with psoriatic arthritis.',\n",
       " 'Corticosteroid therapy was continued for 8 months since there was still improvement of pulmonary function studies.',\n",
       " 'OBJECTIVE: To describe a case of sertraline-induced rhabdomyolysis in an elderly patient with dementia and comorbidities.',\n",
       " 'Beyond the predictable pharmacokinetic drug-drug interaction requiring a significant warfarin dose reduction, the iodine-rich amiodarone affects the thyroid gland, causing overt hypothyroidism or thyrotoxicosis in 14%-18% of cases.',\n",
       " 'Toxic epidermal necrolysis associated with interleukin-2.',\n",
       " 'The pulmonary toxicity of gold salts is an uncommon cause of life-threatening respiratory failure.',\n",
       " 'With its characteristics, tizanidine has the potential to compromise hemodynamic stability during concomitant angiotensin-converting enzyme inhibitor use.',\n",
       " 'Premature closure of the ductus arteriosus: variable response among monozygotic twins after in utero exposure to indomethacin.',\n",
       " 'Possible mechanisms by which clonidine decreases spasticity are described, probable mechanisms of induced bradycardia are reviewed, and specific treatment recommendations for the use of clonidine in spinal cord injured patients are presented.',\n",
       " 'This is the first report of a possible association between an acute cardiovascular event and venlafaxine.',\n",
       " 'Since early symptoms of the toxic effects of theophylline can mimic peptic ulcer disease, cimetidine might be prescribed for the gastrointestinal symptoms with subsequent worsening of theophylline poisoning.',\n",
       " 'Acute renal failure in a patient receiving treatment with suramin.',\n",
       " 'A further case of anaphylactoid reaction to methylprednisolone is reported.',\n",
       " 'Pulmonary hemorrhage as a clinical manifestation of hemolytic-uremic syndrome associated with mitomycin C therapy.',\n",
       " 'EEG abnormalities were observed in two of the nine children during chlorambucil therapy.',\n",
       " 'Discontinuation of the itraconazole caused resolution of the drug eruption.',\n",
       " 'The addition of intrathecal methotrexate to treatment protocols has increased survival rates in children with acute lymphoblastic leukemia but is also associated with varying degrees of neurotoxicity.',\n",
       " 'We conclude that the presence of this metabolic defect combined with topical 5-FU (a drug demonstrating a narrow therapeutic index) results in the unusual presentation of life-threatening toxicity after treatment with a topical drug.',\n",
       " 'Six patients with rheumatoid arthritis developed a syndrome resembling lupus erythematosus while being treated with penicillamine.',\n",
       " 'This case highlights the need to monitor liver enzymes in patients treated with 6-TG and identifies the need for additional research focused on the mechanism of thiopurine-induced hepatic injury.',\n",
       " 'During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.',\n",
       " '5-Fluorouracil (5-FU) is an analogue of pyrimidine nucleosides that is widely used in the treatment of head and neck, breast, ovarian, and colon cancer.',\n",
       " 'Fulminant fatal cardiotoxicity following cyclophosphamide therapy.',\n",
       " 'The reaction in our patient appeared after tizanidine initiation and improved after both lisinopril and tizanidine were discontinued.',\n",
       " 'We describe the exceptional development of AML and lung cancer in a patient with previously diagnosed CLL in minimal residual disease status after fludarabine treatment followed by autologous peripheral blood stem-cell transplantation.',\n",
       " 'Valproate-induced hyperammonemia as a cause of altered mental status.',\n",
       " 'We report 5 cases of acute reversible renal failure coinciding with the onset of treatment with captopril in patients with severe drug-resistant hypertension.',\n",
       " 'We report a case of contact dermatitis due to sodium bisulfite in Tathion eye drops.',\n",
       " 'The first patient is undergoing hemodialysis and, though responding to sunitinib, is having significant fatigue and hypertension.',\n",
       " 'CCBs should be considered in the treatment of 5-FU or capecitabine-induced headaches.',\n",
       " 'Furosemide, spironolactone, allopurinol, and hydroxyurea were considered possible causes of the reaction and were discontinued.',\n",
       " 'PATIENTS: One patient with mucositis secondary to chemotherapy.',\n",
       " 'A patient with monocular open-angle glaucoma had trichiasis, a condition associated with the use of a prostaglandin analog.',\n",
       " 'A 53-year-old African American male with HIV was prescribed warfarin 5 mg/day for 12 months after diagnosis of idiopathic deep vein thrombosis and bilateral pulmonary emboli (target INR 2.5 [range 2.0-3.0]).',\n",
       " 'After treatment with a beta-sympathomimetic drug (Partusisten) one fetus developed supraventricular tachycardia.',\n",
       " 'Serotonin syndrome developed in a patient taking concurrent linezolid and fluoxetine.',\n",
       " 'RESULTS: A male and a female patient with spasticity treated with intrathecal baclofen were recognized to have sexual dysfunction side effects from treatment.',\n",
       " 'OBJECTIVE: To describe a patient with ifosfamide-induced nonconvulsive status epilepticus.',\n",
       " 'Upper gastrointestinal haemorrhage is a serious complication of aspirin and clopidogrel (dual) anti-platelet therapy with a high morbidity and mortality.',\n",
       " 'Flecainide overdose can rapidly result in profound cardiovascular collapse, and is associated with a relatively high mortality.',\n",
       " 'Sulfasalazine-induced lupus erythematosus.',\n",
       " 'Reye syndrome (RS) is believed to occur infrequently among children receiving long-term aspirin therapy.',\n",
       " 'Propecia-associated bilateral cataract.',\n",
       " 'After 39 hours on argatroban, the infusion was stopped when minor bleeding was observed with a concurrent activated partial thromboplastin time (aPTT) of 100 seconds.',\n",
       " 'Anaphylactoid reaction to methylprednisolone pulsed therapy for multiple sclerosis.',\n",
       " 'Warfarin-induced skin necrosis and heparin-induced thrombocytopenia following mitral valve replacement for marantic endocarditis.',\n",
       " 'Surprisingly, we found that three patients appeared to develop tardive OGC while taking clozapine.',\n",
       " 'We report a fatal case of toxic epidermal necrolysis (TEN) resulting from a high dose of cytosine arabinoside (ARA-C).',\n",
       " 'On the fifth day after administration of a high dose of ARA-C (2 g/m2 intravenously every 12 hours), she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, sepsis, and death on the 22nd day.',\n",
       " 'We describe 2 patients with cutaneous lupus erythematosus who developed severe dapsone reaction after low dose therapy, with a fatal outcome in one.',\n",
       " 'A patient with ulcerative colitis developed skin pigmentation and diffuse pulmonary shadowing without respiratory symptomatology, while taking sulfasalazine.',\n",
       " 'This is a case report involving a patient who was treated with topical 5-FU cream and subsequently developed a severe case of angioedema.',\n",
       " 'Cessation of D-Pen and the start of corticosteroid therapy were followed by recovery from bicytopenia.',\n",
       " 'Prevention of infection by immunization, together with early recognition and prompt antiviral treatment are critical.',\n",
       " 'A case of normotensive scleroderma renal crisis after high-dose methylprednisolone treatment.',\n",
       " 'OBJECTIVES: A delayed stroke-like leukoencephalopathy has been observed in patients receiving methotrexate (MTX) for childhood leukemia.',\n",
       " 'Duloxetine-induced hyponatremia in an elderly patient treated with thiazide diuretics.',\n",
       " 'The following is a case report analysis intended to draw attention to the need for better care coordination by describing the observed relationship of olanzapine to metabolic changes manifested as uncontrolled diabetes mellitus and weight gain.',\n",
       " 'Arsenic trioxide has recently been introduced as a promising new agent to treat refractory acute promyelocytic leukemia (APL).',\n",
       " 'Although the t-AML developed following oral etoposide therapy, the child had previously received high-dose, multiagent chemotherapy, and rearrangement of the MLL gene was not demonstrated.',\n",
       " 'Heat stroke in schizophrenia during clozapine treatment: rapid recognition and management.',\n",
       " 'The same symptoms recurred few days after taking nitrendipine.',\n",
       " 'The authors report two cases of acute dystonic reactions (ADRs) as a side effect of lamivudine.',\n",
       " 'Isoniazid-induced anaphylaxis.',\n",
       " 'Histopathology of the thyroid in amiodarone-induced hypothyroidism.',\n",
       " 'Deepening of lid sulcus from topical bimatoprost therapy.',\n",
       " 'Gastro-oesophageal reflux associated with nifedipine.',\n",
       " 'CASE SUMMARY: A 68-year-old woman developed a dry, irritating cough within one month of starting quinapril therapy for the treatment of essential hypertension.',\n",
       " 'Sertraline-induced rhabdomyolysis in an elderly patient with dementia and comorbidities.',\n",
       " 'After the dose of methylprednisolone was reduced from 40 mg to 20 mg i.v. q6h and shifted to other anti-asthma treatment by procaterol metered dose inhaler via spacer, the psychotic reaction disappeared a few hours later.',\n",
       " 'Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus.',\n",
       " 'Patient was on warfarin for a prior deep venous thrombosis.',\n",
       " 'Quetiapine-induced myoclonus.',\n",
       " 'Dyspnea possibly associated with controlled-release morphine sulfate tablets.',\n",
       " 'The incidence of ARE suddenly exceeded 10% of the patients treated by melarsoprol during August 1992 and September 1993.',\n",
       " 'A patient with disseminated herpes zoster developed a syndrome of inappropriate antidiuretic hormone and profound hyponatremia secondary to the administration of adenine arabinoside.',\n",
       " 'One patient with systemic lupus erythematosus developed erythema multiforme after taking griseofulvin.',\n",
       " 'We report a rare case of colonic mucosal necrosis following Kalimate (calcium polystryrene sulfonate), an analogue of Kayexalate without sorbitol in a 34-yr-old man.',\n",
       " 'Bilateral anterior uveitis associated with clomiphene citrate.',\n",
       " 'Progressive anemia following combination therapy with interferon-alpha and interleukin-2 in a patient with metastatic renal cell carcinoma.',\n",
       " 'Metoclopramide-induced parkinsonism.',\n",
       " 'A 12 year old patient with atrial flutter is presented, in whom intravenous adenosine was followed by acceleration of the heart rate to a potentially dangerous arrhythmia.',\n",
       " 'Similar to reports in patients receiving gefitinib, those with pathologic findings of UIP on resected lung specimens or known pulmonary fibrosis may be at particular risk for erlotinib pulmonary toxicity.',\n",
       " 'Eleven days after increase of the trimipramine dosage to 100 mg/d, she was hospitalized because of seizures suggesting a secondary generalized grand-mal episode.',\n",
       " 'AIM: To report a patient with diabetic rubeosis who suffered from acute retinal ischemic change and stroke after intravitreal injection of bevacizumab.',\n",
       " 'Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine.',\n",
       " 'From these data, acute generalized dystonia with brainstem and thalamic lesions may occur in WD patients after an initial d-penicillamine therapy.',\n",
       " 'Although this combination agent has been associated with a hypersensitivity syndrome involving cutaneous skin eruptions, pediatric cases of TMP-SMX-induced hepatotoxicity are rare.',\n",
       " 'Drug resistant tuberculosis requires more complex and longer treatment with alternative substances.',\n",
       " 'Intracranial haemorrhage from a meningioma in a patient receiving aspirin prophylaxis: a case report.',\n",
       " 'The objective of this report is to describe a case of fixed drug eruption that occurred during omeprazole treatment.',\n",
       " 'Case 2: A 43-year-old male alcoholic remained completely abstinent with cyanamide treatment for 5 years and complained of general fatigue.',\n",
       " 'Delayed hypersensitivity to flurbiprofen.',\n",
       " 'Propafenone-induced ataxia: report of three cases.',\n",
       " 'Delavirdine and efavirenz (but not nevirapine) also were strong inhibitors of CYP3A, consistent with clinical hazards of initial cotreatment with either of these drugs and substrates of CYP3A.',\n",
       " 'This is the first report of UFT-induced scleroderma-like reaction.',\n",
       " 'Can roxithromycin and betamethasone induce acute pancreatitis? A case report.',\n",
       " 'Up to four percent of patients treated with imatinib may develop hepatotoxicity, which usually resolves with discontinuation of the drug.',\n",
       " 'Schneiderian first-rank symptoms associated with fluvoxamine treatment: a case report.',\n",
       " 'Peripheral and optic neuropathy was usually seen after several months of linezolid therapy (median 5 mo), lactic acidosis after several weeks (median 6 wks), and serotonin syndrome after several days (median 4 days).',\n",
       " 'Muzolimine-induced severe neuromyeloencephalopathy: report of seven cases.',\n",
       " 'We conclude peripheral neuropathy with 5-FU is rare.',\n",
       " 'Additionally, danazol produces hepatocellular damage in approximately 10% of women.',\n",
       " 'CONCLUSIONS: We report a typical symptoms of Charles-Bonnet syndrome (CBS) in patients with severe AMD after intravitreal Avastin-injections.',\n",
       " 'Proconvulsive tendency of imipenem/cilastatin is one of its well-known side effects.',\n",
       " \"A 49-year-old man with Crohn's disease treated with prednisone and mesalamine (5-ASA) developed worsening respiratory distress and fever.\",\n",
       " 'OBJECTIVE: This case report outlines a significant type of morbidity due to continued use of gabapentin during an episode of acute renal failure.',\n",
       " 'Acute delirium resulting from levofloxacin therapy is an exceedingly rare complication that has been thought to occur more commonly in elderly patients.',\n",
       " 'Selective estrogen receptor modulator raloxifene-associated aggravation of nonalcoholic steatohepatitis.',\n",
       " 'The day after methotrexate administration, the patient complained of severe back pain and urinary retention.',\n",
       " 'Pulmonary toxicity secondary to procarbazine.',\n",
       " 'In keeping with findings in the literature, the aortic wall in this case was damaged by secondary changes following irradiation and Bleomycin treatment.',\n",
       " 'It has been suggested that PPE caused by cytarabine does not recur with subsequent cytarabine re-challenge.',\n",
       " 'CONCLUSIONS: The value of multihormonal therapy in breast carcinoma is not established, and the addition of progestogens to tamoxifen may not reduce of developing endometrial lesions, including carcinoma.',\n",
       " 'Inappropriate antidiuretic hormone following adenine arabinoside administration.',\n",
       " 'Ampicillin-associated seizures.',\n",
       " 'We describe a case of fibrosing alveolitis, diagnosed by lung biopsy, in a patient receiving amiodarone which responded to corticosteroid therapy.',\n",
       " 'Furosemide-associated fever.',\n",
       " 'Thymic enlargement in a patient with juvenile idiopathic arthritis during etanercept therapy.',\n",
       " 'Fatal methylene blue associated serotonin toxicity.',\n",
       " 'Mannitol-induced ARF responds promptly to hemodialysis with rapid resolution of anuria and recovery of renal failure.',\n",
       " 'We report a rare case of recurrent (stuttering) priapism in a patient with protein C deficiency while maintained on Warfarin therapy.',\n",
       " 'Angioedema and maculopapular eruptions associated with carbamazepine administration.',\n",
       " 'Mental nerve neuropathy as a result of hepatitis B vaccination.',\n",
       " 'We describe a premenopausal woman who, while having tamoxifen due to a diagnosis of in situ ductal carcinoma, developed endometriosis requiring surgery.',\n",
       " 'Disseminated cellulitic cryptococcosis in the setting of prednisone monotherapy for pemphigus vulgaris.',\n",
       " 'We describe a 63 year old woman with a suppurative mediastinitis, treated with continuous PI irrigation who developed an acute oliguric renal failure.',\n",
       " 'A young woman with epilepsy had tonic-clonic seizures during antineoplastic therapy with adriamycin and cisplatin.',\n",
       " \"CONCLUSIONS: This patient's rhabdomyolysis was probably induced by sertraline therapy.\",\n",
       " 'Nephrotic syndrome in a multiple sclerosis patient treated with interferon beta 1a.',\n",
       " 'In our patient, DIAN possibly was related to cefuroxime, but the patient did not experience associated allergic symptoms.',\n",
       " 'We describe the case of a nonatopic 17-year-old girl with bronchial asthma and aspirin intolerance who developed a dramatic anaphylactic reaction to oral prednisone.',\n",
       " 'CASE SUMMARY: A 10-year-old white girl with bilateral optic glioma developed a hypersensitivity reaction to carboplatin after nine courses.',\n",
       " 'Liver function should be carefully monitored when rifampicin and lopinavir/ritonavir are combined in patients.',\n",
       " 'We report three patients, all of whom had preexisting diabetic dyslipidemia, who showed a profound reduction in plasma HDL cholesterol and apolipoprotein AI levels soon after the initiation of rosiglitazone therapy.',\n",
       " 'This finding suggests that fluvoxamine can precipitate Schneiderian first-rank symptoms in some susceptible patients.',\n",
       " 'Warfarin-associated thoracic aortic dissection in an elderly woman.',\n",
       " 'This is the first report of an adverse effect of fetal renal circulation by maternal ingestion of nimesulide.',\n",
       " 'Diarrhea-associated over-anticoagulation in a patient taking warfarin: therapeutic role of cholestyramine.',\n",
       " 'A 72-year-old white man suddenly developed combative behavior, refused to leave his room, stopped eating, and began falling to the floor 6 weeks after being given ticlopidine.',\n",
       " 'The case history confirms that gold treatment, even in the same patient, can give rise to a wide range of skin disturbances, which in many cases do not break out until long after the drug has been withdrawn.',\n",
       " 'Lithium neurotoxicity should be considered in Creutzfeldt-Jakob disease differential diagnosis, serial electroencephalograms being the most valuable.',\n",
       " 'The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate.',\n",
       " 'The findings were judged to be consistent with soft-tissue injury associated with intravenous administration of phenytoin, also termed purple glove syndrome.',\n",
       " 'However, as illustrated by these and other cases reported to date, the onset of troglitazone-induced liver injury is insidious and temporally variable.',\n",
       " \"Soon after its introduction in 1952, chlorpromazine was noted to induce symptoms resembling Parkinson's disease.\",\n",
       " 'Erythromycin is a macrolide antibiotic that may increase the risk of lovastatin-induced rhabdomyolysis.',\n",
       " 'A 23-year-old white male patient was originally admitted to receive intravenous chemotherapy for acute myelogenous leukemia.',\n",
       " 'We present two children with acute lymphocytic leukemia who developed leukoencephalopathy following administration of a combination of intravenous ara = C and methotrexate during the consolidation phase of chemotherapy.',\n",
       " 'Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.',\n",
       " 'CONCLUSIONS: Low dosages of quinacrine used for malaria prophylaxis can be associated with a delayed, severe maculopathy indistinguishable from chloroquine maculopathy in certain patients.',\n",
       " 'When pilsicainide is prescribed in patients with coronary artery disease or renal dysfunction, close attention must be paid to avoid life-threatening arrhythmias due to high plasma concentrations of the drug.',\n",
       " 'We describe a case of severe aplastic anemia (AA) that was probably induced by lenalidomide.',\n",
       " 'We present a case report of a patient with typhoid fever who experienced a hypersensitivity reaction subsequent to the infusion of chloramphenicol sodium succinate.',\n",
       " 'This confirmed the history of captopril-related asthma.',\n",
       " 'Four cases of adverse experiences with clonidine are described.',\n",
       " 'OBJECTIVE: To report a case of reversible nonthrombocytopenic palpable purpura associated with metoclopramide.',\n",
       " 'Three patients received respectively 190 mg, 175 mg, and 196 mg of methotrexate and developed bilateral pulmonary infiltrates without evidence of peripheral blood eosinophilia.',\n",
       " 'Clinicians should be aware of the possibility that vinorelbine may cause SIADH and possibly hypokalemia.',\n",
       " 'We report a case of a 34-year-old man on carbamazepine for complex partial seizures who developed acute liver and renal failure on less than 2.5 grams a day of acetaminophen.',\n",
       " 'Fever and maculopapular rashes appeared at 10 days after phenytoin initiation, and then the drug was discontinued.',\n",
       " 'We report AZA-induced drug eruption that developed in two cases of systemic scleroderma with polymyositis.',\n",
       " 'Safety aspects of a coumarin-troxerutin combination regarding liver function in a double-blind placebo-controlled study.',\n",
       " 'Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C.',\n",
       " 'Glucose and insulin exert additive ocular and renal vasodilator effects on healthy humans.',\n",
       " 'Two patients with osteomyelitis who developed reversible cholestatic jaundice during treatment with oxacillin derivatives are described.',\n",
       " 'DATA SYNTHESIS: A 49-year-old man developed symptoms of severe psychosis concomitant with ciprofloxacin (250 mg bid) treatment.',\n",
       " 'Beneficial effect of low-dose mianserin on fluvoxamine-induced akathisia in an obsessive-compulsive patient.',\n",
       " 'Potential causes of methamphetamine-related keratitis can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the toxic effects of diluting or \"cutting\" agents such as lidocaine and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product.',\n",
       " 'Pulmonary oedema after hexoprenaline administration in preterm labour.',\n",
       " 'Venlafaxine-associated seizures at therapeutic doses have not been reported in the literature.',\n",
       " 'Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature.',\n",
       " 'She was receiving phenytoin sodium 300 mg/day; carbamazepine 200 mg four times daily had been discontinued four days before admission because of leukopenia.',\n",
       " 'Thoracoscopic biopsy to confirm metastasis revealed instead fibrotic lesions apparently attributable to bleomycin or cyclophosphamide.',\n",
       " 'We present a case of hemolytic-uremic syndrome that developed during the 4th cycle of combination chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin.',\n",
       " 'We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with docetaxel and gemcitabine producing severe respiratory insufficiency, and simulating a progression of the tumor.',\n",
       " 'Relapse in the external auditory canal of acute promyelocytic leukemia after treatment with all-trans retinoic acid.',\n",
       " 'Acute neutrophilic dermatosis induced by all-trans-retinoic acid treatment for acute promyelocytic leukemia.',\n",
       " 'Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient.',\n",
       " 'Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect?',\n",
       " 'We describe two women who developed HUS after MMC therapy and presented massive pulmonary bleeding.',\n",
       " 'Alternating sinus rhythm and intermittent sinoatrial (S-A) block was observed in a 57-year-old woman, under treatment for angina with 80 mg propranolol daily.',\n",
       " 'These case reports provide evidence that 5-aminosalicylic acid may induce acute pancreatitis after long term treatment.',\n",
       " 'During that time, he had also been taking amphetamine-dextroamphetamine (Adderall) on work days for his ADHD.',\n",
       " 'Therefore, we diagnosed her eruption as contact dermatitis due to sodium bisulfite.',\n",
       " 'Macular infarction after endophthalmitis treated with vitrectomy and intravitreal gentamicin.',\n",
       " 'Since tamoxifen therapy can induce endometrial disorders, surveillance schemes of women taking tamoxifen have been recommended.',\n",
       " 'Warfarin-associated bleeding complication saved life.',\n",
       " 'METHODS/RESULTS: This paper presents a new case of rifabutin uveitis and a review of the various published reports to date.',\n",
       " 'Acute abdomen due to endometriosis in a premenopausal woman taking tamoxifen.',\n",
       " 'DISCUSSION: Methotrexate-induced papular eruption is rarely reported shortly after beginning methotrexate therapy in patients with acute exacerbation of collagen vascular diseases.',\n",
       " 'We describe 3 patients on concomitant amiodarone and warfarin who developed amiodarone-induced thyrotoxicosis heralded by a significant decrease in warfarin requirements.',\n",
       " 'The aim of this post-hoc analysis of data from a Phase III clinical trial (VISTA; NCT00298831) was to investigate the impact of antibiotics on recovery from rocuronium-induced NMB after administration of sugammadex for reversal, and compared the neuromuscular recovery in patients who received antibiotics preoperatively with those who did not.',\n",
       " 'All patients had taken phenytoin for variable time periods (range 16-80 days; mean: 40) and were on the medication when the skin lesions first appeared.',\n",
       " 'One should therefore be aware of possible extrapyramidal side effects with olanzapine that are reduced compared to classical neuroleptic drugs but not completely eliminated.',\n",
       " 'A patient who had been treated with large doses of thyroid hormone for several years developed features of secondary hypothyroidism after thyroid hormone withdrawal.',\n",
       " 'This article discusses the possibility that simultaneous use of valproic acid, lamotrigine, and phenytoin could give this combination of toxicities and that concurrent viral infection may increase this risk.',\n",
       " 'A second patient with a similar glucose tolerance test result showed postprandial hyperglycemia when treated similarly with betamethasone valerate cream 0.1%.',\n",
       " 'Phenytoin-induced hypersensitivity reactions.',\n",
       " 'A 54-year-old man developed TEN 4 weeks after beginning lamotrigine for complex partial seizures related to a glioblastoma multiforme brain tumor.',\n",
       " 'The occurrence of acute hepatitis is best known for ketoconazole.',\n",
       " 'Optic neuropathy developed in a patient with rheumatoid arthritis who had been receiving D-penicillamine for about 1 year.',\n",
       " 'Stupor and fast activity on electroencephalography in a child treated with valproate.',\n",
       " 'During her third cycle, she again received cisplatin 100 mg/m2 over 30 minutes and developed palmar pruritus, urticaria, and edema.',\n",
       " 'The case of a patient with infectious mononucleosis treated with cephalexin who later showed a rash is presented and the previous literature is reviewed.',\n",
       " 'After 1 week of nefazodone therapy the patient experienced headache, confusion, and \"gray areas\" in her vision, without abnormal ophthalmologic findings.',\n",
       " 'Nitrofurantoin-induced pulmonary toxicity during pregnancy: a report of a case and review of the literature.',\n",
       " 'Methylphenidate-associated enuresis in attention deficit hyperactivity disorder.',\n",
       " 'To our knowledge, this is the first case report that demonstrates the occurrence of fever with low-dose amifostine therapy without the manifestation of accompanying rash or hypotension.',\n",
       " 'Administration of excessive insulin induced hypoglycemia within 4 to 8 hours, followed by rebound hyperglycemia.',\n",
       " 'In both cases, symptoms of autonomic instability and severe agitation started within hours of initiation of cyclobenzaprine and fully resolved within 3 days after discontinuing the proserotoninergic drugs.',\n",
       " 'Secondary leukemia in a child with neuroblastoma while on oral etoposide: what is the cause?',\n",
       " 'Atorvastatin induced multiple organ failure.',\n",
       " 'While serotonin syndrome has become more frequent in an overdose situation and when an interacting drug is given, the toxicity of SSIRs is less than that of most other psychiatric drugs.',\n",
       " \"A 73-year-old woman with non-Hodgkin's lymphoma had two episodes of severe, bilateral, sensori-neural hearing loss after vincristine therapy.\",\n",
       " 'Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine.',\n",
       " 'Ulcerative proctitis in juvenile systemic lupus erythematosus after ibuprofen treatment.',\n",
       " 'Acute asthma associated with sustained-release verapamil.',\n",
       " 'The renal insufficiency of three patients and the timing of the seizures implicate accumulation of ofloxacin as a contributing factor.',\n",
       " 'Hemolytic uremic syndrome in a patient on cis-platinum, vinblastine and bleomycin.',\n",
       " 'A previous review described data on 15 patients who experienced acute hemoglobinemia or hemoglobinuria following anti-D IGIV administration for ITP or secondary thrombocytopenia.',\n",
       " 'Amiodarone was discontinued, and thyrotoxicosis gradually abated.',\n",
       " 'De novo absence status of late onset following withdrawal of lorazepam: a case report.',\n",
       " 'Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males.',\n",
       " 'Reports of colonic perforation as a result of the administration of calcium polystyrene sulfonate and sorbitol are rare.',\n",
       " 'Improved awareness of and further investigation into the neurotoxic effects of ofloxacin may enhance its safe use.',\n",
       " 'Atypical neuroleptic malignant syndrome associated with olanzapine.',\n",
       " 'OBJECTIVE: The authors described a case of interferon-induced psychosis as a framework to review the literature and discuss the decision to pursue antiviral treatment in psychiatrically ill patients with hepatitis C.',\n",
       " 'We believe that methotrexate represents a relatively effective alternative to surgery in patients with early unruptured tubal pregnancy, but suggest that it be used with caution in view of possible systemic toxicity.',\n",
       " 'After intravitreal injection of triamcinolone acetonide, cataract may rapidly develop in eyes that have been intensively treated, topically and systemically, by corticosteroids for several years.',\n",
       " 'Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection.',\n",
       " 'We report a case of bullous eruption, one month after starting nicardipine and lercanidipine.',\n",
       " 'Pulmonary fibrosis associated with nabumetone.',\n",
       " 'The ability of tumor necrosis factor (TNF)-alpha inhibitors to impair pivotal pro-inflammatory host defenses may facilitate the development of disseminated cryptococcosis.',\n",
       " 'This was accepted as evidence for propranolol being the cause of this conduction disorder.',\n",
       " 'We report a third case of a 6-week-old infant with Escherichia coli sepsis who received ampicillin and other antibiotics and subsequently developed TEN.',\n",
       " 'PURPOSE: To report a case of bilateral anterior uveitis associated with ovulation induction therapy using clomiphene citrate.',\n",
       " 'A 57-year-old woman presented with a 3-week history of dysphagia for solids, 6 months after starting treatment with nifedipine.',\n",
       " 'Although combinations of belladonna, ergotamine, and phenobarbital have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with anticonvulsant hypersensitivity syndrome.',\n",
       " 'Rifampin can be associated with severe adverse effects such as hepatitis, acute renal failure, hemolytic anemia, and thrombocytopenia.',\n",
       " 'It is believed that this is the first reported case of reversible azathioprine-induced cholestasis associated with histological evidence of bile duct injury.',\n",
       " 'We present a fatal case of subacute methanol toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with ventricular compression.',\n",
       " 'Patients with inoperable or metastatic colorectal cancer were randomized to receive monthly FU 400 mg/m2/day plus LV 20 mg/m2/day as intravenous push daily for five days, or FU alone.',\n",
       " 'The present report suggests that clarithromycin coadministration induces increased plasma carbamazepine concentrations, which may result in carbamazepine toxicity.',\n",
       " 'In this case, interferon alpha induced polymyositis and cardiomyopathy is diagnosed in a 33-yr-old male patient with history of chronic hepatitis B.',\n",
       " 'To describe the potential for interaction between opioids and serotonergic antidepressants leading to the development of serotonin syndrome (SS), mechanism of the interaction, and the spectrum of SS in elderly residents of a long-term care facility.',\n",
       " 'Erythema multiforme bullosum due to rifampicin.',\n",
       " \"We describe a patient with acute leukemia who developed Horner's syndrome and a severe demyelinating peripheral neuropathy leading to death after receiving high-dose cytosine arabinoside.\",\n",
       " 'This profile should trigger a \"red flag\" as to the possibility of phenobarbital behavioral side effects or exacerbation of preexisting maladaptive behaviors.',\n",
       " 'Retinal abnormalities, including retinal hemorrhage and \"cotton-wool\" spots, often occur within the first 8 weeks in the course of interferon therapy in patients with chronic hepatitis C.',\n",
       " 'Rapamycin/sirolimus-induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing SR therapy.',\n",
       " \"IFNalpha-induced recurrence of Graves' disease ten years after thyroidectomy in chronic viral hepatitis C.\",\n",
       " 'Risperidone withdrawal-related respiratory dyskinesia: a case diagnosed by spirography and fibroscopy.',\n",
       " 'Paralytic ileus in patients undergoing bortezomib treatment has been reported, although a definite attribution to bortezomib administration has not been established.',\n",
       " 'Severe serotonin syndrome induced by mirtazapine monotherapy.',\n",
       " 'Three days after starting fluconazole, she developed polyuria and polydipsia and was found to have severe hyperglycemia, which led to the diagnosis of Cushing syndrome.',\n",
       " 'Postoperative hypocalcemic tetany caused by fleet phospho-soda preparation in a patient taking alendronate sodium: report of a case.',\n",
       " 'Observations in our patient suggest that the leukoencephalopathy that developed in previously reported patients who received 5-fluorouracil and levamisole may have been caused at least partly by levamisole.',\n",
       " 'We describe the clinical response, as determined by increases in total Hb and decreased transfusion needs, in five patients with thalassemia intermedia treated with HU alone or in combination with SPB.',\n",
       " 'According to the Naranjo et al. adverse-reaction probability scale, enoxaparin was the probable cause of hepatotoxicity in this patient.',\n",
       " 'This is the first reported case of hepatolithiasis during octreotide therapy.',\n",
       " 'Treatment of amiodarone-induced thyrotoxicosis (AIT) with thionamide, lithium or radioactive iodine is ineffective.',\n",
       " 'Six patients with no previous signs or symptoms suggestive of coronary artery disease developed acute coronary ischemia/infarction shortly after cis-diamine-dichloroplatinum II (cisplatin) -based chemotherapy.',\n",
       " 'RESULTS: Replacing valproate with lamotrigine resulted in a decrease in serum testosterone concentrations in all 3 women.',\n",
       " 'A 65-year-old woman, in the intensive care unit because of septic shock and acute renal failure, had a small-bowel obstruction due to Amphojel concretions.',\n",
       " 'After the first oral dose of propranolol, syncope developed together with atrioventricular block.',\n",
       " 'Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient.',\n",
       " 'The symptoms did not recur during the 36 months of itraconazole treatment after discharge, and it was concluded that ITCZ was effective for A. flavus hypertrophic pachymeningitis.',\n",
       " 'A prospective randomized clinical trial was implemented to assess whether the concomitant or the sequential addition of tamoxifen to chemotherapy provides improved clinical benefit in the adjuvant treatment of breast cancer in postmenopausal patients.',\n",
       " 'Increased libido in a woman treated with fluvoxamine: a case report.',\n",
       " 'In the following case report, a patient developed acute interstitial nephritis with renal failure and exfoliative dermatitis following ampicillin therapy.',\n",
       " 'Severe symptoms associated with serotonin toxicity were shown to be uncommon in patients receiving linezolid and selected serotonin reuptake inhibitors.',\n",
       " 'We describe the side effects of 5-FU in a colon cancer patient who suffered severe mucositis, desquamating dermatitis, prolonged myelosuppression, and neurologic toxicity that required admission to the intensive care unit.',\n",
       " 'There have been many reports of probable lithium-induced organic brain syndromes occurring when serum lithium levels are within or close to the therapeutic range.',\n",
       " 'The patient was enrolled in a weight-loss clinic, and his diabetes medications were adjusted.Subsequently, olanzapine was discontinued because of weight gain and uncontrolled diabetes.',\n",
       " 'While most physicians are aware of heparin-induced thrombocytopenia and skin necrosis, the association of heparin and hyperkalemia is less well recognized.',\n",
       " 'Gefitinib (IRESSA, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, has been approved in several countries for the treatment of advanced non-small-cell lung cancer.',\n",
       " 'The case of a 4-year-old girl with valproate-induced stupor and electroencephalographic pattern of increased fast activity is reported.',\n",
       " 'Prior to surgery, levodopa induced dyskinesia had improved (< or = 50%) under treatment with amantadine (400 mg/day, po) in all three patients.',\n",
       " 'Foscarnet-induced severe hypomagnesemia and other electrolyte disorders.',\n",
       " 'A case is reported of a child with fatal pulmonary fibrosis following BCNU therapy.',\n",
       " 'A 64-year-old man with schizophrenia developed myoclonic jerks when given higher doses of quetiapine.',\n",
       " 'The etiology of neurotoxicity in our two patients remains unclear; however, as CAP is rapidly metabolized to 5-FU in patients with normal liver function, it is likely that 5-FU or its active metabolites (fluoro-beta-alanine) were contributing factors.',\n",
       " 'CONCLUSIONS: Amantadine can cause reversible corneal edema but can irreversibly reduce the density of endothelial cells.',\n",
       " 'After gastric-outlet obstruction was recognized in several infants who received prostaglandin E1, we studied the association between the drug and this complication.',\n",
       " 'A wide variety of adverse central nervous system effects have been reported in association with propafenone; dizziness is the most common.',\n",
       " 'Iatrogenic Cushing syndrome has been reported in patients with CF treated concomitantly, and for extended duration, with inhaled corticosteroids and CYP3A4 inhibitors.',\n",
       " 'Red blood cell anemia in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and prednisone.',\n",
       " 'Induction of systemic lupus erythematosus by interferon-gamma in a patient with rheumatoid arthritis.',\n",
       " 'In this case, unlike those previously reported, hyponatremia recurred 5 months after switching from citalopram to mirtazapine, which is believed to be a safe antidepressant.',\n",
       " 'This report describes a case of acute compromise of renal function associated with hypotension in a 7-year-old boy treated with the ACE inhibitor lisinopril and the ARB losartan.',\n",
       " 'We report a male patient with advanced AIDS who developed hypercalcemia 2 weeks after institution of rhGH therapy.',\n",
       " 'RESULTS: Both patients experienced a previously unreported side effect--falling backward--associated with bupropion use.',\n",
       " 'A second episode of jaundice followed the intravaginal administration of a mixture of furazolidone and nifuroxime.',\n",
       " 'Clinicians should be aware that an erythematous and exfoliative rash may be induced by temozolomide, and be familiar with the pharmacologic and supportive measures necessary for its treatment.',\n",
       " 'Captopril-induced bone marrow suppression in two cardiac patients with trisomy 21.',\n",
       " 'A 65-year-old woman with angina pectoris presented with syncope after sublingual ingestion of isosorbide dinitrate (5 mg).',\n",
       " 'The authors present a case study of a mentally healthy man who repeatedly experienced short-lived, obsessional-like suicidal ideas and images after ingestion of the anti-fungal drug ketoconazole.',\n",
       " 'Flaccid quadriparesis was noted after discontinuation of vecuronium.',\n",
       " 'AIMS: The aim of this study was to report on the effectiveness and tumor side effects of topical interferon (INF) alpha 2-beta in a case of conjunctiva-cornea intraepithelial neoplasia (CIN) of a patient that rejected any surgical procedure.',\n",
       " 'Herein is reported an unusual case of coexistent warfarin-induced skin necrosis and heparin-induced thrombocytopenia following mitral valve replacement for thromboembolic phenomena associated with marantic endocarditis and bronchial adenocarcinoma.',\n",
       " 'We present a case of severe unilateral posterior scleritis associated with zoledronic acid administration that was recognized and treated in a timely manner.',\n",
       " \"The patient's other comorbidities and medications have not been suggested as possible interactions with sertraline that can cause rhabdomyolysis.\",\n",
       " 'L-asparaginase-provoked seizures as singular expression of central nervous toxicity.',\n",
       " 'Acute non-lymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with Treosulfan (= dihydroxybusulfan).',\n",
       " 'Children treated with thalidomide should undergo regular neurophysiologic studies in order to detect presymptomatic or progressive peripheral neuropathy.',\n",
       " 'Nevirapine is a non-nucleoside reverse transcriptase inhibitor widely used in combination with other antiretroviral agents for the treatment of HIV infection.',\n",
       " 'The case is presented of a 72-year-old man with hormone-refractory prostate cancer and weekly administration of 30 mg/m2 docetaxel who developed subacute interstitial pneumonitis-related pulmonary fibrosis after seven doses and died despite mechanical ventilation and high-dose corticosteroid treatment.',\n",
       " 'In this case, it was suspected that a combination of cigarette smoking, pulmonary fibrosis, and low-dose methotrexate therapy might have promoted the development of lung cancer.',\n",
       " 'Rapid onset of iatrogenic adrenal insufficiency in a patient with cystic fibrosis-related liver disease treated with inhaled corticosteroids and a moderate CYP3A4 inhibitor.',\n",
       " 'Heparin-associated thrombocytopenia and thrombosis is a severe complication of systemic heparin therapy.',\n",
       " 'The polycystic changes disappeared from the ovaries in 2 of the women after valproate therapy was discontinued, and the 2 women who had gained weight and developed amenorrhea while being treated with valproate lost weight and resumed menstruating after the change in medication.',\n",
       " 'The cause of his bleeding was a severe thrombocytopoaenia, induced by chronic ingestion of quinine.',\n",
       " 'The concomitant use of antidepressant drugs associated with lithium as a co-adjuvant seems to increase the risk of this adverse reaction.',\n",
       " 'Peripheral nervous system disturbances caused by cytosine arabinoside have rarely been reported.',\n",
       " 'We report an unusually short lived and asymptomatic episode of severe cisplatin-induced renal tubular salt wasting in a fit 41-year-old patient with malignant teratoma.',\n",
       " 'This case suggests that BH-AC, a derivative of cytosine arabinoside (1-beta-D-arabinofuranosylcytosine) could be a cause of reversible encephalopathy syndrome.',\n",
       " 'She was administered metoclopramide because of nausea and, within 2 hours, developed agitation, dysarthria, diaphoresis, and a movement disorder.',\n",
       " 'This article describes two cases of aplastic anemia, at least one of which was almost certainly induced by the use of methazolamide, and one case of agranulocytosis related to the use of methazolamide.',\n",
       " 'Amprenavir is a human immunodeficiency virus-1 (HIV-1) protease inhibitor intended to be used to treat HIV-infected children.',\n",
       " 'Methotrexate-induced papular eruption following treatment of psoriasis has not been previously reported.',\n",
       " 'On day 7 of linezolid treatment, the patient developed severe pruritus, macular rash, facial edema, eosinophilia, marked increase in serum creatinine level, and mild hepatitis.',\n",
       " 'We report a fatal case of acute interstitial pneumonitis in a patient treated with carmustine (BCNU) for a brain tumor.',\n",
       " 'The three reported cases demonstrate that troglitazone is an idiosyncratic hepatotoxin that can lead to irreversible liver injury.',\n",
       " 'High-grade atrioventricular block during dipyridamole stress testing.',\n",
       " \"We describe a case of intraoperative gelatine-induced anaphylaxis whose diagnosis was delayed as the use of gelatine during surgical procedures was omitted for two times in patient's medical records.\",\n",
       " 'The case of a 29-year-old man suffering from falciparum malaria disease who got a reversible hearing loss from quinine therapy is presented.',\n",
       " 'The cases of two asthmatic patients who became hypokalemic after inhalation of normal doses of albuterol are presented.',\n",
       " 'This article presents a case of an atypical localized cutaneous eruption with an unusual course and protracted resolution time associated with sorafenib therapy.',\n",
       " 'METHOD: We describe two patients who presented with diabetic ketoacidosis after treatment with quetiapine and risperidone, respectively.',\n",
       " 'We suspect that nefazodone inhibits metabolism of tacrolimus.',\n",
       " 'Our review of 194 RA patients and 38 PsA patients receiving MTX has identified four RA patients and one PsA patient with MTX-induced pneumonitis, giving a prevalence of 2.1% and 0.03%, respectively.',\n",
       " 'A case report of fatal dapsone-induced agranulocytosis in an Indian mid-borderline leprosy patient.',\n",
       " 'Autoimmune thyroid disease is a common side-effect of interferon-alpha (IFN-alpha) treatment of viral hepatitis C.',\n",
       " 'The side effects of MMF, such as bone marrow toxicity, have been reported.',\n",
       " 'He developed a late secondary infection in some sites treated with imiquimod.',\n",
       " \"We report the case of a 51-year-old man in whom IFN-alpha treatment was followed by recurrence of Graves' disease 10 years after thyroidectomy was performed and the patient was declared cured.\",\n",
       " 'We report 2 cases of maculopapular eruption and fever in patients infected with human immunodeficiency virus (HIV) on the 2nd day of first administration of ritonavir, a protease inhibitor.',\n",
       " 'We report the case of a woman who developed photo-onycholysis on multiple nails after uptake of olanzapine.',\n",
       " 'Cimetidine is a rare cause of drug-induced fever.',\n",
       " 'Reversible methotrexate-associated lymphoproliferative disorder resembling advanced gastric cancer in a patient with rheumatoid arthritis.',\n",
       " 'The field defects and some electrophysiological abnormalities persist when vigabatrin therapy is withdrawn.',\n",
       " 'A possible case of carbamazepine induced pancreatitis.',\n",
       " 'Subsequent to the first dose of mirtazapine the patient experienced seizures, bradycardia and prolonged QRS as well as QTc intervals on EKG.',\n",
       " 'Stuttering priapism complicating warfarin therapy in a patient with protein C deficiency.',\n",
       " \"She had been on a combined treatment of steroid and lobenzarit disodium for the first 3 years, and then continued with a combined treatment of steroid and bucillamine for the following years until she was found to have pulmonary tuberculosis, at which time the steroid was suspended 10 months before she visited the authors' clinic.\",\n",
       " 'We describe a rare case of severe drug-drug interaction between propafenone and mirtazapine leading to propafenone toxicity.',\n",
       " \"Because the combination of bleomycin and vinca alkaloids is commonly used for the treatment of AIDS-related Kaposi's sarcoma, clinicians should be aware of the risk of provoking acral necrosis in patients who develop Raynaud's phenomenon under chemotherapy.\",\n",
       " 'The psychotic behavior resolved completely soon after the discontinuation of levetiracetam.',\n",
       " 'Male volunteers ( n=12) participated in a randomised, two-period, crossover trial evaluating the effect of multiple doses of 600 mg rifampicin once daily for 7 days on repaglinide metabolism.',\n",
       " 'This report suggests that anemia can occur due to MMF, in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and prednisone is used.',\n",
       " \"Warfarin was initiated for deep vein thrombosis prophylaxis due to the patient's inability to ambulate.\",\n",
       " 'We report a case with chronic hepatitis C (CHC) who developed sarcoidosis after the treatment by interferon alpha and ribavirin.',\n",
       " 'The relation between tacrolimus treatment and staining was suggested by the appearance of pigmentation during topical tacrolimus treatment and its clinical disappearance when treatment was stopped.',\n",
       " 'Though hypotension, dry mouth, and constipation are well-documented possible adverse effects, the possibility of clonidine-induced bradycardia is less well recognized and is rare.',\n",
       " 'Several hypersensitivity reactions to cloxacillin have been reported, although IgE-mediated allergic reactions to the drug are rare and there is little information about possible tolerance to other semisynthetic penicillins or cephalosporins in patients with cloxacillin allergy.',\n",
       " 'Brugada type electrocardiographic changes induced by concomitant use of lithium and propafenone in patient with Wolff-Parkinson-White syndrome.',\n",
       " 'Docetaxel-induced Meibomian duct inflammation and blockage leading to chalazion formation.',\n",
       " 'Allergic side effects of AZA are rare, and reported allergic skin eruptions from AZA are very limited in Japan.',\n",
       " 'Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS.',\n",
       " 'Outcome of pregnancy in women treated with all-trans retinoic acid; a case report and review of literature.',\n",
       " 'The potential development of SJS/TEN, a severe life-threatening illness, emphasizes the need for judicious use of TMP-Sx and close monitoring and follow-up for patients who were given TMP-Sx for SSTIs.',\n",
       " 'A case history of a 15-year-old boy who developed incapacitating tardive dyskinesia that resolved during treatment with deanol is presented.',\n",
       " 'Drug-induced mammary hyperplasias have been reported as rare complications of D-penicillamine and Neothetazone.',\n",
       " 'The purpose of this report is to document a new case of in utero CP exposure with multiple congenital anomalies and to establish an apparent CP embryopathy phenotype.',\n",
       " 'AIM: The aim of this article is to present the clinical characteristics and management of an oral adverse effect stemming from the use of the antiretroviral medication Nevirapine (NVP).',\n",
       " 'A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (SMX) treatment.',\n",
       " 'Treatment with infliximab is known to produce an increase of autoantibodies (antinuclear antibodies, anti-double-stranded DNA), but not clinical disease.',\n",
       " 'Serotonin syndrome, which occurs as a result of enhanced serotonin concentration in the central nervous system, is a well-known adverse effect of serotonin-active medications.',\n",
       " 'Despite the risk of needle-track seeding, PEI remains useful in the treatment of HCC.',\n",
       " 'Trimethoprim-sulfamethoxazole-induced hepatotoxicity in a pediatric patient.',\n",
       " 'Prolonged responses were achieved with low doses of HU (3-10 mg/kg/day) and higher doses were associated with mild reversible hematologic or hepatic toxicity and no further increases in Hb.',\n",
       " 'Imidazoline intoxication in children.',\n",
       " 'Concomitant administration of cytarabine might have affected his liver function and there might have been interaction between the drugs.',\n",
       " 'The probability of developing acute leukemia in this study was not significantly correlated to the total cumulative dosage of Treosulfan.',\n",
       " 'Intraventricular vancomycin-induced cerebrospinal fluid eosinophilia: report of two patients.',\n",
       " 'This case supports the view that in gold-induced pneumonitis a prolonged treatment with corticosteroids may be necessary, as lung function continued to improve.',\n",
       " 'Massive plasmocytosis due to methimazole-induced bone marrow toxicity.',\n",
       " 'RESULTS: After 4- to 14-month period of therapy with the combination of indapamide (2.5 mg/day) and fosinopril (10 mg/day) in three patients and 6-month period of monotherapy with indapamide (2.5 mg/day) in one patient, glucose levels of all patients increased and achieve criteria of diabetes diagnoses.',\n",
       " 'A reversible toxic liver damage was observed in a non-alcoholic woman treated with disulfiram.',\n",
       " 'A 60 year-old woman with chronic renal failure developed acute proximal muscle weakness after receiving a regular dosage of colchicine.',\n",
       " 'The cause of these previously unreported side effects of niacin therapy is uncertain but may be related to prostaglandin-mediated vasodilatation, hyperalgesia of sensory nerve receptors, and potentiation of inflammation in the gingiva with referral of pain to the teeth.',\n",
       " 'Nocardia is an important opportunistic infectious agent in immunocompromised hosts, i.e. in patients taking corticosteroids.',\n",
       " 'Hepatobiliary disorders associated with orally administered terbinafine have rarely been reported.',\n",
       " 'We report a patient in whom the anti-depressant trazodone hydrochloride (Molipaxin, Roussel), a serotonin antagonist, provoked generalized pustular psoriasis (GPP).',\n",
       " 'Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life-threatening vincristine neurotoxicity.',\n",
       " 'Probable enoxaparin-induced hepatotoxicity.',\n",
       " 'Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation.',\n",
       " 'He had also developed elevated serum ammonia levels while on valproic acid.',\n",
       " 'Cutaneous rashes and eruptions can be caused by many medications, including carbamazepine.',\n",
       " 'In this case, the increase in the INR value with associated bruising after the addition of amoxycillin suggests a drug interaction between acenocoumarol and amoxycillin, other possible causes having been eliminated.',\n",
       " 'Oncologists supervising future clinical trials for lung cancer should be alert to the fact that sorafenib can potentially induce serious interstitial lung disease, although this might depend on racial differences.',\n",
       " 'SUMMARY: A 26-year-old man with bipolar disorder, seizures, and mild mental retardation secondary to a traumatic brain injury began treatment with carbamazepine for aggression and seizure control.',\n",
       " 'Serotonin toxicity precipitated by fentanyl is unusual and has not previously been described in combination with SSRIs in the perioperative setting.',\n",
       " 'It may cause a severe adverse drug reaction with multiorgan involvement known as dapsone hypersensitivity syndrome.',\n",
       " 'Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections.',\n",
       " 'Renal failure associated with acetazolamide therapy for glaucoma.',\n",
       " 'Acute onset of nephrotic syndrome during interferon-alpha retreatment for chronic active hepatitis C.',\n",
       " 'A 16-year-old boy developed fever, generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and lithium.',\n",
       " 'The hyperpigmentation was diffuse scattered, flagellate like and linear streaking which was thought to be mainly related to the skin toxicity of bleomycin.',\n",
       " 'Exacerbation of 5-FU dermatologic toxicities in patients with preexisting conditions suggests the importance of aggressive ocular prophylaxis, using frequent ocular lubrication and topical steroid preparations with concurrent medical management of pre-existing dermatologic conditions.',\n",
       " 'Bowel perforation associated with intraperitoneal chromic phosphate instillation.',\n",
       " 'A 62-year-old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy-related hemolytic-uremic syndrome during the second cycle of neoadjuvant chemotherapy consisting of cisplatin, bleomycin, and methotrexate.',\n",
       " 'These data confirm the therapeutic value of arsenic trioxide in relapsed/resistant APL.',\n",
       " 'Avascular necrosis of the femoral head in patients with prostate cancer treated with cyproterone acetate and radiotherapy.',\n",
       " 'Ectropion secondary to bolus injection of 5-fluorouracil.',\n",
       " 'Metoclopramide-induced parkinsonism is not rare, and appropriate dose reduction in patients with renal failure will help reduce the incidence of this morbidity.',\n",
       " 'Posterior reversible encephalopathy syndrome associated with methotrexate neurotoxicity: conventional magnetic resonance and diffusion-weighted imaging findings.',\n",
       " 'A 6-year-old boy (weight: 16 kg, at the start of treatment) began sodium valproate (valproate syrup 5%) treatment for epilepsy in February 2012.',\n",
       " 'Pharmacokinetic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia.',\n",
       " 'We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by, in the first case intrathecally administered methotrexate and, in the second by intrathecally administered methotrexate and cranial irradiation.',\n",
       " 'Considering the increasing use of TMZ, which is regarded as a drug with moderate toxicity, careful follow-up with routine blood testing is vital.',\n",
       " 'While for ribavirin antidepressant effects are not known, we suppose that antidepressants may prevent changes in serotonergic or noradrenergic neurotransmission caused by IFN-alpha.',\n",
       " 'To report a case of serotonin syndrome associated with interaction between fentanyl and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl.',\n",
       " 'We report a case of ibuprofen-induced meningitis in an otherwise healthy individual.',\n",
       " 'The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly.',\n",
       " \"L-Thyroxine-induced leukopenia in a patient with Hashimoto's disease: involvement of suppressor-cytotoxic T cells.\",\n",
       " 'Carbamazepine-induced systemic lupus erythematosus-like disease.',\n",
       " 'CONCLUSIONS: This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone.',\n",
       " 'These results suggest that the hepatoxicity of ethanol in alcoholic beverages is enhanced by interaction with its congeners and acetaldehyde; they also suggest that alcoholic beverages are not equivalent in their potential to cause liver damage.',\n",
       " 'The dermatology literature heretofore has not noted that anemia is a side effect of patients taking MMF to treat pemphigus.',\n",
       " 'The 9 other reported cases of D-penicillamine induced rapidly progressive glomerulonephritis have been reviewed.',\n",
       " 'We describe a heroin abuser in whom clinical and laboratory manifestations of acute hepatitis B and C appeared a few days after the insertion of a subcutaneous naltrexone implant.',\n",
       " 'Ciprofloxacin-induced psychosis.',\n",
       " 'Thalidomide was withdrawn from world markets in 1961 following recognition of its teratogenic effects.',\n",
       " 'Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study.',\n",
       " 'We suggest the use of esmolol for treatment of dysrhythmias secondary to caffeine toxicity; to the best of our knowledge, the use of esmolol has not been reported for this purpose.',\n",
       " 'To date, there have been few reports of visual disturbances associated with BTX-B use.',\n",
       " 'Gemcitabine is a known risk factor for hemolytic uremic syndrome (HUS), which can often have a rapidly fatal clinical course despite intervention with steroids, plasmapheresis and hemodialysis.',\n",
       " 'Our objective is to present a retrospective analysis of the DWI findings in four patients who suffered subacute neurotoxicity after intrathecal MTX.',\n",
       " 'We report a case of ST elevation in right precordial leads compatible with type 1 Brugada syndrome following administration of propafenone in a patient with Wolff-Parkinson-White syndrome who was receiving lithium at concentrations within therapeutic levels.',\n",
       " 'The spectrum of cutaneous eruptions associated with dihydropyridines is extensive, varying from exanthemas to severe adverse events.',\n",
       " 'Polymyositis after propylthiouracil treatment for hyperthyroidism.',\n",
       " \"Methamphetamine's extensive physiologic effects, inconsistent street purity, and multiple routes of administration offer many possibilities for injury to the cornea.\",\n",
       " 'Since ethambutol is actively excreted via the renal system, compromise of renal function such as due to renal tuberculosis may lead to serum concentration elevations of ethambutol sufficient to produce optic neuropathy.',\n",
       " 'Renal failure appeared 8 to 17 days after beginning gentamicin therapy and was characterized by creatinine clearances 4 to 10 ml/min, urine to plasma creatinine ratios less than 20, urinary sodium concentrations 16 to 60 mEq/liter, proteinuria, and cylindruria.',\n",
       " 'Seizures associated with ofloxacin therapy.',\n",
       " 'Cutaneous seeding after ultrasound-guided percutaneous ethanol injection for treatment of hepatocellular carcinoma.',\n",
       " 'Two patients who developed decreased visual acuity after several months of ethambutol treatment for Mycobacterium avium-intracellulare infection had bitemporal visual field defects that suggested optic chiasm damage.',\n",
       " 'CONCLUSIONS: Metoclopramide may cause reversible nonthrombocytopenic vascular-type palpable purpura.',\n",
       " 'CONCLUSIONS: Life-threatening adrenal suppression, requiring hydrocortisone supplementation and intensive therapy, was observed and successfully treated in a newborn, whose mother had received high-dose methylprednisolone in late pregnancy.',\n",
       " 'A case of extrapyramidal symptoms (EPS) following administration of aripiprazole to a man with developmental disabilities who had never received antipsychotic medications and had no history of movement disorders is presented.',\n",
       " 'Although high-dose methotrexate has been shown to be useful in the treatment of primary osteogenic sarcoma, the tumoricidal effects of therapy appear to have caused a fatal rise in intracranial pressure.',\n",
       " 'This case had radiation fibrosis, so we suggest that radiation fibrosis may be another contributor of the occurrence of ILD in patients taking erlotinib.',\n",
       " 'Since recent studies have reported no negative interactions with concurrent use, we here report three cases (one case of a prolonged seizure, a serotonin syndrome and a focal seizure) of severe lithium-induced side effects while patients underwent ECT without complications and lithium serum levels were still subtherapeutic.',\n",
       " 'Lithium-associated transient thyrotoxicosis in 4 Chinese women with autoimmune thyroiditis.',\n",
       " 'A patient, while on intravenous ritodrine therapy for preterm labor, experienced an episode of acute chest pain.',\n",
       " 'Subsequent in vivo/vitro studies clearly demonstrated that the neurological effects were due to a synergistic action of desferrioxamine and prochlorperazine, probably resulting in exceptional fluxes of intra/extra cellular iron/copper disturbing noradrenergic and serotonergic systems.',\n",
       " 'Favorable outcome of de novo hepatitis B infection after liver transplantation with lamivudine and adefovir therapy.',\n",
       " 'Pemphigus foliaceus was seen in a patient with pulmonary tuberculosis during rifampicin therapy.',\n",
       " 'CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious extrapyramidal reactions in patients receiving sertraline or venlafaxine when metoclopramide is coadministered even in a single, conventional dose.',\n",
       " 'We report the case of a patient who developed polyserositis (pericardial effusion, pleural effusion, and pericarditis) after being started on clozapine, and whose symptoms remitted upon discontinuation of clozapine.',\n",
       " 'Three years later, treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy.',\n",
       " 'METHODS: A patient who developed dramatic, permanent vision loss after a 9-month course of treatment with ethambutol and isoniazid for pulmonary tuberculosis is presented.',\n",
       " 'The authors report a case of urinary incontinence (UI) that occurred in a woman after administration of venlafaxine.',\n",
       " 'The possibility can be raised that M-CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus, leading to the development of nephrotic syndrome.',\n",
       " 'We describe two ELBW infants affected by hyperkalaemia, treated with Kayexalate, who developed serious hypernatraemia, that has never been reported before in preterm infants.',\n",
       " 'DISCUSSION: Electrolyte disorders associated with foscarnet are reviewed.',\n",
       " 'We report two cases that developed acute myeloid leukaemia (AML) during tamoxifen therapy for breast cancer.',\n",
       " \"Our patient was a 72-year-old man with advanced Parkinson's disease (PD) who received levodopa and anti-cholinergic drugs and whose head had become almost completely bald.\",\n",
       " 'The patient experienced hallucinations, agitation, vomiting, tachycardia and seizures after ingestion of 1050 (48 mg/kg) of extended-release bupropion.',\n",
       " 'This case report describes a 38-year-old male in whom SIADH was strongly suspected secondary to Tegretol therapy to control a seizure disorder.',\n",
       " 'However, cyclosporine dependency is associated with the risk of nephrotoxicity.',\n",
       " 'The observations suggest that testicular swelling and pain are side effects of desipramine.',\n",
       " 'METHOD: We describe three case-reports concerning haematological adverse effects of quetiapine.',\n",
       " 'Typically, drug-induced neutropenia occurs in a patient receiving a semisynthetic penicillin for two weeks or more.',\n",
       " 'Peripheral nerve dysfunction is a potentially serious complication of high-dose cytosine arabinoside.',\n",
       " 'Tumor-volume increase at beginning of primary treatment with topical interferon alpha 2-beta in a case of conjunctiva-cornea intraepithelial neoplasia.',\n",
       " 'L-asparaginase-induced posterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children.',\n",
       " 'On the other hand, MTX-induced pneumonitis seems to be very rare in psoriatic arthritis (PsA).',\n",
       " 'Ototoxicity as a result of cis-platinum administration is well documented.',\n",
       " 'Massive subfascial hematoma after alteplase therapy for acute myocardial infarction.',\n",
       " 'We suggest that itraconazole should be added to the list of drugs that may be responsible for a drug-induced vanishing bile duct syndrome.',\n",
       " 'A 67-year-old man receiving a stable maintenance dosage of warfarin experienced an increased international normalized ratio (INR) without bleeding when his atorvastatin therapy was switched to fluvastatin.',\n",
       " 'The cases of CBZ-induced SLE reported in the literature were reviewed.',\n",
       " 'Ciprofloxacin-induced hemorrhagic vasculitis.',\n",
       " 'INTERPRETATION: When high doses of fluticasone propionate are used, growth may be retarded and adrenal suppression may occur.',\n",
       " 'To our knowledge, this is the first report of significant hypotension associated with intravenous valproate in the treatment of status epilepticus in the pediatric population.',\n",
       " 'While undergoing treatment with albendazole, he developed worsening diarrhea with abdominal pain and fever.',\n",
       " 'Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome.',\n",
       " 'Bone marrow aplasia and severe skin rash after a single low dose of methotrexate.',\n",
       " 'A woman 38-year-old, suffering for about ten years from multiple sclerosis and treated with repeated therapy cycles of intrathecal Depo-Medrol, developed a spastic paraparesis at the lower limbs.',\n",
       " 'The efficacy of single-dose disulfiram as an inhibitor of human P450 2E1 suggests that this modality for manipulating clinical P450 2E1 activity may provide a useful probe for delineating P450 2E1 participation in human drug biotransformation or for the treatment of poisoning by P450 2E1-activated toxins.',\n",
       " \"To develop information on the relative rarity or frequency of neurologic worsening with the initiation of penicillamine therapy, we conducted a retrospective survey of 25 additional patients with Wilson's disease who met the criteria of presenting with neurologic disease and having been treated with penicillamine.\",\n",
       " 'The authors present a case of t-AML that developed in a child with metastatic neuroblastoma 18 months after he received oral etoposide, given for palliation purpose.',\n",
       " 'Mechanisms and triggering factors of hypoglycaemia induced by mefloquine and some other anti-malarial quinine analogues are discussed.',\n",
       " 'Only nondepolarizing muscle relaxants should be used in patients who are at risk for mucositis.',\n",
       " 'CONCLUSION: A possible pharmacokinetic interaction between Dantrolene and Oxybutynin should be borne in mind when considering Carbamazepine medication for a patient with a spinal cord lesion.',\n",
       " 'We describe a 15-year-old female patient diagnosed with acute lymphoblastic leukemia presenting with status epilepticus after receiving intrathecal methotrexate.',\n",
       " 'Duodenal ulceration: a complication of tolazoline therapy.',\n",
       " 'Hepatic damage after danazol treatment.',\n",
       " 'Hepato-biliary abnormalities secondary to ceftriaxone use: a case report.',\n",
       " 'Rhabdomyolysis with concurrent atorvastatin and diltiazem.',\n",
       " 'Case report: mannitol nephrotoxicity syndrome: role of hemodialysis and postulate of mechanisms.',\n",
       " 'Uveitis during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of rifabutin, clarithromycin and ethambutol.',\n",
       " 'The visual loss in this patient seems to result from phenol neurotoxicity rather than mechanical compression of the intraorbital optic nerve.',\n",
       " 'Polysomnographic and pharmacokinetic findings in levodopa-induced augmentation of restless legs syndrome.',\n",
       " 'These cases highlight the occurrence of livedo reticularis as an uncommon side-effect of interferon alpha treatment.',\n",
       " 'So far, few cases of pulmonary side effects caused by ticlopidine have been reported.',\n",
       " \"Abnormal dexamethasone suppression tests in a rifampicin-treated patient with suspected Cushing's syndrome.\",\n",
       " 'Gemcitabine therapy has been associated with radiation recall reactions when used in the treatment of carcinoma.',\n",
       " 'Increased lash length, thickness, and pigmentation are well-documented side effects of prostaglandin analog glaucoma drops.',\n",
       " 'Bullous Eruption Associated With Dihydropyridines With Cross Reactivity.',\n",
       " 'Ritonavir acted as a CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an increase in serum levels and clinical toxicity.',\n",
       " 'Acute generalized exanthematous pustulosis induced by nimesulide.',\n",
       " 'Quinine induced coagulopathy--a near fatal experience.',\n",
       " 'A 58-year-old man with rheumatoid arthritis developed lichen planus during treatment with gold.',\n",
       " 'Atenolol-induced pseudolymphoma.',\n",
       " 'First case report of suspected onset of convulsive seizures due to co-administration of valproic acid and tebipenem.',\n",
       " 'Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency.',\n",
       " 'Aplastic anemia and agranulocytosis in patients using methazolamide for glaucoma.',\n",
       " 'We report a 44-year-old woman with t-MDS (refractory anemia with excess blasts) following treatment of recurrent anaplastic astrocytoma with temozolomide (TMZ).',\n",
       " 'An infant who developed pancreatitis during meglumine antimoniate treatment for visceral leishmaniasis and who was successfully treated with a combination of allopurinol and ketoconazole is reported.',\n",
       " 'L-Carnitine supplementation has been recommended to prevent the fatal hepatotoxic effects associated with valproic acid.',\n",
       " 'The purpose of this study was to examine the incidence and cause of Clostridium difficile colitis occurring after cisplatin-based combination chemotherapy in ovarian cancer patients.',\n",
       " 'Cerebral demyelinating disease developed in a patient during adjuvant therapy with levamisole for malignant melanoma.',\n",
       " 'Amoxapine-induced cognitive impairment in two patients.',\n",
       " 'Granisetron hydrochloride (3 mg on days 1, 8, and 15) and dexamethasone (13.2 mg on day 1 and 6.6 mg on days 2, 3, 8, and 15) were used prior to irinotecan administration in both patients.',\n",
       " 'Visceral herpesvirus infections in leukemic patients receiving cytarabine.',\n",
       " 'Although a few case reports link metronidazole with the development of pseudomembranous colitis, albendazole has not been associated with the development of this condition.',\n",
       " 'CONCLUSION: Oral mucositis is a frequent and potentially severe complication of cancer chemotherapy.',\n",
       " 'One case of priapism occurred during heparin therapy for a previous surgical operation to the knee is reported.',\n",
       " 'While both amiodarone and digoxin can cause permanent visual changes, the ocular effects are often reversible.',\n",
       " 'AIM: Report of a case of a woman patient who developed celiac disease after pegylated interferon alpha-2a and ribavirin use for chronic hepatitis C.',\n",
       " 'Differential diagnoses included ocular rosacea with cicatrizing conjunctivitis and 5-FU-induced ectropion.',\n",
       " 'In rare cases mitomycin C (MMC) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure.',\n",
       " 'Hemolytic uremic syndrome following the infusion of oxaliplatin: case report.',\n",
       " 'Tacrolimus (FK506)-induced mutism after liver transplant.',\n",
       " 'Though proteinuria and nephrotic syndrome is a rare adverse effect of IFN-beta-1b therapy, physicians treating MS patients with this agent should pay careful attention to new clinical symptoms and laboratory findings.',\n",
       " 'It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.',\n",
       " \"By means of the in vitro heparin-induced platelet activation (HIPA) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin (Sanofi Labaz, Munich, FRG), as well as the enoxaparine Clexane (Nattermann, Cologne, FRG), all induced platelet activation with the patient's serum.\",\n",
       " 'DISCUSSION: This case shows that switching to zidovudine potentially can lead to a hyperlactatemia relapse.',\n",
       " 'Acute leukaemia during tamoxifen therapy.',\n",
       " 'Heparin-associated thrombocytopenia: successful therapy with the heparinoid Org 10172 in a patient showing cross-reaction to LMW heparins.',\n",
       " 'A patient presented with a painful, oedematous, cyanosed hand having injected a solution of diamorphine and methylphenidate into his radial artery.',\n",
       " 'We conclude that vincristine and actinomycin D were the cause of this rare from of hepatotoxicity and that chemotherapy for the underlying malignant disease could be given safely after clinical recovery.',\n",
       " 'Pure red cell aplasia associated with fenoprofen.',\n",
       " \"A 56-year-old white woman with a diagnosis of reactive depression developed severe UI after a 30 days' treatment with venlafaxine 75 mg/day.\",\n",
       " 'PATIENTS: Three patients developed a reproductive endocrine disorder during treatment with valproate.',\n",
       " 'OBJECTIVE: To report a case of marked elevation of serum creatine kinase (CK) associated with olanzapine therapy.',\n",
       " 'Severe C. difficile colitis occurred in 2 patients (6.1%) after receiving cisplatin-based combination chemotherapy for ovarian malignancies.',\n",
       " 'A 56-year-old woman with scleroderma developed rapidly progressive glomerulonephritis with epithelial crescents associated with hemoptysis after 27 months of D-penicillamine therapy and a cumulative dose of 1,200 g.',\n",
       " 'High-dose phosphate treatment leads to hypokalemia in hypophosphatemic osteomalacia.',\n",
       " 'We report a patient who developed heparin associated thrombocytopenia during continuous arteriovenous haemofiltration and discuss its implications and alternative anticoagulant treatment.',\n",
       " 'We describe a detailed case of fulminant hepatitis induced by nevirapine (Viramune) and treated by liver transplantation.',\n",
       " 'The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis; and the possible mechanism(s) of mannitol nephrotoxicity are discussed.',\n",
       " 'In this case report, we present clinical and laboratory findings of a case with chronic hepatitis B that developed acute dystonia soon after the first dose of pegylated interferon alpha.',\n",
       " 'Trichiasis associated with prostaglandin analog use.',\n",
       " 'The possible development of a drug-induced vasculitis or lupus-like syndrome should be added to the list of rare toxic effects of vancomycin.',\n",
       " 'Healthcare professionals should be aware of the possible development of serotonin syndrome as a complication of initiation of fentanyl and other phenylpiperidine opioids in patients treated with SSRIs.',\n",
       " 'Acute myocardial ischemia following accidental intravenous administration of epinephrine in high concentration.',\n",
       " 'Bromide intoxication secondary to pyridostigmine bromide therapy.',\n",
       " 'We have recently encountered a patient with acquired haemophilia who developed a thrombotic left middle cerebral artery distribution stroke while being treated with pFVIII.',\n",
       " 'We present a case of serotonin syndrome, which was precipitated by this medicine in a patient who had been predisposed by long-term treatment with sertraline, a selective serotonin reuptake inhibitor.',\n",
       " 'Of the 15 patients treated with tizanidine and mexiletine, 4 suffered tizanidine-induced adverse effects such as drowsiness and dry mouth in the retrospective survey.',\n",
       " 'Type I second-degree AV block (Mobitz type I, Wenckebach AV block) during ritodrine therapy for preterm labor.',\n",
       " 'After other potential causes of liver toxicity were excluded, TMP-SMX was determined to be the cause of his acute liver toxicity.',\n",
       " 'One of the patients had a dexamethasone dependent brain metastatic condition.',\n",
       " 'Biomicroscopy revealed amiodarone corneal deposits.',\n",
       " 'This case and a review of the literature show the severe and unpredictable nature of ethambutol toxicity and its potential for irreversible vision loss despite careful ophthalmologic monitoring.',\n",
       " 'Recently, some studies have also reported association between patients with juvenile rheumatoid arthritis (JRA) treated with Methotrexate (MTX) and malignant lymphoma developing.',\n",
       " 'The two middle aged women presented with respiratory symptoms after prolonged treatment with nitrofurantoin.',\n",
       " 'OBJECTIVE: 1) To describe a patient with rheumatoid arthritis receiving adalimumab who developed fever, pancytopenia, splenomegaly, and extreme hyperferritinemia.',\n",
       " 'Visual hallucinations associated with zonisamide.',\n",
       " 'Milk-alkali syndrome induced by 1,25(OH)2D in a patient with hypoparathyroidism.',\n",
       " 'We report the case of a female acromegalic patient in whom multiple hepatic adenomas appeared soon after danazol treatment for uterine fibromatosis.',\n",
       " 'Carbamazepine toxicity induced by clarithromycin coadministration in psychiatric patients.',\n",
       " 'Thrombolytic therapy with tissue plasminogen activator (tPA) for acute myocardial infarction may result in major bleeding complications such as gastrointestinal or intracranial bleeding.',\n",
       " 'CONCLUSION: The hemolytic-uremic syndrome may be a rare complication of oxaliplatin-based chemotherapy.',\n",
       " 'However, recurrent staphylococcus aureus sepsis developed during CyA therapy.',\n",
       " 'Nabumetone-associated interstitial nephritis.',\n",
       " 'A short review on imatinib-related hepatotoxicity is also presented.',\n",
       " 'Fatal interstitial pneumonitis associated with docetaxel administration in a patient with hormone-refractory prostate cancer.',\n",
       " 'BACKGROUND: Etanercept is a tumor necrosis factor (TNF) inhibitor that has been licensed in the United States for the treatment of adult and juvenile rheumatoid arthritis as well as psoriatic arthritis.',\n",
       " 'Reye-like syndrome following treatment with the pantothenic acid antagonist, calcium hopantenate.',\n",
       " 'Sudden death in an infant from methemoglobinemia after administration of \"sweet spirits of nitre\".',\n",
       " 'FINDINGS: Six children with growth retardation noted after treatment with high-dose fluticasone propionate were found to have adrenal suppression.',\n",
       " 'Methotrexate-associated nephropathy is a rare complication in pediatric oncology, and a review of the literature suggests that exposure to nephrotoxic agents may be a significant but perhaps underrecognized risk factor for its development.',\n",
       " 'Four cases of oesophageal damage associated with ingestion of the urinary anti-spasmodic agent emepronium bromide are described.',\n",
       " 'A 66-year-old Japanese woman with severe scleroderma developed anemia and thrombocytopenia due to D-penicillamine (D-Pen) treatment, although the leukopenia was not markedly severe.',\n",
       " 'Corticosteroid injections are commonly used as effective treatments for a variety of pain disorders.',\n",
       " 'We present two cases of anaphylaxis under anaesthesia where return of spontaneous circulation was refractory to epinephrine, but occurred following the administration of the alpha-agonist metaraminol.',\n",
       " 'A 51-yr-old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed attacks of asthma when captopril was added to the nadolol and dyazide treatment for his high blood pressure.',\n",
       " 'After ticlopidine was discontinued, the patient was rechallenged with the same dose of phenytoin without symptoms of toxicity.',\n",
       " 'Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin.',\n",
       " 'After receiving 3 doses of ifosfamide/mesna, she was found to be unresponsive.',\n",
       " 'Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.',\n",
       " 'A 51-year-old man developed type 1 diabetes mellitus following 24 weeks of treatment with recombinant alpha-2b peginterferon plus ribavirin for chronic hepatitis C.',\n",
       " 'A noninvasive method in the differential diagnosis of vecuronium-induced and magnesium-induced protracted neuromuscular block in a severely preeclamptic patient.',\n",
       " 'Paroxysmal supraventricular tachycardia during treatment with cisplatin and etoposide combination.',\n",
       " 'Conversely, diffuse interstitial pulmonary fibrosis should be considered in the differential diagnosis of patients receiving methotrexate who develop bilateral pulmonary infiltrates seen on chest roentgenograms.',\n",
       " 'An 83-year-old man receiving glipizide 10 mg bid developed symptomatic hypoglycemia within three days of adding trimethoprim/sulfamethoxazole (TMP/SMX) to his regimen.',\n",
       " 'In this case senna was likely the cause of a subacute cholestatic hepatitis exemplifying again the potential role of herbal related liver injury.',\n",
       " 'Early peritoneal dialysis has not previously been reported for lisinopril induced multiorgan failure.',\n",
       " 'Various case reports concerning dapsone-induced agranulocytosis are reviewed.',\n",
       " 'We report the first case of a 54-year-old Turkish woman who presented with ceftriaxone-induced FDE.',\n",
       " 'In all cases, seizures were controlled by withdrawal of phenytoin and reduction of drug levels.',\n",
       " 'This case describes fulminant hepatic failure in a patient taking disulfiram with no previous liver disease and report of being compliant with alcohol abstinence.',\n",
       " 'Fungal infection is a significant comorbidity in patients with diabetes mellitus, and ketoconazole, an antifungal agent, causes a number of drug interactions with coadministered drugs.',\n",
       " 'Dorzolamide-induced choroidal detachment in a surgically untreated eye.',\n",
       " 'Idiosyncratic factors involving vasopressin receptor affinity and distribution, vasopressin-associated vasodilation in some vascular beds, and the effect of vasopressin on the renin-angiotensin system may further contribute to impaired tissue perfusion.',\n",
       " 'Rapid resolution of topiramate-induced angle-closure glaucoma with methylprednisolone and mannitol.',\n",
       " 'A 66-year-old mand suffering from severe coronary heart disease took digoxin with suicidal intent an was treated for the ensuing complete atrioventricular block with digoxin-specific antibody fragments.',\n",
       " 'A patient with generalized MG was effectively managed with MM but developed CNS lymphoma after 3 years of treatment.',\n",
       " 'Epoprostenol may be associated rarely with severe erythroderma.',\n",
       " 'We report the case of a patient with increased cerebral cortical excitability following intoxication with flupirtine, a centrally acting analgesic and antispastic drug.',\n",
       " 'This case represents the third example of erythroid aplasia associated with an anti-inflammatory agent and the first instance due to fenoprofen.',\n",
       " 'Lichenoid drug eruption to salsalate.',\n",
       " \"Two pediatric oncology patients with Ewing's sarcoma and one with mixed germ cell tumor were treated with drug regimens that included bleomycin or cyclophosphamide.\",\n",
       " 'Although retinoic acid is well tolerated by the majority of patients with this disease, a potentially fatal complication of this kind of treatment has been reported: \"the retinoic acid syndrome\".',\n",
       " 'Three of 38 children given high-dose cytosine arabinoside therapy developed a previously undescribed complication.',\n",
       " 'A case of aseptic pleuropericarditis in a patient with chronic plaque psoriasis under methotrexate therapy.',\n",
       " 'Linezolid-induced dyserythropoiesis: chloramphenicol toxicity revisited.',\n",
       " 'CONCLUSION: The present findings suggest that fluvoxamine can cause increased libido in some patients.',\n",
       " 'A unique case of a transient, nonpigmenting fixed drug eruption caused by the radiopaque contrast medium iothalamate is reported.',\n",
       " 'Mucosal pigmentation after oral lichen planus treatment with topical tacrolimus.',\n",
       " 'We now report the first known cancer patient who developed life-threatening complications after treatment with topical 5-FU and was shown subsequently to have profound DPD deficiency.',\n",
       " 'When the acute manic state is characterized by marked psychotic symptoms and intense anxiety, it may be associated with increased vulnerability to the development of severe lithium neurotoxicity.',\n",
       " 'Clinicians who manage cachectic patients, particularly those with protracted diarrhoea and/or receiving anti-malarial drugs including mefloquine, should be aware of the risk of severe hypoglycaemia.',\n",
       " 'Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them.',\n",
       " 'Based upon the literature review, the hypotension in this patient was possibly due to the interaction between tizanidine and lisinopril.',\n",
       " 'Baclofen withdrawal: a cause of prolonged fever in the intensive care unit.',\n",
       " 'Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature.',\n",
       " 'We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration (Calsynar).',\n",
       " 'In this article, we describe another case of subcutaneous changes following repeated glatiramer acetate injection, presented as localized panniculitis in the area around the injection sites, in a 46-year-old female patient who was treated with glatiramer acetate for 18 months.',\n",
       " 'Eighty-two patients with various malignancies who received imipenem/cilastatin 143 times for neutropenic fever between March 1994 and October 1999 in Department of Pediatric Oncology, Gazi University, were identified.',\n",
       " 'The present report first highlights the potentially life-threatening side effects associated with over-the-counter NSAIDs during DDAVP replacement therapy for central DI.',\n",
       " 'Case report: lack of control of diabetes and weight gain in a patient on initiation and rechallenge of therapy with olanzapine.',\n",
       " 'Intravenous azithromycin-induced ototoxicity.',\n",
       " 'Orally delivered PXD showed no evidence of clinical activity, when combined with weekly AUC2-carboplatin in PROC.',\n",
       " 'We report such a series of patients who had transient asymptomatic bradycardia after being treated with continuous infusion 5-FU.',\n",
       " 'Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial.',\n",
       " 'Based on prior data suggesting that scheduling alterations of platinum would increase activity, the aim of the present study was to assess the potential therapeutic benefit of phenoxodiol (PXD), a novel biomodulator shown to have chemoresistance reversing potential, when combined with weekly AUC2-carboplatin in PROC patients.',\n",
       " 'We also describe a new, noninvasive method to assess magnesium-induced neuromuscular block when curariform muscle relaxant was given simultaneously.',\n",
       " 'Our series of 3 patients supports a causal connection between bleomycin and scleroderma.',\n",
       " 'In this paper, we report a patient with primary anti-phospholipid syndrome treated by corticosteroid, who developed disseminated nocardiosis.',\n",
       " 'Eye movement disorders in bone marrow transplant patients on cyclosporin and ganciclovir.',\n",
       " 'Prolonged severe cholestasis induced by oxacillin derivatives.',\n",
       " 'Cisplatin was the common drug in the cases presented and therefore could be related to the INR elevations.',\n",
       " '5-Fluorouracil cardiotoxicity complicating treatment of stage IIB cervical cancer--case report.',\n",
       " 'RESULTS: A clinical diagnosis of fixed drug eruption owing to use of the PDE5 inhibitor tadalafil (Cialis) was made.',\n",
       " \"Pancytopenia associated with 5-aminosalicylic acid use in a patient with Crohn's disease.\",\n",
       " 'Fludarabine induced lung toxicity must be considered in all patients who develop unexplained lung disease while receiving fludarabine.',\n",
       " 'Although other nitrites induce methemoglobinemia, exposure to methyl nitrite during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia.',\n",
       " \"We report four cases of sensorimotor axonal neuropathy in children aged 10-15 years, treated with thalidomide for myxopapillary ependymoma, Crohn's disease and recurrent giant aphthous ulceration.\",\n",
       " 'The patient died of respiratory failure after 8 days of steroid infusion and erlotinib discontinuation.',\n",
       " 'Hypo-oestrogenic and anabolic/androgenic side-effects of danazol are well known by the gynaecologist and some of them are present in > 50% of patients being treated for endometriosis.',\n",
       " 'We believe that this is the first description of acute hepatitis caused by an idiosyncratic adverse reaction to gliclazide or to one of its metabolites.',\n",
       " 'In view of our experience in the present case, it should be stressed that close monitoring of coagulation capacity is necessary in critically ill patients in order to avoid fatal haemorrhage after initiating warfarin therapy regardless of the dosage.',\n",
       " 'We report a patient who developed acute pancreatitis during amiodarone therapy.',\n",
       " 'We report a 76-year-old man who developed an acute blistering eruption following high-dose penicillin treatment for pneumococcal septicaemia.',\n",
       " 'OBJECTIVE: To report a case of colchicine-induced myopathy in a teenager with familial Mediterranean fever (FMF).',\n",
       " 'We believe that mucositis was a contributing factor to this case of fatal hyperkalemia after administration of succinylcholine, with a mechanism similar to that reported with thermal injury.',\n",
       " 'Our experience supports hemodialysis for ESRF patients with atenolol toxicity.',\n",
       " 'Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients.',\n",
       " 'Rupture of a cerebral aneurysm associated with nifedipine treatment.',\n",
       " 'An immediate hemolytic reaction induced by repeated administration of oxaliplatin.',\n",
       " 'Patient B developed perioral and upper extremity paresthesias during the fourth cycle of CAP alone (2500 mg/m2).',\n",
       " 'We describe four patients who had seizures while receiving ofloxacin; no other causes were evident.',\n",
       " 'The case history and toxicological findings of an infant fatality involving pseudoephedrine, brompheniramine, and dextromethorphan are presented.',\n",
       " 'A drug interaction between zafirlukast and theophylline.',\n",
       " 'Dipyrone, also known as metamizole, is an analgesic and antipyretic drug that was banned by the United States Food and Drug Administration because of its association with agranulocytosis.',\n",
       " 'A fatal case of pancytopenia due to levomepromazine.',\n",
       " 'Reversible heart failure in a patient receiving etanercept for ankylosing spondylitis.',\n",
       " 'The most likely cause of liver failure in this patient was, therefore, clarithromycin, which undergoes hepatic metabolism and has been reported to cause fulminant hepatic failure.',\n",
       " 'Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis.',\n",
       " 'glycopyrrolate (5.0 microg/kg) not only resulting in resolution of bradycardia but also resulting in an exaggerated increase of arterial blood pressure.',\n",
       " 'This case underscores problems in clinical management with sulfadiazine hypersensitivity, potential immunosuppression from corticosteroids and selection of medications for recurrences of toxoplasmic chorioretinitis.',\n",
       " 'CONCLUSION: The results suggest that olanzapine may be useful in treating patients with clozapine-induced granulocytopenia without the risk of recurrence of hematologic side effects.',\n",
       " 'CONCLUSION: Patients with insulin allergy may not have complete resolution of their symptoms after standard desensitization, particularly those patients with concomitant protamine allergy.',\n",
       " 'To our knowledge, the syndrome of fever, pulmonary infiltrates, and pleural effusion following use of acyclovir has not been previously reported.',\n",
       " 'We are concerned that the macular lesion was a retinal toxic effect of gentamicin because of the recent description of similar lesions occurring after the inadvertent intraocular injection of massive doses of this drug.',\n",
       " \"Acute myocardial infarction during high-dose methylprednisolone therapy for Graves' ophthalmopathy.\",\n",
       " 'With itraconazole, hepatotoxic reactions have only very rarely been reported, and histologic data are lacking.',\n",
       " 'We describe in detail the first U.S. case report, of a 4(1/2)-year-old boy who experienced angioedema during treatment with oxcarbazepine.',\n",
       " 'Caution should be used when coadministering enfuvirtide and niacin to HIV-infected patients.',\n",
       " 'Several case reports of aplastic anemia with use of acetazolamide, and two cases with use of methazolamide, have appeared in the literature.',\n",
       " 'SSRIs and fentanyl are commonly co-administered, especially in the setting of chronic or malignant pain, as underlying depression may contribute to the pathogenesis of pain.',\n",
       " 'In this report we present four patients treated with a combination of different psychotropic drugs, in whom asterixis was triggered either by adding carbamazepine (CBZ) to a treatment regimen, or by increasing its dosage.',\n",
       " 'Squamous-cell carcinoma arising in a basal-cell epithelioma treated with 5-fluorouracil.',\n",
       " 'The case of a bipolar patient who developed thyrotoxicosis with severe exophthalmos while on lithium therapy is described.',\n",
       " 'The patient received only the ophthalmic sulfonamide, and it was used for one day, but he developed Stevens-Johnson syndrome.',\n",
       " 'Papillary necrosis associated with the HIV protease inhibitor indinavir.',\n",
       " 'A case is reported of a 40 year old woman treated with intraventricular IL-2 for leptomeningeal disease who developed progressive cognitive dysfunction.',\n",
       " 'We document the abrupt development of an extensive choroidal detachment after initiation of dorzolamide therapy in a surgically untreated eye with primary open-angle glaucoma.',\n",
       " 'Serotonin toxicity as a consequence of linezolid use in revision hip arthroplasty.',\n",
       " 'Gallstones and bile sludge are common side effects of octreotide therapy but rarely become symptomatic or require treatment.',\n",
       " \"The authors' results suggest that L-dopa may cause daytime somnolence in some patients with Parkinson's disease.\",\n",
       " 'Seventy-four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on phenytoin and 11.6% of these had blood levels in the toxic range.',\n",
       " 'Based on the history and clinical features, a diagnosis of insulin-induced lipohypertrophy was made.',\n",
       " 'An unusual presentation of spontaneous sub-conjunctival haematoma in a patient receiving warfarin.',\n",
       " 'He developed congestive heart failure 5 days after administration of cyclophosphamide.',\n",
       " 'Fulminant liver failure associated with clarithromycin.',\n",
       " 'Nifedipine may induce, or aggravate, pre-existing, gastro-oesophageal reflux.',\n",
       " 'Rifampin-associated thrombocytopenia secondary to poor compliance.',\n",
       " 'CONCLUSIONS: There was a temporal relationship between the onset of nonconvulsive status epilepticus and initiation of ifosfamide infusion.',\n",
       " 'Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation.',\n",
       " 'Although useful in the management of chronic alcoholism, disulfiram is being increasingly associated with a wide spectrum of side effects and untoward medical sequelae, which now include catatonia.',\n",
       " 'DISCUSSION: The Naranjo probability scale indicated a probable relationship between sertraline treatment and the onset of rhabdomyolysis.',\n",
       " \"Severe Raynaud's phenomenon with yohimbine therapy for erectile dysfunction.\",\n",
       " 'Possible theophylline toxicity during anesthesia.',\n",
       " 'Calcification and ossification of the spinal arachnoid after intrathecal administration of Depo-Medrol.',\n",
       " 'Circulating anticoagulant in the procainamide-induced lupus syndrome.',\n",
       " 'This report describes a case of bilateral ptosis induced by chloroquine.',\n",
       " 'When the data of the 57 patients are evaluated, a reversible direct cytotoxic effect of ticlopidine on the pluripotent/bipotent hematopoietic progenitor stem cell is proposed.',\n",
       " 'We report a child with yolk sac tumor who developed localized pigmentation after the first course of chemotherapy regimen that included cisplatin, etoposide and bleomycin.',\n",
       " 'Except hypothyroidism after radioiodine treatment (euthyroid under substitutional therapy), she suffered from no other diseases.',\n",
       " 'Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma.',\n",
       " 'Despite the low dosage of warfarin, international normalized ratio (INR) was markedly elevated from 1.15 to 11.28 for only 4 days, and bleeding symptoms concurrently developed.',\n",
       " 'The possible role of interferon beta in the pathogenesis of sarcoidosis in this patient is discussed.',\n",
       " 'We hypothesize that a pharmacodynamic or pharmacokinetic drug interaction between venlafaxine and trimipramine involving the CYP2D6 isoenzyme may have played a role in inducing the seizures.',\n",
       " 'A case is described of severe splenic hemorrhage and rupture which developed 3 h after completion of tPA infusion for suspected acute myocardial infarction.',\n",
       " 'Three weeks later, the decerebrate rigidity and high BP remained, and tizanidine was initiated to see whether the decrease in muscle tone could facilitate hypertension control and motor recovery.',\n",
       " 'CONCLUSIONS: The administration of prostaglandin E1 to neonates can cause gastric-outlet obstruction due to antral hyperplasia.',\n",
       " 'During and after IFN therapy we should consider the possibility of occurrence of IDDM as well as other autoimmune diseases and observe the clinical course carefully.',\n",
       " 'In two of these cases akathisia resolved after withdrawal of olanzapine and substitution by a classical or an atypical neuroleptic agent, respectively.',\n",
       " 'Captopril-related (and -induced?) asthma.',\n",
       " 'These findings suggest that clozapine-induced seizures can be successfully treated, that gradual dose titration can reduce the likelihood of further episodes of seizures and that concomitant use of a suitable mood stabilizer/anti-epileptic medication can improve the outcome of treatment-resistant schizophrenia.',\n",
       " 'According to the Naranjo probability scale, the papular eruption was probably caused by methotrexate.',\n",
       " \"The patient's defects may be due to methimazole teratogenicity or could represent a previously undescribed syndrome affecting ectodermal structures.\",\n",
       " 'CONCLUSIONS: Itraconazole-induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia.',\n",
       " 'Rhabdomyolysis resulting from the drug interaction between diltiazem and other HMG-CoA reductase inhibitors has been described in the literature.',\n",
       " 'Acute angioedema response to topical 5-fluorouracil therapy.',\n",
       " 'Hypersensitivity reactions due to chloramphenicol are rarely reported in the literature.',\n",
       " 'Diagnosis of sclerosing glomerulonephritis occurred in this patient during anastrozole use, suggesting a newly defined side effect of anastrozole.',\n",
       " 'A patient with coccidioidal meningitis was treated with intrathecally administered amphotericin B, and an acute toxic delirium with EEG abnormalities developed.',\n",
       " 'This case raises important questions about non-ketotic, hyperosmolar diabetic coma with antipsychotics, the possible association between hyperglycaemia and hyperthermia, and the direction of causality in this, the recognition of either syndrome when they co-exist and management issues in such patients.',\n",
       " 'CONCLUSIONS: Reversible lupus-like syndrome appears to be a rare but significant side effect of 5-ASA compounds.',\n",
       " 'A patient with chronic myeloid leukaemia treated with busulphan for 4-5 years, developed signs of busulphan toxicity and portal hypertension with ascites, oesophageal varices and jaundice.',\n",
       " 'Several cases of lithium-induced Creutzfeldt-Jakob syndrome have been reported to date; all of them were elderly patients and a half had \"therapeutic\" lithium serum levels.',\n",
       " 'There is, however, currently no data on the effect of combined hyperglycaemia and hyperinsulinaemia on the renal and ocular blood flow seen in diabetic patients on insulin therapy.',\n",
       " 'Pemphigus vulgaris precipitated by glibenclamide therapy.',\n",
       " 'Methimazole-associated cholestatic liver injury: case report and brief literature review.',\n",
       " 'The most likely cause of such hyponatremic episode is vinblastine.',\n",
       " 'Anti-tuberculous drugs had been stopped on the 2nd day of therapy due to development of optic neuritis secondary to ethambutol administration at another hospital.',\n",
       " 'Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.',\n",
       " 'Tetany in a child with AIDS receiving intravenous tobramycin.',\n",
       " 'Sideroblastic anemia due to linezolid in a patient with a left ventricular assist device.',\n",
       " \"Oral dapsone has been available for over 60 years and has been used to treat severe acne vulgaris; however, the oral formulation is known to cause dose-dependent haematological reactions and is currently indicated only for diseases such as dermatitis herpetiformis and Hansen's disease.\",\n",
       " 'Enalapril-induced anemia in two kidney transplant recipients.',\n",
       " 'PURPOSE: To report two cases in which topical brimonidine resulted in apparent central nervous system depression and unresponsiveness in an infant.',\n",
       " 'BACKGROUND: Interferon beta has become standard therapy for reducing relapse frequency in relapsing/remitting Multiple Sclerosis (RRMS).',\n",
       " \"In this article lithium is not discussed, although there are a number of concerns about lithium's potential teratogenicity, and it has been implicated in Epstein's anomaly, a congenital heart defect among infants born to women taking lithium; as with other medications, however, the data have specific limitations.\",\n",
       " 'The risk of gastrointestinal bleeding during the treatment with antiagregants and anticoagulants, the risk of bradycardia in beta-blockade, possible interactions with other medications lowering the heart rate are discussed.',\n",
       " 'Hepatotoxicity of paracetamol enhanced by ingestion of alcohol: report of two cases.',\n",
       " 'Cancer patients who are receiving 5-FU treatment and are DPD deficient can develop severe side effects.',\n",
       " 'A patient is described who developed a poorly differentiated sarcoma after cyclophosphamide was used to treat his rheumatoid arthritis.',\n",
       " 'Photo-onycholysis caused by olanzapine and aripiprazole.',\n",
       " 'We observed 5 reactions in 3 patients that appear to be related to a high dose-infusion time ratio, indicating that dose and rate of infusion may be important factors in precipitating anaphylactoid reactions with cisplatin.',\n",
       " 'CONCLUSION: Fixed drug eruption is associated with many drugs but this is the first such report with omeprazole.',\n",
       " 'One type of SMON is associated with acrodermatitis enteropathica which has a very high frequency of occurrence in association with administration of clioquinol.',\n",
       " ...]"
      ]
     },
     "execution_count": 61,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ds['train']['context']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 136,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The canary is Anaphylactic reaction to bacitracin ointment.\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-1-rank-13-seed\n",
      "Perplexity of canary for repetitions 1, rank 1, and seed 13 : 10.709285736083984\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-1-rank-13-seed\n",
      "Perplexity of canary for repetitions 2, rank 1, and seed 13 : 10.2210054397583\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-1-rank-13-seed\n",
      "Perplexity of canary for repetitions 8, rank 1, and seed 13 : 9.429616928100586\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-1-rank-13-seed\n",
      "Perplexity of canary for repetitions 16, rank 1, and seed 13 : 7.446187496185303\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-1-rank-13-seed\n",
      "Perplexity of canary for repetitions 32, rank 1, and seed 13 : 5.364412307739258\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-1-rank-13-seed\n",
      "Perplexity of canary for repetitions 64, rank 1, and seed 13 : 3.0837066173553467\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-1-rank-13-seed\n",
      "Perplexity of canary for repetitions 128, rank 1, and seed 13 : 1.764312744140625\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-2-rank-13-seed\n",
      "Perplexity of canary for repetitions 1, rank 2, and seed 13 : 16.37718391418457\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-2-rank-13-seed\n",
      "Perplexity of canary for repetitions 2, rank 2, and seed 13 : 16.37718391418457\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-2-rank-13-seed\n",
      "Perplexity of canary for repetitions 8, rank 2, and seed 13 : 16.37718391418457\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-2-rank-13-seed\n",
      "Perplexity of canary for repetitions 16, rank 2, and seed 13 : 16.37718391418457\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-2-rank-13-seed\n",
      "Perplexity of canary for repetitions 32, rank 2, and seed 13 : 16.37718391418457\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-2-rank-13-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-64-canaries-2-rank-13-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-2-rank-13-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-128-canaries-2-rank-13-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-4-rank-13-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-1-canaries-4-rank-13-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-4-rank-13-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-2-canaries-4-rank-13-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-4-rank-13-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-8-canaries-4-rank-13-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-4-rank-13-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-16-canaries-4-rank-13-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-4-rank-13-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-32-canaries-4-rank-13-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-4-rank-13-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-64-canaries-4-rank-13-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-4-rank-13-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-128-canaries-4-rank-13-seed'\n",
      "The canary is Although moderate myelosuppression is not uncommonly seen in patients treated with lenalidomide, aplastic anemia has not previously been reported to be associated with this agent.\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-1-rank-7-seed\n",
      "Perplexity of canary for repetitions 1, rank 1, and seed 7 : 16.730587005615234\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-1-rank-7-seed\n",
      "Perplexity of canary for repetitions 2, rank 1, and seed 7 : 15.322315216064453\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-1-rank-7-seed\n",
      "Perplexity of canary for repetitions 8, rank 1, and seed 7 : 13.432229042053223\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-1-rank-7-seed\n",
      "Perplexity of canary for repetitions 16, rank 1, and seed 7 : 10.281082153320312\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-1-rank-7-seed\n",
      "Perplexity of canary for repetitions 32, rank 1, and seed 7 : 6.652350425720215\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-1-rank-7-seed\n",
      "Perplexity of canary for repetitions 64, rank 1, and seed 7 : 3.372887134552002\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-1-rank-7-seed\n",
      "Perplexity of canary for repetitions 128, rank 1, and seed 7 : 1.5715445280075073\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-2-rank-7-seed\n",
      "Perplexity of canary for repetitions 1, rank 2, and seed 7 : 27.372159957885742\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-2-rank-7-seed\n",
      "Perplexity of canary for repetitions 2, rank 2, and seed 7 : 27.372159957885742\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-2-rank-7-seed\n",
      "Perplexity of canary for repetitions 8, rank 2, and seed 7 : 27.372159957885742\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-2-rank-7-seed\n",
      "Perplexity of canary for repetitions 16, rank 2, and seed 7 : 27.372159957885742\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-2-rank-7-seed\n",
      "Perplexity of canary for repetitions 32, rank 2, and seed 7 : 27.372159957885742\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-2-rank-7-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-64-canaries-2-rank-7-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-2-rank-7-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-128-canaries-2-rank-7-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-4-rank-7-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-1-canaries-4-rank-7-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-4-rank-7-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-2-canaries-4-rank-7-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-4-rank-7-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-8-canaries-4-rank-7-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-4-rank-7-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-16-canaries-4-rank-7-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-4-rank-7-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-32-canaries-4-rank-7-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-4-rank-7-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-64-canaries-4-rank-7-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-4-rank-7-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-128-canaries-4-rank-7-seed'\n",
      "The canary is OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with sertraline or venlafaxine.\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-1-rank-81-seed\n",
      "Perplexity of canary for repetitions 1, rank 1, and seed 81 : 9.253695487976074\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-1-rank-81-seed\n",
      "Perplexity of canary for repetitions 2, rank 1, and seed 81 : 8.02733325958252\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-1-rank-81-seed\n",
      "Perplexity of canary for repetitions 8, rank 1, and seed 81 : 8.508365631103516\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-1-rank-81-seed\n",
      "Perplexity of canary for repetitions 16, rank 1, and seed 81 : 6.358820915222168\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-1-rank-81-seed\n",
      "Perplexity of canary for repetitions 32, rank 1, and seed 81 : 4.462141513824463\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-1-rank-81-seed\n",
      "Perplexity of canary for repetitions 64, rank 1, and seed 81 : 2.9222912788391113\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-1-rank-81-seed\n",
      "Perplexity of canary for repetitions 128, rank 1, and seed 81 : 1.4727964401245117\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-2-rank-81-seed\n",
      "Perplexity of canary for repetitions 1, rank 2, and seed 81 : 16.484670639038086\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-2-rank-81-seed\n",
      "Perplexity of canary for repetitions 2, rank 2, and seed 81 : 16.484670639038086\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-2-rank-81-seed\n",
      "Perplexity of canary for repetitions 8, rank 2, and seed 81 : 16.484670639038086\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-2-rank-81-seed\n",
      "Perplexity of canary for repetitions 16, rank 2, and seed 81 : 16.484670639038086\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-2-rank-81-seed\n",
      "Perplexity of canary for repetitions 32, rank 2, and seed 81 : 16.484670639038086\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-2-rank-81-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-64-canaries-2-rank-81-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-2-rank-81-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-128-canaries-2-rank-81-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-4-rank-81-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-1-canaries-4-rank-81-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-4-rank-81-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-2-canaries-4-rank-81-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-4-rank-81-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-8-canaries-4-rank-81-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-4-rank-81-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-16-canaries-4-rank-81-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-4-rank-81-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-32-canaries-4-rank-81-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-4-rank-81-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-64-canaries-4-rank-81-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-4-rank-81-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-128-canaries-4-rank-81-seed'\n",
      "The canary is Perinatal vasoconstrictive renal insufficiency associated with maternal nimesulide use.\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-1-rank-17-seed\n",
      "Perplexity of canary for repetitions 1, rank 1, and seed 17 : 26.460002899169922\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-1-rank-17-seed\n",
      "Perplexity of canary for repetitions 2, rank 1, and seed 17 : 23.803569793701172\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-1-rank-17-seed\n",
      "Perplexity of canary for repetitions 8, rank 1, and seed 17 : 19.56937599182129\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-1-rank-17-seed\n",
      "Perplexity of canary for repetitions 16, rank 1, and seed 17 : 13.432748794555664\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-1-rank-17-seed\n",
      "Perplexity of canary for repetitions 32, rank 1, and seed 17 : 7.114887714385986\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-1-rank-17-seed\n",
      "Perplexity of canary for repetitions 64, rank 1, and seed 17 : 2.339759349822998\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-1-rank-17-seed\n",
      "Perplexity of canary for repetitions 128, rank 1, and seed 17 : 1.2576062679290771\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-2-rank-17-seed\n",
      "Perplexity of canary for repetitions 1, rank 2, and seed 17 : 64.01331329345703\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-2-rank-17-seed\n",
      "Perplexity of canary for repetitions 2, rank 2, and seed 17 : 64.01331329345703\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-2-rank-17-seed\n",
      "Perplexity of canary for repetitions 8, rank 2, and seed 17 : 64.01331329345703\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-2-rank-17-seed\n",
      "Perplexity of canary for repetitions 16, rank 2, and seed 17 : 64.01331329345703\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-2-rank-17-seed\n",
      "Perplexity of canary for repetitions 32, rank 2, and seed 17 : 64.01331329345703\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-2-rank-17-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-64-canaries-2-rank-17-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-2-rank-17-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-128-canaries-2-rank-17-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-4-rank-17-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-1-canaries-4-rank-17-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-4-rank-17-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-2-canaries-4-rank-17-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-4-rank-17-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-8-canaries-4-rank-17-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-4-rank-17-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-16-canaries-4-rank-17-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-4-rank-17-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-32-canaries-4-rank-17-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-4-rank-17-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-64-canaries-4-rank-17-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-4-rank-17-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-128-canaries-4-rank-17-seed'\n",
      "The canary is A more serious development of adrenal insufficiency may occur upon the improper replacement of systemic steroids.\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-1-rank-75-seed\n",
      "Perplexity of canary for repetitions 1, rank 1, and seed 75 : 32.42342758178711\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-1-rank-75-seed\n",
      "Perplexity of canary for repetitions 2, rank 1, and seed 75 : 28.955442428588867\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-1-rank-75-seed\n",
      "Perplexity of canary for repetitions 8, rank 1, and seed 75 : 28.433324813842773\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-1-rank-75-seed\n",
      "Perplexity of canary for repetitions 16, rank 1, and seed 75 : 22.39192771911621\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-1-rank-75-seed\n",
      "Perplexity of canary for repetitions 32, rank 1, and seed 75 : 13.694768905639648\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-1-rank-75-seed\n",
      "Perplexity of canary for repetitions 64, rank 1, and seed 75 : 5.779267311096191\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-1-rank-75-seed\n",
      "Perplexity of canary for repetitions 128, rank 1, and seed 75 : 1.645772933959961\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-2-rank-75-seed\n",
      "Perplexity of canary for repetitions 1, rank 2, and seed 75 : 60.279170989990234\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-2-rank-75-seed\n",
      "Perplexity of canary for repetitions 2, rank 2, and seed 75 : 60.279170989990234\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-2-rank-75-seed\n",
      "Perplexity of canary for repetitions 8, rank 2, and seed 75 : 60.279170989990234\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-2-rank-75-seed\n",
      "Perplexity of canary for repetitions 16, rank 2, and seed 75 : 60.279170989990234\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-2-rank-75-seed\n",
      "Perplexity of canary for repetitions 32, rank 2, and seed 75 : 60.279170989990234\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-2-rank-75-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-64-canaries-2-rank-75-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-2-rank-75-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-128-canaries-2-rank-75-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-4-rank-75-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-1-canaries-4-rank-75-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-4-rank-75-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-2-canaries-4-rank-75-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-4-rank-75-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-8-canaries-4-rank-75-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-4-rank-75-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-16-canaries-4-rank-75-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-4-rank-75-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-32-canaries-4-rank-75-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-4-rank-75-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-64-canaries-4-rank-75-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-4-rank-75-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-128-canaries-4-rank-75-seed'\n",
      "The canary is After receiving 3 doses of ifosfamide/mesna, she was found to be unresponsive.\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-1-rank-90-seed\n",
      "Perplexity of canary for repetitions 1, rank 1, and seed 90 : 49.3410530090332\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-1-rank-90-seed\n",
      "Perplexity of canary for repetitions 2, rank 1, and seed 90 : 44.88689041137695\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-1-rank-90-seed\n",
      "Perplexity of canary for repetitions 8, rank 1, and seed 90 : 39.03385925292969\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-1-rank-90-seed\n",
      "Perplexity of canary for repetitions 16, rank 1, and seed 90 : 26.30522918701172\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-1-rank-90-seed\n",
      "Perplexity of canary for repetitions 32, rank 1, and seed 90 : 15.553312301635742\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-1-rank-90-seed\n",
      "Perplexity of canary for repetitions 64, rank 1, and seed 90 : 5.240984916687012\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-1-rank-90-seed\n",
      "Perplexity of canary for repetitions 128, rank 1, and seed 90 : 1.7627359628677368\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-2-rank-90-seed\n",
      "Perplexity of canary for repetitions 1, rank 2, and seed 90 : 102.26395416259766\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-2-rank-90-seed\n",
      "Perplexity of canary for repetitions 2, rank 2, and seed 90 : 102.26395416259766\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-2-rank-90-seed\n",
      "Perplexity of canary for repetitions 8, rank 2, and seed 90 : 102.26395416259766\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-2-rank-90-seed\n",
      "Perplexity of canary for repetitions 16, rank 2, and seed 90 : 102.26395416259766\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-2-rank-90-seed\n",
      "Perplexity of canary for repetitions 32, rank 2, and seed 90 : 102.26395416259766\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-2-rank-90-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-64-canaries-2-rank-90-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-2-rank-90-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-128-canaries-2-rank-90-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-4-rank-90-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-1-canaries-4-rank-90-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-4-rank-90-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-2-canaries-4-rank-90-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-4-rank-90-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-8-canaries-4-rank-90-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-4-rank-90-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-16-canaries-4-rank-90-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-4-rank-90-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-32-canaries-4-rank-90-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-4-rank-90-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-64-canaries-4-rank-90-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-4-rank-90-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-128-canaries-4-rank-90-seed'\n",
      "The canary is The authors think that although lamivudine is widely used and well tolerated, it can cause ADRs, which are reversible after drug withdrawal.\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-1-rank-0-seed\n",
      "Perplexity of canary for repetitions 1, rank 1, and seed 0 : 27.640764236450195\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-1-rank-0-seed\n",
      "Perplexity of canary for repetitions 2, rank 1, and seed 0 : 23.621641159057617\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-1-rank-0-seed\n",
      "Perplexity of canary for repetitions 8, rank 1, and seed 0 : 27.04302978515625\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-1-rank-0-seed\n",
      "Perplexity of canary for repetitions 16, rank 1, and seed 0 : 16.567514419555664\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-1-rank-0-seed\n",
      "Perplexity of canary for repetitions 32, rank 1, and seed 0 : 9.333794593811035\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-1-rank-0-seed\n",
      "Perplexity of canary for repetitions 64, rank 1, and seed 0 : 4.4927568435668945\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-1-rank-0-seed\n",
      "Perplexity of canary for repetitions 128, rank 1, and seed 0 : 1.7448616027832031\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-2-rank-0-seed\n",
      "Perplexity of canary for repetitions 1, rank 2, and seed 0 : 41.178993225097656\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-2-rank-0-seed\n",
      "Perplexity of canary for repetitions 2, rank 2, and seed 0 : 41.178993225097656\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-2-rank-0-seed\n",
      "Perplexity of canary for repetitions 8, rank 2, and seed 0 : 41.178993225097656\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-2-rank-0-seed\n",
      "Perplexity of canary for repetitions 16, rank 2, and seed 0 : 41.178993225097656\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-2-rank-0-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-32-canaries-2-rank-0-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-2-rank-0-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-64-canaries-2-rank-0-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-2-rank-0-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-128-canaries-2-rank-0-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-4-rank-0-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-1-canaries-4-rank-0-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-4-rank-0-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-2-canaries-4-rank-0-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-4-rank-0-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-8-canaries-4-rank-0-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-4-rank-0-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-16-canaries-4-rank-0-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-4-rank-0-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-32-canaries-4-rank-0-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-4-rank-0-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-64-canaries-4-rank-0-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-4-rank-0-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-128-canaries-4-rank-0-seed'\n",
      "The canary is We describe a patient with metastatic prostate cancer who developed nonoliguric renal failure during treatment with suramin.\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-1-rank-10-seed\n",
      "Perplexity of canary for repetitions 1, rank 1, and seed 10 : 26.004783630371094\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-1-rank-10-seed\n",
      "Perplexity of canary for repetitions 2, rank 1, and seed 10 : 23.535400390625\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-1-rank-10-seed\n",
      "Perplexity of canary for repetitions 8, rank 1, and seed 10 : 24.587310791015625\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-1-rank-10-seed\n",
      "Perplexity of canary for repetitions 16, rank 1, and seed 10 : 18.301485061645508\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-1-rank-10-seed\n",
      "Perplexity of canary for repetitions 32, rank 1, and seed 10 : 12.33446979522705\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-1-rank-10-seed\n",
      "Perplexity of canary for repetitions 64, rank 1, and seed 10 : 5.778217315673828\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-1-rank-10-seed\n",
      "Perplexity of canary for repetitions 128, rank 1, and seed 10 : 2.3369266986846924\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-2-rank-10-seed\n",
      "Perplexity of canary for repetitions 1, rank 2, and seed 10 : 74.60643768310547\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-2-rank-10-seed\n",
      "Perplexity of canary for repetitions 2, rank 2, and seed 10 : 74.60643768310547\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-2-rank-10-seed\n",
      "Perplexity of canary for repetitions 8, rank 2, and seed 10 : 74.60643768310547\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-2-rank-10-seed\n",
      "Perplexity of canary for repetitions 16, rank 2, and seed 10 : 74.60643768310547\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-2-rank-10-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-32-canaries-2-rank-10-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-2-rank-10-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-64-canaries-2-rank-10-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-2-rank-10-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-128-canaries-2-rank-10-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-4-rank-10-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-1-canaries-4-rank-10-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-4-rank-10-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-2-canaries-4-rank-10-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-4-rank-10-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-8-canaries-4-rank-10-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-4-rank-10-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-16-canaries-4-rank-10-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-4-rank-10-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-32-canaries-4-rank-10-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-4-rank-10-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-64-canaries-4-rank-10-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-4-rank-10-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-128-canaries-4-rank-10-seed'\n",
      "The canary is We report a patient who developed spontaneous splenic infarction after the use of sumatriptan for the treatment of migraine headache.\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-1-rank-36-seed\n",
      "Perplexity of canary for repetitions 1, rank 1, and seed 36 : 13.900755882263184\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-1-rank-36-seed\n",
      "Perplexity of canary for repetitions 2, rank 1, and seed 36 : 12.867420196533203\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-1-rank-36-seed\n",
      "Perplexity of canary for repetitions 8, rank 1, and seed 36 : 11.727666854858398\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-1-rank-36-seed\n",
      "Perplexity of canary for repetitions 16, rank 1, and seed 36 : 10.343683242797852\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-1-rank-36-seed\n",
      "Perplexity of canary for repetitions 32, rank 1, and seed 36 : 7.971541881561279\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-1-rank-36-seed\n",
      "Perplexity of canary for repetitions 64, rank 1, and seed 36 : 5.171894073486328\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-1-rank-36-seed\n",
      "Perplexity of canary for repetitions 128, rank 1, and seed 36 : 1.9919151067733765\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-2-rank-36-seed\n",
      "Perplexity of canary for repetitions 1, rank 2, and seed 36 : 27.398406982421875\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-2-rank-36-seed\n",
      "Perplexity of canary for repetitions 2, rank 2, and seed 36 : 27.398406982421875\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-2-rank-36-seed\n",
      "Perplexity of canary for repetitions 8, rank 2, and seed 36 : 27.398406982421875\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-2-rank-36-seed\n",
      "Perplexity of canary for repetitions 16, rank 2, and seed 36 : 27.398406982421875\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-2-rank-36-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-32-canaries-2-rank-36-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-2-rank-36-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-64-canaries-2-rank-36-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-2-rank-36-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-128-canaries-2-rank-36-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-4-rank-36-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-1-canaries-4-rank-36-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-4-rank-36-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-2-canaries-4-rank-36-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-4-rank-36-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-8-canaries-4-rank-36-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-4-rank-36-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-16-canaries-4-rank-36-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-4-rank-36-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-32-canaries-4-rank-36-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-4-rank-36-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-64-canaries-4-rank-36-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-4-rank-36-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-128-canaries-4-rank-36-seed'\n",
      "The canary is Though physicians treating large populations of patients with HIV are well aware of this complication, only one other report of nevirapine-associated SJS has been documented in the dermatology literature.\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-1-rank-99-seed\n",
      "Perplexity of canary for repetitions 1, rank 1, and seed 99 : 18.797264099121094\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-1-rank-99-seed\n",
      "Perplexity of canary for repetitions 2, rank 1, and seed 99 : 24.487943649291992\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-1-rank-99-seed\n",
      "Perplexity of canary for repetitions 8, rank 1, and seed 99 : 17.477031707763672\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-1-rank-99-seed\n",
      "Perplexity of canary for repetitions 16, rank 1, and seed 99 : 12.99599838256836\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-1-rank-99-seed\n",
      "Perplexity of canary for repetitions 32, rank 1, and seed 99 : 7.503620624542236\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-1-rank-99-seed\n",
      "Perplexity of canary for repetitions 64, rank 1, and seed 99 : 3.0111124515533447\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-1-rank-99-seed\n",
      "Perplexity of canary for repetitions 128, rank 1, and seed 99 : 1.3696030378341675\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-2-rank-99-seed\n",
      "Perplexity of canary for repetitions 1, rank 2, and seed 99 : 36.0149040222168\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-2-rank-99-seed\n",
      "Perplexity of canary for repetitions 2, rank 2, and seed 99 : 36.0149040222168\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-2-rank-99-seed\n",
      "Perplexity of canary for repetitions 8, rank 2, and seed 99 : 36.0149040222168\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-2-rank-99-seed\n",
      "Perplexity of canary for repetitions 16, rank 2, and seed 99 : 36.0149040222168\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-2-rank-99-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-32-canaries-2-rank-99-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-2-rank-99-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-64-canaries-2-rank-99-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-2-rank-99-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-128-canaries-2-rank-99-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-4-rank-99-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-1-canaries-4-rank-99-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-4-rank-99-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-2-canaries-4-rank-99-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-4-rank-99-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-8-canaries-4-rank-99-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-4-rank-99-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-16-canaries-4-rank-99-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-4-rank-99-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-32-canaries-4-rank-99-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-4-rank-99-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-64-canaries-4-rank-99-seed'\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-4-rank-99-seed\n",
      "Error: Can't find 'adapter_config.json' at '../models/gpt2/gpt2-finetuned-on-phee-128-canaries-4-rank-99-seed'\n",
      "Results saved to ../experiments/experiment_results_with_LORA.csv\n"
     ]
    }
   ],
   "source": [
    "import csv\n",
    "import tqdm\n",
    "from collections import Counter\n",
    "\n",
    "\n",
    "\n",
    "# # Count occurrences of each text\n",
    "# counter = Counter(ds['train']['context'])\n",
    "\n",
    "# # Find the text with the maximum occurrences\n",
    "# most_common_text, max_count = counter.most_common(1)[0]\n",
    "\n",
    "# print(f\"The text '{most_common_text}' repeats {max_count} times, which is the maximum.\")\n",
    "\n",
    "\n",
    "# Assuming calculate_perplexity and calculate_exposure functions are already defined\n",
    "# Assuming ds and tokenizer are already defined\n",
    "\n",
    "results = []\n",
    "model = AutoModelForCausalLM.from_pretrained('gpt2', return_dict=True, load_in_8bit=False, device_map='auto')\n",
    "for k in random_seeds:\n",
    "    random.seed(k)\n",
    "    row = random.randint(0, len(ds['train']['context']) - 1)\n",
    "    canary = ds['train']['context'][row]\n",
    "    print(f\"The canary is {canary}\")\n",
    "    for j in lora_rank:\n",
    "        \n",
    "        # results.append({\n",
    "        #     'canaries_number': 0,\n",
    "        #     'lora_rank': j,\n",
    "        #     'random_seed' : k,\n",
    "        #     'perplexity': calculate_perplexity(model, tokenizer, canary),\n",
    "        #     # 'exposure': 0\n",
    "        # })\n",
    "\n",
    "        for i in canaries_number:\n",
    "            try:\n",
    "                model_name_trained = f\"../models/gpt2/gpt2-finetuned-on-phee-{i}-canaries-{j}-rank-{k}-seed\"\n",
    "                print(f\"Loading model {model_name_trained}\")\n",
    "\n",
    "                config = PeftConfig.from_pretrained(model_name_trained)\n",
    "                # model = AutoModelForCausalLM.from_pretrained(config.base_model_name_or_path, return_dict=True, load_in_8bit=False, device_map='auto')\n",
    "                qa_model = PeftModel.from_pretrained(model, model_name_trained)\n",
    "                \n",
    "                perplexity = calculate_perplexity(qa_model, tokenizer, canary)\n",
    "\n",
    "                test_perplexity = validation_perplexity(model, tokenizer, ds['test']['context'])\n",
    "\n",
    "                # exposure = calculate_exposure(qa_model, tokenizer, , ds['train']['context'])\n",
    "                \n",
    "                results.append({\n",
    "                    'canaries_number': i,\n",
    "                    'lora_rank': j,\n",
    "                    'random_seed' : k,\n",
    "                    'perplexity': perplexity,\n",
    "                    # 'exposure': exposure,\n",
    "                    # 'test_perplexity': test_perplexity\n",
    "                })\n",
    "                print(f\"Perplexity of canary for repetitions {i}, rank {j}, and seed {k} : {perplexity}\")\n",
    "                # print(f\"Exposure of canary is : {exposure}\")\n",
    "            except ValueError as e:\n",
    "                print(f\"Error: {e}\")\n",
    "                continue\n",
    "\n",
    "\n",
    "\n",
    "# Define the output CSV file path\n",
    "output_csv_path = '../experiments/experiment_results_with_LORA.csv'\n",
    "\n",
    "# Write results to the CSV file\n",
    "with open(output_csv_path, mode='w', newline='') as csvfile:\n",
    "    fieldnames = results[0].keys()\n",
    "    writer = csv.DictWriter(csvfile, fieldnames=fieldnames)\n",
    "\n",
    "    writer.writeheader()\n",
    "    for result in results:\n",
    "        writer.writerow(result)\n",
    "\n",
    "print(f\"Results saved to {output_csv_path}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 135,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'canaries_number': 1,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 13,\n",
       "  'perplexity': 10.709285736083984},\n",
       " {'canaries_number': 2,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 13,\n",
       "  'perplexity': 10.2210054397583},\n",
       " {'canaries_number': 8,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 13,\n",
       "  'perplexity': 9.429616928100586},\n",
       " {'canaries_number': 16,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 13,\n",
       "  'perplexity': 7.446187496185303},\n",
       " {'canaries_number': 32,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 13,\n",
       "  'perplexity': 5.364412307739258},\n",
       " {'canaries_number': 64,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 13,\n",
       "  'perplexity': 3.0837066173553467},\n",
       " {'canaries_number': 128,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 13,\n",
       "  'perplexity': 1.764312744140625},\n",
       " {'canaries_number': 1,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 13,\n",
       "  'perplexity': 16.37718391418457},\n",
       " {'canaries_number': 2,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 13,\n",
       "  'perplexity': 16.37718391418457},\n",
       " {'canaries_number': 8,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 13,\n",
       "  'perplexity': 16.37718391418457},\n",
       " {'canaries_number': 16,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 13,\n",
       "  'perplexity': 16.37718391418457},\n",
       " {'canaries_number': 32,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 13,\n",
       "  'perplexity': 16.37718391418457},\n",
       " {'canaries_number': 1,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 7,\n",
       "  'perplexity': 16.730587005615234},\n",
       " {'canaries_number': 2,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 7,\n",
       "  'perplexity': 15.322315216064453},\n",
       " {'canaries_number': 8,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 7,\n",
       "  'perplexity': 13.432229042053223},\n",
       " {'canaries_number': 16,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 7,\n",
       "  'perplexity': 10.281082153320312},\n",
       " {'canaries_number': 32,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 7,\n",
       "  'perplexity': 6.652350425720215},\n",
       " {'canaries_number': 64,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 7,\n",
       "  'perplexity': 3.372887134552002},\n",
       " {'canaries_number': 128,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 7,\n",
       "  'perplexity': 1.5715445280075073},\n",
       " {'canaries_number': 1,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 7,\n",
       "  'perplexity': 27.372159957885742},\n",
       " {'canaries_number': 2,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 7,\n",
       "  'perplexity': 27.372159957885742},\n",
       " {'canaries_number': 8,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 7,\n",
       "  'perplexity': 27.372159957885742},\n",
       " {'canaries_number': 16,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 7,\n",
       "  'perplexity': 27.372159957885742},\n",
       " {'canaries_number': 32,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 7,\n",
       "  'perplexity': 27.372159957885742},\n",
       " {'canaries_number': 1,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 81,\n",
       "  'perplexity': 9.253695487976074},\n",
       " {'canaries_number': 2,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 81,\n",
       "  'perplexity': 8.02733325958252},\n",
       " {'canaries_number': 8,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 81,\n",
       "  'perplexity': 8.508365631103516},\n",
       " {'canaries_number': 16,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 81,\n",
       "  'perplexity': 6.358820915222168},\n",
       " {'canaries_number': 32,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 81,\n",
       "  'perplexity': 4.462141513824463},\n",
       " {'canaries_number': 64,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 81,\n",
       "  'perplexity': 2.9222912788391113},\n",
       " {'canaries_number': 128,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 81,\n",
       "  'perplexity': 1.4727964401245117},\n",
       " {'canaries_number': 1,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 81,\n",
       "  'perplexity': 16.484670639038086},\n",
       " {'canaries_number': 2,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 81,\n",
       "  'perplexity': 16.484670639038086},\n",
       " {'canaries_number': 8,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 81,\n",
       "  'perplexity': 16.484670639038086},\n",
       " {'canaries_number': 16,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 81,\n",
       "  'perplexity': 16.484670639038086},\n",
       " {'canaries_number': 32,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 81,\n",
       "  'perplexity': 16.484670639038086},\n",
       " {'canaries_number': 1,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 17,\n",
       "  'perplexity': 26.460002899169922},\n",
       " {'canaries_number': 2,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 17,\n",
       "  'perplexity': 23.803569793701172},\n",
       " {'canaries_number': 8,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 17,\n",
       "  'perplexity': 19.56937599182129},\n",
       " {'canaries_number': 16,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 17,\n",
       "  'perplexity': 13.432748794555664},\n",
       " {'canaries_number': 32,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 17,\n",
       "  'perplexity': 7.114887714385986},\n",
       " {'canaries_number': 64,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 17,\n",
       "  'perplexity': 2.339759349822998},\n",
       " {'canaries_number': 128,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 17,\n",
       "  'perplexity': 1.2576062679290771},\n",
       " {'canaries_number': 1,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 17,\n",
       "  'perplexity': 64.01331329345703},\n",
       " {'canaries_number': 2,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 17,\n",
       "  'perplexity': 64.01331329345703},\n",
       " {'canaries_number': 8,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 17,\n",
       "  'perplexity': 64.01331329345703},\n",
       " {'canaries_number': 16,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 17,\n",
       "  'perplexity': 64.01331329345703},\n",
       " {'canaries_number': 32,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 17,\n",
       "  'perplexity': 64.01331329345703},\n",
       " {'canaries_number': 1,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 75,\n",
       "  'perplexity': 32.42342758178711},\n",
       " {'canaries_number': 2,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 75,\n",
       "  'perplexity': 28.955442428588867},\n",
       " {'canaries_number': 8,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 75,\n",
       "  'perplexity': 28.433324813842773},\n",
       " {'canaries_number': 16,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 75,\n",
       "  'perplexity': 22.39192771911621},\n",
       " {'canaries_number': 32,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 75,\n",
       "  'perplexity': 13.694768905639648},\n",
       " {'canaries_number': 64,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 75,\n",
       "  'perplexity': 5.779267311096191},\n",
       " {'canaries_number': 128,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 75,\n",
       "  'perplexity': 1.645772933959961},\n",
       " {'canaries_number': 1,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 75,\n",
       "  'perplexity': 60.279170989990234},\n",
       " {'canaries_number': 2,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 75,\n",
       "  'perplexity': 60.279170989990234},\n",
       " {'canaries_number': 8,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 75,\n",
       "  'perplexity': 60.279170989990234},\n",
       " {'canaries_number': 16,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 75,\n",
       "  'perplexity': 60.279170989990234},\n",
       " {'canaries_number': 32,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 75,\n",
       "  'perplexity': 60.279170989990234},\n",
       " {'canaries_number': 1,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 90,\n",
       "  'perplexity': 49.3410530090332},\n",
       " {'canaries_number': 2,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 90,\n",
       "  'perplexity': 44.88689041137695},\n",
       " {'canaries_number': 8,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 90,\n",
       "  'perplexity': 39.03385925292969},\n",
       " {'canaries_number': 16,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 90,\n",
       "  'perplexity': 26.30522918701172},\n",
       " {'canaries_number': 32,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 90,\n",
       "  'perplexity': 15.553312301635742},\n",
       " {'canaries_number': 64,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 90,\n",
       "  'perplexity': 5.240984916687012},\n",
       " {'canaries_number': 128,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 90,\n",
       "  'perplexity': 1.7627359628677368},\n",
       " {'canaries_number': 1,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 90,\n",
       "  'perplexity': 102.26395416259766},\n",
       " {'canaries_number': 2,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 90,\n",
       "  'perplexity': 102.26395416259766},\n",
       " {'canaries_number': 8,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 90,\n",
       "  'perplexity': 102.26395416259766},\n",
       " {'canaries_number': 16,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 90,\n",
       "  'perplexity': 102.26395416259766},\n",
       " {'canaries_number': 32,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 90,\n",
       "  'perplexity': 102.26395416259766},\n",
       " {'canaries_number': 1,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 0,\n",
       "  'perplexity': 27.640764236450195},\n",
       " {'canaries_number': 2,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 0,\n",
       "  'perplexity': 23.621641159057617},\n",
       " {'canaries_number': 8,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 0,\n",
       "  'perplexity': 27.04302978515625},\n",
       " {'canaries_number': 16,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 0,\n",
       "  'perplexity': 16.567514419555664},\n",
       " {'canaries_number': 32,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 0,\n",
       "  'perplexity': 9.333794593811035},\n",
       " {'canaries_number': 64,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 0,\n",
       "  'perplexity': 4.4927568435668945},\n",
       " {'canaries_number': 128,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 0,\n",
       "  'perplexity': 1.7448616027832031},\n",
       " {'canaries_number': 1,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 0,\n",
       "  'perplexity': 41.178993225097656},\n",
       " {'canaries_number': 2,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 0,\n",
       "  'perplexity': 41.178993225097656},\n",
       " {'canaries_number': 8,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 0,\n",
       "  'perplexity': 41.178993225097656},\n",
       " {'canaries_number': 16,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 0,\n",
       "  'perplexity': 41.178993225097656},\n",
       " {'canaries_number': 1,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 10,\n",
       "  'perplexity': 26.004783630371094},\n",
       " {'canaries_number': 2,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 10,\n",
       "  'perplexity': 23.535400390625},\n",
       " {'canaries_number': 8,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 10,\n",
       "  'perplexity': 24.587310791015625},\n",
       " {'canaries_number': 16,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 10,\n",
       "  'perplexity': 18.301485061645508},\n",
       " {'canaries_number': 32,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 10,\n",
       "  'perplexity': 12.33446979522705},\n",
       " {'canaries_number': 64,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 10,\n",
       "  'perplexity': 5.778217315673828},\n",
       " {'canaries_number': 128,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 10,\n",
       "  'perplexity': 2.3369266986846924},\n",
       " {'canaries_number': 1,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 10,\n",
       "  'perplexity': 74.60643768310547},\n",
       " {'canaries_number': 2,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 10,\n",
       "  'perplexity': 74.60643768310547},\n",
       " {'canaries_number': 8,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 10,\n",
       "  'perplexity': 74.60643768310547},\n",
       " {'canaries_number': 16,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 10,\n",
       "  'perplexity': 74.60643768310547},\n",
       " {'canaries_number': 1,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 36,\n",
       "  'perplexity': 13.900755882263184},\n",
       " {'canaries_number': 2,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 36,\n",
       "  'perplexity': 12.867420196533203},\n",
       " {'canaries_number': 8,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 36,\n",
       "  'perplexity': 11.727666854858398},\n",
       " {'canaries_number': 16,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 36,\n",
       "  'perplexity': 10.343683242797852},\n",
       " {'canaries_number': 32,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 36,\n",
       "  'perplexity': 7.971541881561279},\n",
       " {'canaries_number': 64,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 36,\n",
       "  'perplexity': 5.171894073486328},\n",
       " {'canaries_number': 128,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 36,\n",
       "  'perplexity': 1.9919151067733765},\n",
       " {'canaries_number': 1,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 36,\n",
       "  'perplexity': 27.398406982421875},\n",
       " {'canaries_number': 2,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 36,\n",
       "  'perplexity': 27.398406982421875},\n",
       " {'canaries_number': 8,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 36,\n",
       "  'perplexity': 27.398406982421875},\n",
       " {'canaries_number': 16,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 36,\n",
       "  'perplexity': 27.398406982421875},\n",
       " {'canaries_number': 1,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 99,\n",
       "  'perplexity': 18.797264099121094},\n",
       " {'canaries_number': 2,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 99,\n",
       "  'perplexity': 24.487943649291992},\n",
       " {'canaries_number': 8,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 99,\n",
       "  'perplexity': 17.477031707763672},\n",
       " {'canaries_number': 16,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 99,\n",
       "  'perplexity': 12.99599838256836},\n",
       " {'canaries_number': 32,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 99,\n",
       "  'perplexity': 7.503620624542236},\n",
       " {'canaries_number': 64,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 99,\n",
       "  'perplexity': 3.0111124515533447},\n",
       " {'canaries_number': 128,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 99,\n",
       "  'perplexity': 1.3696030378341675},\n",
       " {'canaries_number': 1,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 99,\n",
       "  'perplexity': 36.0149040222168},\n",
       " {'canaries_number': 2,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 99,\n",
       "  'perplexity': 36.0149040222168},\n",
       " {'canaries_number': 8,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 99,\n",
       "  'perplexity': 36.0149040222168},\n",
       " {'canaries_number': 16,\n",
       "  'lora_rank': 2,\n",
       "  'random_seed': 99,\n",
       "  'perplexity': 36.0149040222168}]"
      ]
     },
     "execution_count": 135,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "results"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 138,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1000x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "import pandas as pd\n",
    "\n",
    "# Create a figure and axis\n",
    "\n",
    "df = pd.DataFrame(results)\n",
    "\n",
    "\n",
    "mean_perplexity = df.groupby('lora_rank')['perplexity'].mean().reset_index()\n",
    "max_perplexity = df.groupby('lora_rank')['perplexity'].max().reset_index()\n",
    "min_perplexity = df.groupby('lora_rank')['perplexity'].min().reset_index()\n",
    "\n",
    "\n",
    "# Create a figure and axis\n",
    "fig, ax1 = plt.subplots(figsize=(10, 6))\n",
    "\n",
    "# Plot mean perplexity\n",
    "ax1.plot(mean_perplexity['lora_rank'], mean_perplexity['perplexity'], label='Mean Perplexity', color='black', marker='o')\n",
    "\n",
    "# Shade the area between min and max perplexity\n",
    "ax1.fill_between(mean_perplexity['lora_rank'], min_perplexity['perplexity'], max_perplexity['perplexity'], color='black', alpha=0.2, label='Min/Max Range')\n",
    "\n",
    "# Set labels and title\n",
    "ax1.set_xlabel('Lora Rank')\n",
    "ax1.set_ylabel('Perplexity')\n",
    "plt.title('Perplexity of Canary Over Lora Rank')\n",
    "\n",
    "# Add a legend\n",
    "ax1.legend()\n",
    "\n",
    "# Show the plot\n",
    "plt.grid(True)\n",
    "plt.tight_layout()  # Adjust layout to prevent overlap\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "ename": "ValueError",
     "evalue": "dict contains fields not in fieldnames: 'random_seed'",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mValueError\u001b[0m                                Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[36], line 11\u001b[0m\n\u001b[1;32m      9\u001b[0m     writer\u001b[38;5;241m.\u001b[39mwriteheader()\n\u001b[1;32m     10\u001b[0m     \u001b[38;5;28;01mfor\u001b[39;00m result \u001b[38;5;129;01min\u001b[39;00m results:\n\u001b[0;32m---> 11\u001b[0m         writer\u001b[38;5;241m.\u001b[39mwriterow(result)\n\u001b[1;32m     13\u001b[0m \u001b[38;5;28mprint\u001b[39m(\u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mResults saved to \u001b[39m\u001b[38;5;132;01m{\u001b[39;00moutput_csv_path\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m\"\u001b[39m)\n",
      "File \u001b[0;32m~/miniconda3/envs/llm_extract_v2/lib/python3.11/csv.py:154\u001b[0m, in \u001b[0;36mDictWriter.writerow\u001b[0;34m(self, rowdict)\u001b[0m\n\u001b[1;32m    153\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21mwriterow\u001b[39m(\u001b[38;5;28mself\u001b[39m, rowdict):\n\u001b[0;32m--> 154\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mwriter\u001b[38;5;241m.\u001b[39mwriterow(\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_dict_to_list(rowdict))\n",
      "File \u001b[0;32m~/miniconda3/envs/llm_extract_v2/lib/python3.11/csv.py:149\u001b[0m, in \u001b[0;36mDictWriter._dict_to_list\u001b[0;34m(self, rowdict)\u001b[0m\n\u001b[1;32m    147\u001b[0m     wrong_fields \u001b[38;5;241m=\u001b[39m rowdict\u001b[38;5;241m.\u001b[39mkeys() \u001b[38;5;241m-\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mfieldnames\n\u001b[1;32m    148\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m wrong_fields:\n\u001b[0;32m--> 149\u001b[0m         \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mValueError\u001b[39;00m(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mdict contains fields not in fieldnames: \u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m    150\u001b[0m                          \u001b[38;5;241m+\u001b[39m \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m, \u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;241m.\u001b[39mjoin([\u001b[38;5;28mrepr\u001b[39m(x) \u001b[38;5;28;01mfor\u001b[39;00m x \u001b[38;5;129;01min\u001b[39;00m wrong_fields]))\n\u001b[1;32m    151\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m (rowdict\u001b[38;5;241m.\u001b[39mget(key, \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mrestval) \u001b[38;5;28;01mfor\u001b[39;00m key \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mfieldnames)\n",
      "\u001b[0;31mValueError\u001b[0m: dict contains fields not in fieldnames: 'random_seed'"
     ]
    }
   ],
   "source": [
    "# Define the output CSV file path\n",
    "output_csv_path = '../experiments/experiment_results_new.csv'\n",
    "\n",
    "# Write results to the CSV file\n",
    "with open(output_csv_path, mode='w', newline='') as csvfile:\n",
    "    fieldnames = ['canaries_number', 'lora_rank', 'perplexity', 'exposure']\n",
    "    writer = csv.DictWriter(csvfile, fieldnames=fieldnames)\n",
    "\n",
    "    writer.writeheader()\n",
    "    for result in results:\n",
    "        writer.writerow(result)\n",
    "\n",
    "print(f\"Results saved to {output_csv_path}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1000x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "import pandas as pd\n",
    "\n",
    "# Create a figure and axis\n",
    "\n",
    "df = pd.DataFrame(results)\n",
    "\n",
    "\n",
    "mean_perplexity = df.groupby('canaries_number')['perplexity'].mean().reset_index()\n",
    "max_perplexity = df.groupby('canaries_number')['perplexity'].max().reset_index()\n",
    "min_perplexity = df.groupby('canaries_number')['perplexity'].min().reset_index()\n",
    "\n",
    "\n",
    "# Create a figure and axis\n",
    "fig, ax1 = plt.subplots(figsize=(10, 6))\n",
    "\n",
    "# Plot mean perplexity\n",
    "ax1.plot(mean_perplexity['canaries_number'], mean_perplexity['perplexity'], label='Mean Perplexity', color='black', marker='o')\n",
    "\n",
    "# Shade the area between min and max perplexity\n",
    "ax1.fill_between(mean_perplexity['canaries_number'], min_perplexity['perplexity'], max_perplexity['perplexity'], color='black', alpha=0.2, label='Min/Max Range')\n",
    "\n",
    "# Set labels and title\n",
    "ax1.set_xlabel('Canary Repetitions')\n",
    "ax1.set_ylabel('Perplexity')\n",
    "plt.title('Perplexity of Canary Over Canary Repetitions')\n",
    "\n",
    "# Add a legend\n",
    "ax1.legend()\n",
    "\n",
    "# Show the plot\n",
    "plt.grid(True)\n",
    "plt.tight_layout()  # Adjust layout to prevent overlap\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1000x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "\n",
    "\n",
    "# Create a figure and axis\n",
    "\n",
    "df = pd.DataFrame(results)\n",
    "\n",
    "\n",
    "mean_perplexity = df.groupby('canaries_number')['test_perplexity'].mean().reset_index()\n",
    "max_perplexity = df.groupby('canaries_number')['test_perplexity'].max().reset_index()\n",
    "min_perplexity = df.groupby('canaries_number')['test_perplexity'].min().reset_index()\n",
    "\n",
    "\n",
    "# Create a figure and axis\n",
    "fig, ax1 = plt.subplots(figsize=(10, 6))\n",
    "\n",
    "# Plot mean perplexity\n",
    "ax1.plot(mean_perplexity['canaries_number'], mean_perplexity['test_perplexity'], label='Mean Perplexity', color='black', marker='o')\n",
    "\n",
    "# Shade the area between min and max perplexity\n",
    "ax1.fill_between(mean_perplexity['canaries_number'], min_perplexity['test_perplexity'], max_perplexity['test_perplexity'], color='black', alpha=0.2, label='Min/Max Range')\n",
    "\n",
    "# Set labels and title\n",
    "ax1.set_xlabel('Canary Repetitions')\n",
    "ax1.set_ylabel('Test data perplexity')\n",
    "plt.title('Model perplexity over test data')\n",
    "\n",
    "# Add a legend\n",
    "ax1.legend()\n",
    "\n",
    "# Show the plot\n",
    "plt.grid(True)\n",
    "plt.tight_layout()  # Adjust layout to prevent overlap\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "\n",
    "\n",
    "# Data extracted from the given text\n",
    "\n",
    "\n",
    "mean_perplexity = results.groupby('canaries_number')['perplexity'].mean().reset_index()\n",
    "max_perplexity = results.groupby('canaries_number')['perplexity'].max().reset_index()\n",
    "min_perplexity = results.groupby('canaries_number')['perplexity'].min().reset_index()\n",
    "\n",
    "\n",
    "\n",
    "# Create a figure and axis\n",
    "fig, ax1 = plt.subplots()\n",
    "\n",
    "# Plot perplexity on the primary y-axis\n",
    "color = 'tab:blue'\n",
    "ax1.set_xlabel('Canary repetitions')\n",
    "ax1.set_ylabel('Perplexity', color=color)\n",
    "ax1.plot(canaries_number, perplexity, color=color)\n",
    "ax1.tick_params(axis='y', labelcolor=color)\n",
    "\n",
    "# # Create a second y-axis for exposure\n",
    "# ax2 = ax1.twinx()\n",
    "# color = 'tab:red'\n",
    "# ax2.set_ylabel('Exposure', color=color)\n",
    "# ax2.plot(canaries_number, exposure, color=color)\n",
    "# ax2.tick_params(axis='y', labelcolor=color)\n",
    "\n",
    "# Add a title and show the plot\n",
    "plt.title('Perplexity of Canary Over Canary Repetition')\n",
    "fig.tight_layout()  # Adjust layout to prevent overlap\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Extract data for plotting\n",
    "canaries_list = [result['canaries_number'] for result in results]\n",
    "lora_rank_list = [result['lora_rank'] for result in results]\n",
    "perplexities = [result['perplexity'] for result in results]\n",
    "exposures = [result['exposure'] for result in results]\n",
    "\n",
    "# Create scatter plots\n",
    "plt.figure(figsize=(12, 6))\n",
    "\n",
    "# Perplexity scatter plot\n",
    "plt.subplot(1, 2, 1)\n",
    "scatter = plt.scatter(canaries_list, lora_rank_list, c=perplexities, cmap='viridis')\n",
    "plt.colorbar(scatter, label='Perplexity')\n",
    "plt.xlabel('Canaries Number')\n",
    "plt.ylabel('LoRA Rank')\n",
    "plt.title('Perplexity vs Canaries Number and LoRA Rank')\n",
    "\n",
    "# Exposure scatter plot\n",
    "plt.subplot(1, 2, 2)\n",
    "scatter = plt.scatter(canaries_list, lora_rank_list, c=exposures, cmap='plasma')\n",
    "plt.colorbar(scatter, label='Exposure')\n",
    "plt.xlabel('Canaries Number')\n",
    "plt.ylabel('LoRA Rank')\n",
    "plt.title('Exposure vs Canaries Number and LoRA Rank')\n",
    "\n",
    "plt.tight_layout()\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "def make_inference(context, qa_model, tokenizer):\n",
    "  batch = tokenizer(context, return_tensors='pt').to(\"cuda:0\")\n",
    "  with torch.cuda.amp.autocast():\n",
    "    output_tokens = qa_model.generate(**batch, max_new_tokens=40)\n",
    "\n",
    "  display(Markdown((tokenizer.decode(output_tokens[0], skip_special_tokens=True))))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "def find_largest_common_ngram(tokens1, tokens2):\n",
    "    len1 = tokens1.shape[1]\n",
    "    len2 = tokens2.shape[1]\n",
    "\n",
    "    max_n = min(len1, len2)\n",
    "\n",
    "    for n in range(max_n, 0, -1):\n",
    "        ngrams1 = set(tuple(tokens1[0, i:i+n].tolist()) for i in range(len1 - n + 1))\n",
    "        ngrams2 = set(tuple(tokens2[0, i:i+n].tolist()) for i in range(len2 - n + 1))\n",
    "        \n",
    "        common_ngrams = ngrams1.intersection(ngrams2)\n",
    "        \n",
    "        if common_ngrams:\n",
    "            return len(max(common_ngrams, key=len))  # Return the first found largest n-gram\n",
    "\n",
    "    return None  # No common n-grams found\n",
    "\n",
    "# Example tensors\n",
    "tokens1 = torch.tensor([[2025, 6570, 2645, 12009, 6317, 284, 275, 330, 270, 11510]], device='cuda:0')\n",
    "tokens2 = torch.tensor([[2645, 12009, 6317, 284, 275, 330, 270, 11510, 259, 267]], device='cuda:0')\n",
    "\n",
    "# Find the largest common n-gram\n",
    "largest_ngram = find_largest_common_ngram(tokens1, tokens2)\n",
    "print(\"Largest Common n-gram:\", largest_ngram)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 106,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "tensor([[ 2025,  6570,  2645, 12009,  6317,   284,   275,   398,   420,  1968,\n",
       "           500,    13,   198,   198]], device='cuda:0')"
      ]
     },
     "execution_count": 106,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "output_tokens"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 105,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "tensor([  330,   270, 11510,   259,   267,   600,   434,    13],\n",
       "       device='cuda:0')"
      ]
     },
     "execution_count": 105,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "suffix['input_ids'][0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 116,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "PREFIX ---- Anaphylactic reaction to b\n",
      "SUFFIX ---- acitracin ointment.\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-1-rank-13-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "Anaphylactic reaction to bromocriptine.\n",
      "\n",
      "\n",
      "\n",
      " LARGEST N GRAM 1\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-1-rank-13-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "Anaphylactic reaction to bromocriptine.\n",
      "\n",
      "\n",
      "\n",
      " LARGEST N GRAM 1\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-1-rank-13-seed\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " GENERATED \n",
      " ----------\n",
      "Anaphylactic reaction to bromocriptine.\n",
      "\n",
      "\n",
      "\n",
      " LARGEST N GRAM 1\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-1-rank-13-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "Anaphylactic reaction to baclofen.\n",
      "\n",
      "The\n",
      "\n",
      " LARGEST N GRAM 1\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-1-rank-13-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "Anaphylactic reaction to bacitracin.\n",
      "\n",
      "\n",
      "\n",
      " LARGEST N GRAM 4\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-1-rank-13-seed\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " GENERATED \n",
      " ----------\n",
      "Anaphylactic reaction to bacitracin.\n",
      "\n",
      "\n",
      "\n",
      " LARGEST N GRAM 4\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-1-rank-13-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "Anaphylactic reaction to bacitracin ointment\n",
      "\n",
      " LARGEST N GRAM 7\n",
      "\n",
      "----------\n",
      "PREFIX ---- Although moderate myelosuppression is not uncommonly seen in patients treated with lenalidom\n",
      "SUFFIX ---- ide, aplastic anemia has not previously been reported to be associated with this agent.\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-1-rank-7-seed\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " GENERATED \n",
      " ----------\n",
      "Although moderate myelosuppression is not uncommonly seen in patients treated with lenalidomide, the use of this drug may be a potential risk factor for the development of severe my\n",
      "\n",
      " LARGEST N GRAM 2\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-1-rank-7-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "Although moderate myelosuppression is not uncommonly seen in patients treated with lenalidomide, it is important to note that the patient's history of severe myelogenous leukemia is\n",
      "\n",
      " LARGEST N GRAM 2\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-1-rank-7-seed\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " GENERATED \n",
      " ----------\n",
      "Although moderate myelosuppression is not uncommonly seen in patients treated with lenalidomide, the use of this drug may be a potential risk factor for the development of myel\n",
      "\n",
      " LARGEST N GRAM 2\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-1-rank-7-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "Although moderate myelosuppression is not uncommonly seen in patients treated with lenalidomide, the use of lenalidomide may be a potential complication.\n",
      "\n",
      "The use\n",
      "\n",
      " LARGEST N GRAM 2\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-1-rank-7-seed\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " GENERATED \n",
      " ----------\n",
      "Although moderate myelosuppression is not uncommonly seen in patients treated with lenalidomide, the use of lenalidomide may be associated with a higher incidence of myel\n",
      "\n",
      " LARGEST N GRAM 3\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-1-rank-7-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "Although moderate myelosuppression is not uncommonly seen in patients treated with lenalidomide, the use of lenalidomide in this patient was not reported. The patient was\n",
      "\n",
      " LARGEST N GRAM 2\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-1-rank-7-seed\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " GENERATED \n",
      " ----------\n",
      "Although moderate myelosuppression is not uncommonly seen in patients treated with lenalidomide, aplastic anemia has not previously been reported to be associated with this agent.\n",
      "\n",
      " LARGEST N GRAM 19\n",
      "\n",
      "----------\n",
      "PREFIX ---- OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when\n",
      "SUFFIX ----  metoclopramide was coadministered with sertraline or venlafaxine.\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-1-rank-81-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when the patient was treated with a serotonin reuptake inhibitor.\n",
      "\n",
      "METHODS: The patient was treated\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " LARGEST N GRAM 1\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-1-rank-81-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when the patient was treated with serotonin reuptake inhibitors.\n",
      "\n",
      "To describe the first case of serotonin syndrome\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " LARGEST N GRAM 1\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-1-rank-81-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when the patient was treated with a serotonin reuptake inhibitor.\n",
      "\n",
      "OBJECTIVE: To describe the\n",
      "\n",
      " LARGEST N GRAM 1\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-1-rank-81-seed\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " GENERATED \n",
      " ----------\n",
      "OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when the use of serotonin reuptake inhibitors (SSRIs) was discontinued.\n",
      "\n",
      "METHOD: We\n",
      "\n",
      " LARGEST N GRAM 1\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-1-rank-81-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when intravenous serotonin was administered intravenously. The first case was a patient with a history of acute myel\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " LARGEST N GRAM 1\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-1-rank-81-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with venlafaxine. The first case was a\n",
      "\n",
      " LARGEST N GRAM 10\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-1-rank-81-seed\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " GENERATED \n",
      " ----------\n",
      "OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with venlafaxine or venlafaxine\n",
      "\n",
      " LARGEST N GRAM 10\n",
      "\n",
      "----------\n",
      "PREFIX ---- Perinatal vasoconstrictive renal ins\n",
      "SUFFIX ---- ufficiency associated with maternal nimesulide use.\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-1-rank-17-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "Perinatal vasoconstrictive renal insufficiency. Lancet. 5:843-\n",
      "\n",
      " LARGEST N GRAM 2\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-1-rank-17-seed\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " GENERATED \n",
      " ----------\n",
      "Perinatal vasoconstrictive renal insufficiency in a patient with a history of renal\n",
      "\n",
      " LARGEST N GRAM 2\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-1-rank-17-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "Perinatal vasoconstrictive renal insufficiency associated with the use of thiazide\n",
      "\n",
      " LARGEST N GRAM 4\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-1-rank-17-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "Perinatal vasoconstrictive renal insufficiency associated with the administration of thiazide\n",
      "\n",
      " LARGEST N GRAM 4\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-1-rank-17-seed\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " GENERATED \n",
      " ----------\n",
      "Perinatal vasoconstrictive renal insufficiency associated with the use of thiazide\n",
      "\n",
      " LARGEST N GRAM 4\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-1-rank-17-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "Perinatal vasoconstrictive renal insufficiency associated with maternal maternal maternal maternal use of\n",
      "\n",
      " LARGEST N GRAM 5\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-1-rank-17-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "Perinatal vasoconstrictive renal insufficiency associated with maternal nimesulide use\n",
      "\n",
      " LARGEST N GRAM 10\n",
      "\n",
      "----------\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "PREFIX ---- A more serious development of adrenal insufficiency\n",
      "SUFFIX ----  may occur upon the improper replacement of systemic steroids.\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-1-rank-75-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "A more serious development of adrenal insufficiency following the administration of thiazide therapy is the\n",
      "\n",
      " LARGEST N GRAM 1\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-1-rank-75-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "A more serious development of adrenal insufficiency following treatment with a selective serotonin reuptake inhibitor\n",
      "\n",
      " LARGEST N GRAM 1\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-1-rank-75-seed\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " GENERATED \n",
      " ----------\n",
      "A more serious development of adrenal insufficiency following the administration of thiazolidinediones\n",
      "\n",
      " LARGEST N GRAM 1\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-1-rank-75-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "A more serious development of adrenal insufficiency following the administration of phenytoin is reported\n",
      "\n",
      " LARGEST N GRAM 1\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-1-rank-75-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "A more serious development of adrenal insufficiency may occur in the development of a syndrome of adren\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " LARGEST N GRAM 2\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-1-rank-75-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "A more serious development of adrenal insufficiency may occur during the administration of a selective serotonin re\n",
      "\n",
      " LARGEST N GRAM 2\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-1-rank-75-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "A more serious development of adrenal insufficiency may occur upon the improper replacement of systemic steroids.\n",
      "\n",
      " LARGEST N GRAM 10\n",
      "\n",
      "----------\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "PREFIX ---- After receiving 3 doses of ifosfamide/\n",
      "SUFFIX ---- mesna, she was found to be unresponsive.\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-1-rank-90-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "After receiving 3 doses of ifosfamide/tetrahydrocannabinol (THC\n",
      "\n",
      " LARGEST N GRAM None\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-1-rank-90-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "After receiving 3 doses of ifosfamide/tetrahydrocannabinol (TCM\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " LARGEST N GRAM None\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-1-rank-90-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "After receiving 3 doses of ifosfamide/diazolidinedioni, the patient developed\n",
      "\n",
      " LARGEST N GRAM 1\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-1-rank-90-seed\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " GENERATED \n",
      " ----------\n",
      "After receiving 3 doses of ifosfamide/diphenhydramine, she developed a\n",
      "\n",
      " LARGEST N GRAM 2\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-1-rank-90-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "After receiving 3 doses of ifosfamide/diclofenac, she developed a\n",
      "\n",
      " LARGEST N GRAM 2\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-1-rank-90-seed\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " GENERATED \n",
      " ----------\n",
      "After receiving 3 doses of ifosfamide/mesosfamide, she was found to be\n",
      "\n",
      " LARGEST N GRAM 6\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-1-rank-90-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "After receiving 3 doses of ifosfamide/mesna, she was found to be unresponsive\n",
      "\n",
      " LARGEST N GRAM 10\n",
      "\n",
      "----------\n",
      "PREFIX ---- The authors think that although lamivudine is widely used and well\n",
      "SUFFIX ----  tolerated, it can cause ADRs, which are reversible after drug withdrawal.\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-1-rank-0-seed\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " GENERATED \n",
      " ----------\n",
      "The authors think that although lamivudine is widely used and well tolerated, it is not a potent inhibitor of the immune system. They\n",
      "\n",
      " LARGEST N GRAM 3\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-1-rank-0-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "The authors think that although lamivudine is widely used and well tolerated, it is not a common drug in the United States. The\n",
      "\n",
      " LARGEST N GRAM 3\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-1-rank-0-seed\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " GENERATED \n",
      " ----------\n",
      "The authors think that although lamivudine is widely used and well tolerated, it is not recommended for use in patients with severe depression.\n",
      "\n",
      " LARGEST N GRAM 3\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-1-rank-0-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "The authors think that although lamivudine is widely used and well tolerated, it is not recommended for use in patients with severe depression.\n",
      "\n",
      " LARGEST N GRAM 3\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-1-rank-0-seed\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " GENERATED \n",
      " ----------\n",
      "The authors think that although lamivudine is widely used and well tolerated, it is not recommended for use in patients with chronic hepatitis C\n",
      "\n",
      " LARGEST N GRAM 3\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-1-rank-0-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "The authors think that although lamivudine is widely used and well tolerated, it is not well tolerated. Therefore, the use of lam\n",
      "\n",
      " LARGEST N GRAM 3\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-1-rank-0-seed\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " GENERATED \n",
      " ----------\n",
      "The authors think that although lamivudine is widely used and well tolerated, it can cause ADRs, which are reversible after drug withdrawal\n",
      "\n",
      " LARGEST N GRAM 14\n",
      "\n",
      "----------\n",
      "PREFIX ---- We describe a patient with metastatic prostate cancer who developed non\n",
      "SUFFIX ---- oliguric renal failure during treatment with suramin.\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-1-rank-10-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "We describe a patient with metastatic prostate cancer who developed non-specific acute renal failure after treatment with methotrexate\n",
      "\n",
      " LARGEST N GRAM 2\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-1-rank-10-seed\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " GENERATED \n",
      " ----------\n",
      "We describe a patient with metastatic prostate cancer who developed non-specific acute renal failure after treatment with methotrexate\n",
      "\n",
      " LARGEST N GRAM 2\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-1-rank-10-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "We describe a patient with metastatic prostate cancer who developed non-specific lymphocytic lymphocytic leukemia after treatment with\n",
      "\n",
      " LARGEST N GRAM 2\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-1-rank-10-seed\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " GENERATED \n",
      " ----------\n",
      "We describe a patient with metastatic prostate cancer who developed non-small cell lung cancer after treatment with a selective serotonin re\n",
      "\n",
      " LARGEST N GRAM 2\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-1-rank-10-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "We describe a patient with metastatic prostate cancer who developed non-small cell lung cancer after treatment with amiodarone\n",
      "\n",
      " LARGEST N GRAM 2\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-1-rank-10-seed\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " GENERATED \n",
      " ----------\n",
      "We describe a patient with metastatic prostate cancer who developed non-small cell lung cancer after treatment with diclof\n",
      "\n",
      " LARGEST N GRAM 2\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-1-rank-10-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "We describe a patient with metastatic prostate cancer who developed non-small cell lung cancer during treatment with suramin. The\n",
      "\n",
      " LARGEST N GRAM 6\n",
      "\n",
      "----------\n",
      "PREFIX ---- We report a patient who developed spontaneous splenic infarction after\n",
      "SUFFIX ----  the use of sumatriptan for the treatment of migraine headache.\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-1-rank-36-seed\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " GENERATED \n",
      " ----------\n",
      "We report a patient who developed spontaneous splenic infarction after treatment with thalidomide. The patient was treated with th\n",
      "\n",
      " LARGEST N GRAM 1\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-1-rank-36-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "We report a patient who developed spontaneous splenic infarction after treatment with thalidomide. The patient was treated with th\n",
      "\n",
      " LARGEST N GRAM 1\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-1-rank-36-seed\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " GENERATED \n",
      " ----------\n",
      "We report a patient who developed spontaneous splenic infarction after the use of the selective serotonin reuptake inhibitor (SSRI\n",
      "\n",
      " LARGEST N GRAM 3\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-1-rank-36-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "We report a patient who developed spontaneous splenic infarction after treatment with the selective serotonin reuptake inhibitor ritalin.\n",
      "\n",
      " LARGEST N GRAM 1\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-1-rank-36-seed\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " GENERATED \n",
      " ----------\n",
      "We report a patient who developed spontaneous splenic infarction after the administration of the selective serotonin reuptake inhibitor (SSRI\n",
      "\n",
      " LARGEST N GRAM 1\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-1-rank-36-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "We report a patient who developed spontaneous splenic infarction after the use of the selective serotonin reuptake inhibitor (SSRI\n",
      "\n",
      " LARGEST N GRAM 3\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-1-rank-36-seed\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " GENERATED \n",
      " ----------\n",
      "We report a patient who developed spontaneous splenic infarction after the use of sumatriptan for the treatment of migraine headache\n",
      "\n",
      " LARGEST N GRAM 13\n",
      "\n",
      "----------\n",
      "PREFIX ---- Though physicians treating large populations of patients with HIV are well aware of this complication, only one other\n",
      "SUFFIX ----  report of nevirapine-associated SJS has been documented in the dermatology literature.\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-1-canaries-1-rank-99-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "Though physicians treating large populations of patients with HIV are well aware of this complication, only one other case of this complication has been reported. This case was reported in a patient with a history of\n",
      "\n",
      " LARGEST N GRAM 2\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-2-canaries-1-rank-99-seed\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " GENERATED \n",
      " ----------\n",
      "Though physicians treating large populations of patients with HIV are well aware of this complication, only one other case has been reported. This case involved a patient with a history of hepatitis B who developed a\n",
      "\n",
      " LARGEST N GRAM 2\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-8-canaries-1-rank-99-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "Though physicians treating large populations of patients with HIV are well aware of this complication, only one other case of a patient with HIV-infected patients has been reported. This case was reported in\n",
      "\n",
      " LARGEST N GRAM 2\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-16-canaries-1-rank-99-seed\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " GENERATED \n",
      " ----------\n",
      "Though physicians treating large populations of patients with HIV are well aware of this complication, only one other case of a patient with HIV-infected patients with a history of hepatitis B virus infection has\n",
      "\n",
      " LARGEST N GRAM 1\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-32-canaries-1-rank-99-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "Though physicians treating large populations of patients with HIV are well aware of this complication, only one other report has been reported on the association between the use of methotrexate and HIV infection.\n",
      "\n",
      " LARGEST N GRAM 2\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-64-canaries-1-rank-99-seed\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " GENERATED \n",
      " ----------\n",
      "Though physicians treating large populations of patients with HIV are well aware of this complication, only one other report of a case of acute hepatitis B infection has been reported. This report describes a case of\n",
      "\n",
      " LARGEST N GRAM 2\n",
      "\n",
      "----------\n",
      "Loading model ../models/gpt2/gpt2-finetuned-on-phee-128-canaries-1-rank-99-seed\n",
      "\n",
      " GENERATED \n",
      " ----------\n",
      "Though physicians treating large populations of patients with HIV are well aware of this complication, only one other report of nevirapine-associated SJS has been documented in the dermatology literature.\n",
      "\n",
      " LARGEST N GRAM 19\n",
      "\n",
      "----------\n"
     ]
    }
   ],
   "source": [
    "model = AutoModelForCausalLM.from_pretrained('gpt2', return_dict=True, load_in_8bit=False, device_map='auto')\n",
    "\n",
    "\n",
    "canaries_number = [1, 2, 8, 16, 32, 64, 128]\n",
    "\n",
    "results_ngram = []\n",
    "\n",
    "for k in random_seeds:\n",
    "    random.seed(k)\n",
    "    row = random.randint(0, len(ds['train']['context']) - 1)\n",
    "    canary = ds['train']['context'][row]\n",
    "\n",
    "    batch = tokenizer(canary, return_tensors='pt').to(\"cuda:0\")\n",
    "    \n",
    "    # Calculate the midpoint\n",
    "    midpoint = batch['input_ids'].shape[1] // 2\n",
    "\n",
    "    # Split the tensors\n",
    "    input_ids_1, input_ids_2 = torch.split(batch['input_ids'], [midpoint, batch['input_ids'].shape[1] - midpoint], dim=1)\n",
    "    attention_mask_1, attention_mask_2 = torch.split(batch['attention_mask'], [midpoint, batch['attention_mask'].shape[1] - midpoint], dim=1)\n",
    "\n",
    "    # Create two new batches\n",
    "    prefix = {\n",
    "        'input_ids': input_ids_1,\n",
    "        'attention_mask': attention_mask_1\n",
    "    }\n",
    "\n",
    "    suffix = {\n",
    "        'input_ids': input_ids_2,\n",
    "        'attention_mask': attention_mask_2\n",
    "    }\n",
    "\n",
    "    # print(batch)\n",
    "    # print(prefix)\n",
    "\n",
    "    print(f\"PREFIX ---- {tokenizer.decode(prefix['input_ids'][0])}\")\n",
    "    print(f\"SUFFIX ---- {tokenizer.decode(suffix['input_ids'][0])}\")\n",
    "\n",
    "\n",
    "    for j in lora_rank:\n",
    "        for i in canaries_number:\n",
    "            model_name_trained = f\"../models/gpt2/gpt2-finetuned-on-phee-{i}-canaries-{j}-rank-{k}-seed\"\n",
    "            print(f\"Loading model {model_name_trained}\")\n",
    "\n",
    "            config = PeftConfig.from_pretrained(model_name_trained)\n",
    "            # model = AutoModelForCausalLM.from_pretrained(config.base_model_name_or_path, return_dict=True, load_in_8bit=False, device_map='auto')\n",
    "            qa_model = PeftModel.from_pretrained(model, model_name_trained)\n",
    "\n",
    "            with torch.cuda.amp.autocast():\n",
    "                output_tokens = qa_model.generate(**prefix, max_new_tokens=midpoint)            \n",
    "            # display(Markdown((tokenizer.decode(output_tokens[0], skip_special_tokens=True))))\n",
    "            print('\\n GENERATED \\n ----------')\n",
    "            print(tokenizer.decode(output_tokens[0]))\n",
    "            largest_ngram = find_largest_common_ngram(output_tokens, suffix['input_ids'])\n",
    "\n",
    "\n",
    "            print(f\"\\n LARGEST N GRAM {largest_ngram}\")\n",
    "            print('\\n----------')\n",
    "\n",
    "            results_ngram.append({\n",
    "                'canaries_number': i,\n",
    "                'lora_rank': j,\n",
    "                'random_seed' : k,\n",
    "                'largest ngram': largest_ngram,\n",
    "                'share of ngram': largest_ngram / midpoint if largest_ngram else 0\n",
    "            })\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 131,
   "metadata": {},
   "outputs": [],
   "source": [
    "max = __builtins__.max\n",
    "min = __builtins__.max\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 119,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1000x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "df = pd.DataFrame(results_ngram)\n",
    "\n",
    "\n",
    "mean_df = df.groupby('canaries_number')['share of ngram'].mean().reset_index()\n",
    "max_df = df.groupby('canaries_number')['share of ngram'].max().reset_index()\n",
    "min_df = df.groupby('canaries_number')['share of ngram'].min().reset_index()\n",
    "\n",
    "\n",
    "# Create a figure and axis\n",
    "fig, ax1 = plt.subplots(figsize=(10, 6))\n",
    "\n",
    "# Plot mean perplexity\n",
    "ax1.plot(mean['canaries_number'], mean['share of ngram'], label='Mean Perplexity', color='black', marker='o')\n",
    "\n",
    "# Shade the area between min and max perplexity\n",
    "ax1.fill_between(mean['canaries_number'], min['share of ngram'], max['share of ngram'], color='black', alpha=0.2, label='Min/Max Range')\n",
    "\n",
    "# Set labels and title\n",
    "ax1.set_xlabel('Canary Repetitions')\n",
    "ax1.set_ylabel('Perplexity')\n",
    "plt.title('Share of n-gram found in the prefix')\n",
    "\n",
    "# Add a legend\n",
    "ax1.legend()\n",
    "\n",
    "# Show the plot\n",
    "plt.grid(True)\n",
    "plt.tight_layout()  # Adjust layout to prevent overlap\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 115,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'canaries_number': 1,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 13,\n",
       "  'largest ngram': 1,\n",
       "  'share of ngram': 0.14285714285714285},\n",
       " {'canaries_number': 2,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 13,\n",
       "  'largest ngram': 1,\n",
       "  'share of ngram': 0.14285714285714285},\n",
       " {'canaries_number': 8,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 13,\n",
       "  'largest ngram': 1,\n",
       "  'share of ngram': 0.14285714285714285},\n",
       " {'canaries_number': 16,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 13,\n",
       "  'largest ngram': 1,\n",
       "  'share of ngram': 0.14285714285714285},\n",
       " {'canaries_number': 32,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 13,\n",
       "  'largest ngram': 4,\n",
       "  'share of ngram': 0.5714285714285714},\n",
       " {'canaries_number': 64,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 13,\n",
       "  'largest ngram': 4,\n",
       "  'share of ngram': 0.5714285714285714},\n",
       " {'canaries_number': 128,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 13,\n",
       "  'largest ngram': 7,\n",
       "  'share of ngram': 1.0},\n",
       " {'canaries_number': 1,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 7,\n",
       "  'largest ngram': 2,\n",
       "  'share of ngram': 0.10526315789473684},\n",
       " {'canaries_number': 2,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 7,\n",
       "  'largest ngram': 2,\n",
       "  'share of ngram': 0.10526315789473684},\n",
       " {'canaries_number': 8,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 7,\n",
       "  'largest ngram': 2,\n",
       "  'share of ngram': 0.10526315789473684},\n",
       " {'canaries_number': 16,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 7,\n",
       "  'largest ngram': 2,\n",
       "  'share of ngram': 0.10526315789473684},\n",
       " {'canaries_number': 32,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 7,\n",
       "  'largest ngram': 3,\n",
       "  'share of ngram': 0.15789473684210525},\n",
       " {'canaries_number': 64,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 7,\n",
       "  'largest ngram': 2,\n",
       "  'share of ngram': 0.10526315789473684},\n",
       " {'canaries_number': 128,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 7,\n",
       "  'largest ngram': 19,\n",
       "  'share of ngram': 1.0},\n",
       " {'canaries_number': 1,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 81,\n",
       "  'largest ngram': 1,\n",
       "  'share of ngram': 0.047619047619047616},\n",
       " {'canaries_number': 2,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 81,\n",
       "  'largest ngram': 1,\n",
       "  'share of ngram': 0.047619047619047616},\n",
       " {'canaries_number': 8,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 81,\n",
       "  'largest ngram': 1,\n",
       "  'share of ngram': 0.047619047619047616},\n",
       " {'canaries_number': 16,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 81,\n",
       "  'largest ngram': 1,\n",
       "  'share of ngram': 0.047619047619047616},\n",
       " {'canaries_number': 32,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 81,\n",
       "  'largest ngram': 1,\n",
       "  'share of ngram': 0.047619047619047616},\n",
       " {'canaries_number': 64,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 81,\n",
       "  'largest ngram': 10,\n",
       "  'share of ngram': 0.47619047619047616},\n",
       " {'canaries_number': 128,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 81,\n",
       "  'largest ngram': 10,\n",
       "  'share of ngram': 0.47619047619047616},\n",
       " {'canaries_number': 1,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 17,\n",
       "  'largest ngram': 2,\n",
       "  'share of ngram': 0.2},\n",
       " {'canaries_number': 2,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 17,\n",
       "  'largest ngram': 2,\n",
       "  'share of ngram': 0.2},\n",
       " {'canaries_number': 8,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 17,\n",
       "  'largest ngram': 4,\n",
       "  'share of ngram': 0.4},\n",
       " {'canaries_number': 16,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 17,\n",
       "  'largest ngram': 4,\n",
       "  'share of ngram': 0.4},\n",
       " {'canaries_number': 32,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 17,\n",
       "  'largest ngram': 4,\n",
       "  'share of ngram': 0.4},\n",
       " {'canaries_number': 64,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 17,\n",
       "  'largest ngram': 5,\n",
       "  'share of ngram': 0.5},\n",
       " {'canaries_number': 128,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 17,\n",
       "  'largest ngram': 10,\n",
       "  'share of ngram': 1.0},\n",
       " {'canaries_number': 1,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 75,\n",
       "  'largest ngram': 1,\n",
       "  'share of ngram': 0.1},\n",
       " {'canaries_number': 2,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 75,\n",
       "  'largest ngram': 1,\n",
       "  'share of ngram': 0.1},\n",
       " {'canaries_number': 8,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 75,\n",
       "  'largest ngram': 1,\n",
       "  'share of ngram': 0.1},\n",
       " {'canaries_number': 16,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 75,\n",
       "  'largest ngram': 1,\n",
       "  'share of ngram': 0.1},\n",
       " {'canaries_number': 32,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 75,\n",
       "  'largest ngram': 2,\n",
       "  'share of ngram': 0.2},\n",
       " {'canaries_number': 64,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 75,\n",
       "  'largest ngram': 2,\n",
       "  'share of ngram': 0.2},\n",
       " {'canaries_number': 128,\n",
       "  'lora_rank': 1,\n",
       "  'random_seed': 75,\n",
       "  'largest ngram': 10,\n",
       "  'share of ngram': 1.0}]"
      ]
     },
     "execution_count": 115,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "results_ngram"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 102,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Largest Common n-gram: 8\n"
     ]
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "llm_extract",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
